Achondroplasia

Mendelian MONDO:0007037 Pathograph 53 Show in embeddings browser FGFR3-related skeletal dysplasia Rhizomelic limb shortening syndrome

Achondroplasia is the most common cause of disproportionate short stature. It is caused by heterozygous gain-of-function variation in FGFR3, almost always p.Gly380Arg, which prolongs inhibitory FGFR3 signaling in growth-plate chondrocytes and impairs endochondral ossification. Rhizomelic limb shortening, macrocephaly, frontal bossing, midface retrusion, and trident hands are characteristic. Important complications include craniocervical-junction compression in infancy, sleep-disordered breathing, middle-ear dysfunction, limb bowing, obesity, and symptomatic spinal stenosis in adulthood. Daily vosoritide and once-weekly navepegritide increase growth velocity in eligible children with open epiphyses; both US indications use annualized growth velocity as an accelerated-approval endpoint, so final-height and complication-prevention benefits remain under study. Oral infigratinib, which inhibits the FGFR kinase directly, increased height velocity in a phase 3 trial; meclizine and the soluble FGFR3 decoy recifercept have not shown a height-velocity effect in children. Life expectancy is reduced by about ten years.

Ask OpenScientist

Ask a research question about Achondroplasia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

ISDS Skeletal Nosology

👪

Inheritance

Autosomal dominant HP:0000006

Achondroplasia has complete-penetrance autosomal-dominant inheritance. About 80% of affected individuals have average-stature parents and a de novo FGFR3 variant. In informative sporadic cases, the recurrent variant arose on the paternal chromosome; increased paternal age is an established association.

Autosomal dominant inheritance Penetrance: COMPLETE De novo rate: approximately 80%

Parent-of-origin effect: De novo variants are predominantly paternal in origin and associated with increased paternal age

Show evidence (5 references)

PMID:8078586 SUPPORT Human Clinical

"Affected individuals are fertile and achondroplasia is transmitted as a fully penetrant autosomal dominant trait, accounting for rare familial forms of the disease (10%)."

Establishes autosomal dominant inheritance with full penetrance for achondroplasia.

PMID:8078586 SUPPORT Human Clinical

"More than 90% of cases are sporadic and there is an increased paternal age at the time of conception of affected individuals,"

An older series documents a high sporadic fraction and paternal-age association; the structured estimate is calibrated to the current approximately 80% estimate.

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"Approximately 80% of individuals with achondroplasia have parents of average stature and have achondroplasia as the result of a"

The 2026 GeneReviews revision gives the current approximately 80% de novo estimate.

+ 2 more references

◈

Mechanistic Hypotheses

FGFR3 Growth-Plate Signaling Model

canonical_fgfr3_gain_of_function_chondrocyte_model CANONICAL

Evidence balance 4 support

Recurrent heterozygous FGFR3 p.Gly380Arg gain-of-function prolongs receptor signaling in growth-plate chondrocytes. Experiments support delayed receptor down-regulation while G380R activation remains predominantly ligand dependent. MAPK-mediated inhibition of hypertrophic differentiation and a qualified STAT-p21 branch impair endochondral ossification.

Strict constitutive activation is not asserted as the sole receptor-level mechanism. CNP-analogue growth-velocity responses support therapeutic counter-regulation but do not establish final-height or complication benefit.

Pathograph links

FGFR3 p.Gly380Arg gain-of-function with impaired receptor down-regulation -> Prolonged FGFR3 signaling in growth-plate chondrocytes DIRECT Delayed down-regulation expands mutant-receptor signaling in growth plate.

Prolonged FGFR3 signaling in growth-plate chondrocytes -> Growth-plate chondrocyte dysregulation DIRECT Prolonged signaling engages MAPK and STAT-p21 growth-inhibitory programs.

Prolonged FGFR3 signaling in growth-plate chondrocytes -> Primary cilium shortening and disrupted ciliary signaling DIRECT Sustained receptor activity shortens the chondrocyte primary cilium and misroutes IFT20; pharmacologic FGFR inhibition restores both, placing the ciliary change downstream of receptor activation.

Primary cilium shortening and disrupted ciliary signaling -> Growth-plate chondrocyte dysregulation INDIRECT UNKNOWN INTERMEDIATES Restoring ciliary organization pharmacologically increases bone elongation in a mouse model, supporting a contributory route from the ciliary defect back to growth-plate dysfunction.

Growth-plate chondrocyte dysregulation -> Impaired endochondral ossification and chondrodysplasia DIRECT Dysregulated growth-plate maturation impairs endochondral bone growth.

Impaired endochondral ossification and chondrodysplasia -> Reduced longitudinal growth of endochondral bones DIRECT Impaired hypertrophic differentiation reduces longitudinal growth.

Impaired endochondral ossification and chondrodysplasia -> Cranial-base and vertebral synchondrosis dysplasia UNKNOWN The endochondral process affects synchondroses, but ordinary-heterozygous causal evidence is incomplete.

Impaired endochondral ossification and chondrodysplasia -> Congenital spinal-canal constraint with superimposed degeneration UNKNOWN Impaired vertebral growth plausibly contributes to congenital constraint; adult degeneration adds a second component.

Impaired endochondral ossification and chondrodysplasia -> Elbow contracture UNKNOWN Elbow contractures are observed during childhood in the chondrodysplasia; the specific growth-plate route to the joint restriction is not established by the cited source.

Impaired endochondral ossification and chondrodysplasia -> Radial head dislocation UNKNOWN Radial head dislocation is observed during childhood in the chondrodysplasia; the specific route through elbow joint dysplasia is not established by the cited source.

Impaired endochondral ossification and chondrodysplasia -> Limited elbow extension UNKNOWN Limitation of elbow extension is part of the characteristic skeletal pattern of the chondrodysplasia; the specific articular mechanism is not established by the cited source.

Impaired endochondral ossification and chondrodysplasia -> Thoracic hypoplasia UNKNOWN The ribs and thoracic vertebral elements grow by endochondral ossification and a small chest is part of the skeletal phenotype; the cited source documents the finding rather than the specific growth-plate route.

Impaired endochondral ossification and chondrodysplasia -> Restrictive ventilatory defect INDIRECT KNOWN INTERMEDIATES A small, hypercompliant thoracic cage reduces lung volumes, producing restrictive pulmonary physiology in a subset of infants. Intermediates: Small thoracic cage with increased chest-wall compliance; Reduced lung volumes

Impaired endochondral ossification and chondrodysplasia -> Bowing of the legs UNKNOWN Lower-limb bowing overlaps clinically with genu varum; the specific growth-plate route is not established by the cited source.

Reduced longitudinal growth of endochondral bones -> Disproportionate short stature DIRECT Reduced longitudinal growth produces disproportionate stature.

Reduced longitudinal growth of endochondral bones -> Rhizomelia INDIRECT KNOWN INTERMEDIATES Proximal long-bone undergrowth produces rhizomelia. Intermediates: Preferential undergrowth of proximal long-bone segments

Reduced longitudinal growth of endochondral bones -> Limb undergrowth DIRECT Reduced longitudinal growth is expressed as limb undergrowth.

Reduced longitudinal growth of endochondral bones -> Brachydactyly INDIRECT KNOWN INTERMEDIATES Shortening of endochondral hand bones produces brachydactyly. Intermediates: Reduced longitudinal growth of metacarpals and phalanges

Reduced longitudinal growth of endochondral bones -> Trident hand INDIRECT KNOWN INTERMEDIATES Hand-bone shortening contributes to the trident configuration. Intermediates: Phalangeal shortening and separation of the third and fourth digits

Reduced longitudinal growth of endochondral bones -> Short middle phalanx of finger INDIRECT KNOWN INTERMEDIATES Shortening of the endochondral hand bones includes the middle phalanges, a component of the brachydactyly and trident-hand pattern. Intermediates: Reduced longitudinal growth of metacarpals and phalanges

Reduced longitudinal growth of endochondral bones -> Short proximal phalanx of finger INDIRECT KNOWN INTERMEDIATES Shortening of the endochondral hand bones includes the proximal phalanges, a component of the brachydactyly and trident-hand pattern. Intermediates: Reduced longitudinal growth of metacarpals and phalanges

Reduced longitudinal growth of endochondral bones -> Delayed gross motor development INDIRECT KNOWN INTERMEDIATES The disproportionate body habitus alters the biomechanics of early motor skills and head support. Infantile hypotonia and joint hypermobility, which are documented but not themselves mechanistically explained, add to the delay (see the associated knowledge-gap discussion). Intermediates: Disproportionate body habitus with rhizomelic limbs and relatively large head

Cranial-base and vertebral synchondrosis dysplasia -> Foramen magnum stenosis INDIRECT KNOWN INTERMEDIATES Skull-base growth restriction contributes to narrowing. Intermediates: Restricted endochondral growth of the skull base; Reduced bony dimensions of the foramen magnum

Cranial-base and vertebral synchondrosis dysplasia -> Jugular-foramen venous outflow impairment INDIRECT KNOWN INTERMEDIATES Skull-base undergrowth can narrow jugular foramina. Intermediates: Reduced skull-base dimensions; Jugular-foramen narrowing

Cranial-base and vertebral synchondrosis dysplasia -> Craniofacial and upper-airway restriction INDIRECT KNOWN INTERMEDIATES Premature skull-base synchondrosis fusion restricts anteroposterior facial growth, producing maxillary and midfacial retrusion; imaging associations corroborate coupled skull-base and midface severity. Intermediates: Anteroposterior restriction of facial growth

Cranial-base and vertebral synchondrosis dysplasia -> Depressed nasal bridge UNKNOWN Nasal-root depression at the nasofrontal junction is associated with the restricted anteroposterior skull-base growth; the cited source reports the association rather than a resolved causal route.

Cranial-base and vertebral synchondrosis dysplasia -> Cervical myelopathy INDIRECT KNOWN INTERMEDIATES The stenotic foramen magnum compresses the cervicomedullary cord; constriction severity predicts myelopathy in screened young children. Intermediates: Foramen magnum stenosis; Cervicomedullary cord compression

Cranial-base and vertebral synchondrosis dysplasia -> Central sleep apnea INDIRECT KNOWN INTERMEDIATES Craniocervical-junction compression can injure medullary respiratory control centers, producing the central apnea component of sleep-disordered breathing in infancy; this edge covers the compression-associated component rather than all central apnea. Intermediates: Foramen magnum stenosis with cervicomedullary compression; Injury to medullary respiratory control centers

Cranial-base and vertebral synchondrosis dysplasia -> Caudal interpedicular narrowing UNKNOWN Vertebral dysplasia is associated with the caudal interpedicular pattern.

Jugular-foramen venous outflow impairment -> Hydrocephalus INDIRECT KNOWN INTERMEDIATES Venous hypertension and impaired CSF resorption can produce hydrocephalus. Intermediates: Raised intracranial venous pressure; Impaired cerebrospinal-fluid resorption

Craniofacial and upper-airway restriction -> Midface retrusion UNKNOWN Midface retrusion is an anatomical component of restriction.

Craniofacial and upper-airway restriction -> Obstructive sleep apnea INDIRECT KNOWN INTERMEDIATES Midface retrusion reduces airway size, and lymphoid hypertrophy, airway malacia, and airway hypotonia combine with it to produce obstruction; retrusion severity correlates with apnea severity. Intermediates: Reduced upper-airway dimensions from midface retrusion; Lymphoid-ring hypertrophy, airway malacia, and airway hypotonia

Craniofacial and upper-airway restriction -> Functional abnormality of the middle ear INDIRECT KNOWN INTERMEDIATES Midface hypoplasia with short Eustachian tubes and a small pharynx predisposes to recurrent upper-airway infection and impaired middle-ear ventilation. Intermediates: Short Eustachian tubes with impaired middle-ear ventilation

Craniofacial and upper-airway restriction -> Otitis media with effusion INDIRECT KNOWN INTERMEDIATES Eustachian-tube dysfunction from the craniofacial anatomy produces chronic middle-ear effusion. Intermediates: Eustachian-tube dysfunction with impaired middle-ear drainage

Craniofacial and upper-airway restriction -> Conductive hearing impairment INDIRECT KNOWN INTERMEDIATES Chronic middle-ear effusion from Eustachian-tube dysfunction impairs sound conduction, producing the predominantly conductive hearing loss of achondroplasia. Intermediates: Chronic middle-ear effusion

Craniofacial and upper-airway restriction -> Delayed speech and language development INDIRECT KNOWN INTERMEDIATES Conductive hearing loss during the language-acquisition window contributes to speech and language delay; oral motor hypotonia is a documented co-contributor that is not itself mechanistically explained. Intermediates: Conductive hearing loss during language acquisition

Congenital spinal-canal constraint with superimposed degeneration -> Spinal canal stenosis DIRECT Congenital constraint and degeneration produce recognized stenosis.

Congenital spinal-canal constraint with superimposed degeneration -> Cervical spinal canal stenosis DIRECT The congenital component can affect the cervical canal.

Deep research

OpenScientist citations 29 citations 2026-05-23T16:17:13.173615

Show evidence (4 references)

PMID:10611230 SUPPORT In Vitro

"We found that dimerization and activation of the G380R mutant receptor are predominantly ligand dependent."

Direct receptor experiments qualify strict constitutive-activation shorthand.

PMID:10611230 SUPPORT In Vitro

"Metabolic pulse-chase experiments, cell surface labeling, and kinetics of uptake of radiolabeled ligand demonstrated a selective delay in the down-regulation of the mutant receptor."

Direct experiments identify delayed receptor down-regulation.

PMID:20624921 SUPPORT In Vitro

"The data analysis presented here suggests that the mutation does not increase FGFR3 dimerization, as proposed previously. Instead, FGFR3 activity in achondroplasia is increased due to increased probability for phosphorylation of the unliganded mutant dimers."

Quantitative receptor-activation measurements attribute the gain of function to a higher phosphorylation probability within unliganded dimers rather than to increased dimerization, independently supporting the entry's decision not to assert strict constitutive activation.

+ 1 more reference

Discussions and Knowledge Gaps

What mechanism links FGFR3 p.Gly380Arg to macrocephaly and the calvarial and upper-facial features (frontal bossing, prominent forehead, parietal bossing, wide anterior fontanel, anteverted nares)?

KNOWLEDGE GAP OPEN ach_calvarial_vault_feature_mechanism

Attached to

phenotypes#Macrocephaly phenotypes#Frontal bossing phenotypes#Prominent forehead phenotypes#Parietal bossing phenotypes#Wide anterior fontanel phenotypes#Anteverted nares

These features are well documented, but the cited sources provide descriptive or association-level statements only. Proposed contributors include relative sparing of membranous calvarial growth against a restricted endochondral skull base, markedly delayed sutural closure, frontal-bone ossification delay (raised as a possibility in the craniofacial 3D study), and, for macrocephaly, brain and CSF-compartment factors related to venous outflow. None is established as the causal route in ordinary heterozygous achondroplasia, so no causal edge is asserted for these phenotypes.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"Sutural closure is markedly delayed (as evidenced by anterior fontanelle closure as late as age 5-6 years)."

Documents the delayed membranous sutural closure that is a candidate contributor to the calvarial phenotype without stating a causal route.

By what mechanism does FGFR3 gain of function produce infantile hypotonia and generalized joint hypermobility, and through them thoracolumbar kyphosis?

KNOWLEDGE GAP OPEN ach_hypotonia_joint_laxity_mechanism

Attached to

phenotypes#Floppy infant phenotypes#Knee joint hypermobility phenotypes#Hip joint hypermobility phenotypes#Thoracolumbar kyphosis

Hypotonia and generalized joint laxity are documented proximate contributors to motor delay and dynamic knee instability, and infantile thoracolumbar kyphosis is managed clinically as a consequence of truncal hypotonia during unsupported sitting, usually resolving as trunk strength increases and walking begins. No cited source establishes how FGFR3 gain of function produces the hypotonia or the ligamentous laxity (candidate contributors include craniocervical compression for hypotonia), so no causal edge is asserted for these phenotypes.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"This results in delayed acquisition of gross motor skills and dynamic knee varus in some children"

Documents childhood joint hypermobility as a proximate contributor to motor delay while leaving its own mechanism unexplained.

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"Kyphosis improves significantly or resolves in the majority of children upon assuming an orthograde posture and beginning to walk"

Supports the postural, trunk-strength-dependent behavior of infantile thoracolumbar kyphosis.

Why is obesity so prevalent from early childhood in achondroplasia, beyond reduced stature-adjusted caloric needs?

KNOWLEDGE GAP OPEN ach_obesity_mechanism

Attached to

phenotypes#Obesity

Obesity begins in early childhood and is prevalent at all ages, and caloric needs are reduced, but no cited source establishes a mechanistic route from FGFR3 gain of function to the energy-balance phenotype. Wiring obesity through the skeletal growth-plate nodes would manufacture a causal claim, so the phenotype is deliberately left without a causal edge.

Is acanthosis nigricans in achondroplasia driven directly by FGFR3 activation in epidermal keratinocytes, as in other FGFR3-activating disorders, rather than by insulin resistance?

KNOWLEDGE GAP OPEN ach_acanthosis_nigricans_mechanism

Attached to

phenotypes#Acanthosis nigricans

Acanthosis nigricans recurs across the FGFR3-activating disorder family (SADDAN, thanatophoric dysplasia, Crouzon syndrome with acanthosis nigricans, familial acanthosis nigricans), suggesting direct receptor activation in skin. Direct evidence in ordinary heterozygous achondroplasia is not present in the cited sources, and the skeletal growth-plate nodes would be the wrong upstream route regardless, so the phenotype is left without a causal edge.

Which achondroplasia features depend on the MAPK arm, which on the STAT1 arm, and what weight should the p38 branch carry, given that the only approved and late-stage drugs act on one arm?

KNOWLEDGE GAP OPEN ach_signaling_arm_attribution

Attached to

pathophysiology#Prolonged FGFR3 signaling in growth-plate chondrocytes pathophysiology#CNP-NPR2 counter-regulation of FGFR3-MAPK signaling

Mouse genetics separates the arms — CNP overexpression corrects matrix synthesis through MAPK without touching STAT1, constitutively active MEK1 causes Stat1-independent dwarfism — and a CDK8 inhibitor now moves the STAT1-Ser727 branch in a mouse model without affecting MAPK activation. No study has tested the two interventions together, and no human data assign specific clinical features to specific arms; the vosoritide result is consistent with the model but does not rank the arms against each other. A third, p38 branch is proposed on the strength of a single ATDC5 cell-line study and is not curated as a pathophysiology node here for that reason.

Proposed experiments

Combined CNP-analogue and CDK8-inhibitor treatment in a humanized knock-in model

ach_cnp_analogue_plus_cdk8_inhibition

Treat humanized FGFR3 p.Gly380Arg knock-in mice with a CNP analogue alone, a CDK8 inhibitor alone, both together, and vehicle, then compare long-bone length, growth-plate zone architecture, and phospho-STAT1 Ser727 versus phospho-ERK in the growth plate.

Perturbations

CNP-analogue treatment

pathophysiology#CNP-NPR2 counter-regulation of FGFR3-MAPK signaling

Activates the counter-regulatory branch that brakes MAPK output.

CDK8 inhibition

pathophysiology#Growth-plate chondrocyte dysregulation

Targets the STAT1-Ser727 arm reported to act independently of MAPK.

Readouts

Long-bone length and growth-plate zone architecture

pathophysiology#Impaired endochondral ossification and chondrodysplasia

Direction: RESTORED

Interpretation: A more-than-additive effect of the two agents would indicate that the arms contribute separably to the growth deficit.

Controls

Vehicle-treated knock-in littermates

Untreated disease-model arm establishing the untreated growth trajectory.

Wild-type littermates

Isogenic unaffected comparator for growth-plate architecture.

Single-agent arms

Each agent given alone, so that any combined effect can be judged against the better single agent rather than against vehicle.

Decision criterion

Whether combined treatment exceeds the better single agent on long-bone length while each agent moves only its own phospho-marker.

Would support

pathophysiology#Growth-plate chondrocyte dysregulation

Supporting outcome

Combined treatment produces greater long-bone elongation than either agent alone, with each agent reducing only its own phospho-readout, establishing that the two arms contribute separably.

Refuting outcome

Combined treatment matches the better single agent, indicating the arms converge on a shared limiting step rather than acting separably.

Corresponds to gap KG-1 in the OpenScientist report for this hypothesis.

Show evidence (2 references)

PMID:39674288 SUPPORT Model Organism

"The CDK8 expression and STAT1Ser727 phosphorylation were upregulated in chondrocytes isolated from ACH model mice, and KY-065 repressed its phosphorylation and restored normal chondrogenic differentiation without affecting MAPK activation."

Establishes that the STAT1 arm is separately druggable in a mouse model without engaging MAPK, which is what makes the arm-attribution question experimentally answerable.

PMID:40373614 SUPPORT In Vitro

"These results suggest that TACC3 might play a role through the p38 signaling pathway in chondrocyte differentiation defects caused by FGFR3 mutations."

The whole current basis for a p38 branch is this ATDC5 cell-line result, whose authors state it only as a suggestion; it is recorded here rather than curated as an established signaling arm.

How much of the human growth-plate phenotype is attributable to the ciliary branch, as opposed to the direct MAPK and STAT arms it lies downstream of?

KNOWLEDGE GAP OPEN ach_ciliary_contribution_unquantified

Attached to

pathophysiology#Primary cilium shortening and disrupted ciliary signaling

Cilium shortening and IFT20 mis-sorting are reproducible in chondrocytes from human achondroplasia and thanatophoric dysplasia cartilage and in mouse models, and a ciliogenesis-restoring compound increases bone elongation in the mouse. What has not been done is a measurement that separates the ciliary contribution from the receptor's direct signaling output: every available intervention acts upstream of both, and the rescue compound is not cilia-selective. Until such an experiment exists, the "achondroplasia is a ciliopathy" reading found in the source literature is an interpretive proposal rather than an established classification, and this entry curates the branch without adopting that label.

Corresponds to gap KG-3 in the OpenScientist report for this hypothesis.

Show evidence (1 reference)

PMID:35078974 SUPPORT Model Organism

"Transcriptomic analysis in an Fgfr3 mouse model showed that ciliary mRNA expression was modified and influenced significantly by the Indian hedgehog and PKA pathways."

Shows the ciliary program is transcriptionally entangled with hedgehog and PKA signaling in the model, which is why an intervention that restores ciliogenesis does not isolate a ciliary contribution.

If statins do not act on FGFR signaling in cartilage, what mechanism accounts for the previously reported statin rescue of FGFR3-related chondrodysplasia?

KNOWLEDGE GAP OPEN ach_statin_rescue_mechanism_unresolved

Attached to

pathophysiology#Prolonged FGFR3 signaling in growth-plate chondrocytes treatments#

A dedicated study found no effect of four statins on FGFR3 protein levels or on FGFR-mediated growth arrest, matrix loss, senescence, or hypertrophic differentiation across chondrocyte lines, embryonic tibia cultures, and limb-bud micromasses. That result narrows the earlier rescue reports: it rules out a chondrocyte-intrinsic FGFR mechanism, but it does not exclude an indirect or systemic effect, so statins are recorded here as an unresolved question rather than as a refuted therapy outright. No statin treatment entry is curated for this disease.

Corresponds to gap KG-7 in the OpenScientist report for this hypothesis.

Show evidence (1 reference)

PMID:28583899 SUPPORT In Vitro

"We conclude that statins do not inhibit the FGFR signaling in chondrocytes. Therefore the statin-mediated rescue of FGFR3-related chondrodysplasia, described before, is likely not intrinsic to the growth plate cartilage."

The authors state both halves of the gap: the chondrocyte-intrinsic FGFR mechanism is excluded, and the mechanism behind the earlier rescue is left open.

⚙

Pathophysiology

FGFR3 p.Gly380Arg gain-of-function with impaired receptor down-regulation

Nearly all individuals have one of two substitutions producing p.Gly380Arg. The receptor is gain of function, but experiments show predominantly ligand-dependent activation with delayed down-regulation and resistance to ligand-mediated internalization.

FGFR3 Growth-Plate Signaling Model

FGFR3 hgnc:3690

fibroblast growth factor receptor signaling pathway GO:0008543 ↑ INCREASED

transmembrane receptor protein tyrosine kinase activity GO:0004714 ↑ INCREASED

Downstream

Prolonged FGFR3 signaling in growth-plate chondrocytes Delayed down-regulation expands mutant-receptor signaling in growth plate.

Show evidence (4 references)

PMID:7847369 SUPPORT Human Clinical

"All but one, an atypical case, were found to have a glycine-to-arginine substitution at codon 380. Of these, 150 had a G-to-A transition at nt 1138, and 3 had a G-to-C transversion at this same position."

A 154-person series demonstrates the near-uniform recurrent p.Gly380Arg genotype.

PMID:10611230 SUPPORT In Vitro

"Moreover, this receptor was now resistant to ligand-mediated internalization, even at saturating ligand concentrations."

Directly supports impaired internalization.

CGGV:assertion_0adafa1b-e609-4b99-8e90-f73473b70771-2023-09-28T040000.000Z SUPPORT Other

ClinGen classifies the autosomal-dominant FGFR3 relationship as definitive.

+ 1 more reference

Prolonged FGFR3 signaling in growth-plate chondrocytes

Delayed internalization expands mutant FGFR3 immunoreactivity in epiphyseal growth plates, where signal kinetics regulate chondrocyte maturation.

FGFR3 Growth-Plate Signaling Model

growth plate cartilage chondrocyte CL:1000217

MAPK cascade GO:0000165 ↑ INCREASED ERK1 and ERK2 cascade GO:0070371 ↑ INCREASED cell surface receptor signaling pathway via STAT GO:0097696 ↑ INCREASED

Downstream

Growth-plate chondrocyte dysregulation Prolonged signaling engages MAPK and STAT-p21 growth-inhibitory programs.

Primary cilium shortening and disrupted ciliary signaling Sustained receptor activity shortens the chondrocyte primary cilium and misroutes IFT20; pharmacologic FGFR inhibition restores both, placing the ciliary change downstream of receptor activation.

Show evidence (1 reference)

PMID:10611230 SUPPORT Model Organism

"transgenic mice expressing the human G380R mutant receptor under the mouse receptor transcriptional control demonstrated a markedly expanded area of FGFR3 immunoreactivity within their epiphyseal growth plates, compatible with an in vivo defect in receptor down-regulation."

Transgenic mice provide in vivo evidence for expanded receptor persistence.

Primary cilium shortening and disrupted ciliary signaling

Sustained FGFR3 activity shortens the chondrocyte primary cilium and disrupts sorting and intraflagellar transport of IFT20, with downstream change in cilium-based Hedgehog signaling. This branch is curated as an emerging consequence of receptor activation, not as an independent cause: its quantitative contribution relative to the direct MAPK and STAT arms has not been isolated in human growth plate, and the entry does not classify achondroplasia as a ciliopathy on this evidence.

FGFR3 Growth-Plate Signaling Model

growth plate cartilage chondrocyte CL:1000217

cilium assembly GO:0060271 ↕ DYSREGULATED intraciliary transport GO:0042073 ↕ DYSREGULATED smoothened signaling pathway GO:0007224 ↕ DYSREGULATED

Downstream

Growth-plate chondrocyte dysregulation Restoring ciliary organization pharmacologically increases bone elongation in a mouse model, supporting a contributory route from the ciliary defect back to growth-plate dysfunction.

Show evidence (2 references)

PMID:29040558 SUPPORT In Vitro

"Here we showed that in chondrocytes from human (ACH, TD) and mouse Fgfr3Y367C/+ cartilage, the constitutively active FGFR3 perturbed PC length and the sorting and trafficking of intraflagellar transport (IFT) 20 to the PC."

Chondrocytes taken from human achondroplasia and thanatophoric dysplasia cartilage, alongside a mouse model, show the ciliary length and IFT20 trafficking defect.

PMID:29360984 SUPPORT Model Organism

"Here, we report in vivo evidence for significantly shortened primary cilia in ACH and TD cartilage growth plates."

Supplies the in vivo growth-plate measurement of cilium shortening. The achondroplasia arm of this experiment is an Fgfr3 p.Gly369Cys mouse and the thanatophoric arm is a transfected cell line, so it is graded as model-organism evidence despite the title's ciliopathy framing.

Growth-plate chondrocyte dysregulation

MAPK inhibits hypertrophic differentiation in models. Human fetal growth plates support altered FGFR3/STAT/p21 expression and premature cell-cycle exit. STAT1 is not treated as sufficient to explain all growth inhibition.

FGFR3 Growth-Plate Signaling Model

growth plate cartilage chondrocyte CL:1000217 prehypertrophic chondrocyte CL:0020022

MAPK cascade GO:0000165 ↑ INCREASED chondrocyte differentiation GO:0002062 ↕ DYSREGULATED cell population proliferation GO:0008283 ↓ DECREASED

Downstream

Impaired endochondral ossification and chondrodysplasia Dysregulated growth-plate maturation impairs endochondral bone growth.

Show evidence (2 references)

PMID:14871928 SUPPORT Model Organism

"These observations indicate that the MAPK pathway inhibits hypertrophic differentiation of chondrocytes and negatively regulates bone growth without inhibiting chondrocyte proliferation."

Active MEK1 supports inhibition of hypertrophic differentiation by MAPK.

PMID:14751560 SUPPORT Human Clinical

"Immunohistochemical analysis of fetal growth plates showed a phenotype-related reduction of the collagen type X-positive hypertrophic zone."

Human fetal histology documents a reduced hypertrophic zone.

Impaired endochondral ossification and chondrodysplasia

Altered growth-plate maturation reduces the hypertrophic zone and impairs endochondral ossification. Anatomical consequences are represented through calibrated branches rather than an unsupported all-phenotype fan-out.

FGFR3 Growth-Plate Signaling Model

hypertrophic chondrocyte CL:0000743 columnar chondrocyte CL:0000744

endochondral ossification GO:0001958 ↓ DECREASED growth plate cartilage development GO:0003417 ↕ DYSREGULATED

Animal models

Humanized FGFR3 p.Gly380Arg knock-in mouse Mouse recapitulates The model carries the human disease allele at the endogenous locus and develops the skeletal phenotype the node describes.

Downstream

Reduced longitudinal growth of endochondral bones Impaired hypertrophic differentiation reduces longitudinal growth.

Cranial-base and vertebral synchondrosis dysplasia The endochondral process affects synchondroses, but ordinary-heterozygous causal evidence is incomplete.

Congenital spinal-canal constraint with superimposed degeneration Impaired vertebral growth plausibly contributes to congenital constraint; adult degeneration adds a second component.

Elbow contracture Elbow contractures are observed during childhood in the chondrodysplasia; the specific growth-plate route to the joint restriction is not established by the cited source.

Radial head dislocation Radial head dislocation is observed during childhood in the chondrodysplasia; the specific route through elbow joint dysplasia is not established by the cited source.

Limited elbow extension Limitation of elbow extension is part of the characteristic skeletal pattern of the chondrodysplasia; the specific articular mechanism is not established by the cited source.

Thoracic hypoplasia The ribs and thoracic vertebral elements grow by endochondral ossification and a small chest is part of the skeletal phenotype; the cited source documents the finding rather than the specific growth-plate route.

Restrictive ventilatory defect A small, hypercompliant thoracic cage reduces lung volumes, producing restrictive pulmonary physiology in a subset of infants.

Bowing of the legs Lower-limb bowing overlaps clinically with genu varum; the specific growth-plate route is not established by the cited source.

Show evidence (1 reference)

DOI:10.1038/s41574-021-00595-x SUPPORT Other

"This mutation leads to impaired endochondral ossification of the human skeleton."

International consensus identifies the central consequence.

Reduced longitudinal growth of endochondral bones

Reduced long-bone growth produces disproportionate short stature, rhizomelic limb shortening, and characteristic hand shortening.

FGFR3 Growth-Plate Signaling Model

Downstream

Disproportionate short stature Reduced longitudinal growth produces disproportionate stature.

Rhizomelia Proximal long-bone undergrowth produces rhizomelia.

Limb undergrowth Reduced longitudinal growth is expressed as limb undergrowth.

Brachydactyly Shortening of endochondral hand bones produces brachydactyly.

Trident hand Hand-bone shortening contributes to the trident configuration.

Short middle phalanx of finger Shortening of the endochondral hand bones includes the middle phalanges, a component of the brachydactyly and trident-hand pattern.

Short proximal phalanx of finger Shortening of the endochondral hand bones includes the proximal phalanges, a component of the brachydactyly and trident-hand pattern.

Delayed gross motor development The disproportionate body habitus alters the biomechanics of early motor skills and head support. Infantile hypotonia and joint hypermobility, which are documented but not themselves mechanistically explained, add to the delay (see the associated knowledge-gap discussion).

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"Individuals with achondroplasia have short stature with rhizomelic shortening of the limbs, macrocephaly, characteristic facies with frontal bossing and midface retrusion, exaggerated lumbar lordosis, limitation of elbow extension and rotation, genu varum, brachydactyly, and trident appearance..."

The current review documents the characteristic pattern.

Cranial-base and vertebral synchondrosis dysplasia

FGFR3-MAPK activation promotes premature closure in models and severe human FGFR3 dysplasias. CT in heterozygous achondroplasia documents skull-base fusion and age-associated craniofacial severity.

FGFR3 Growth-Plate Signaling Model

growth plate cartilage chondrocyte CL:1000217

Downstream

Foramen magnum stenosis Skull-base growth restriction contributes to narrowing.

Jugular-foramen venous outflow impairment Skull-base undergrowth can narrow jugular foramina.

Craniofacial and upper-airway restriction Premature skull-base synchondrosis fusion restricts anteroposterior facial growth, producing maxillary and midfacial retrusion; imaging associations corroborate coupled skull-base and midface severity.

Depressed nasal bridge Nasal-root depression at the nasofrontal junction is associated with the restricted anteroposterior skull-base growth; the cited source reports the association rather than a resolved causal route.

Cervical myelopathy The stenotic foramen magnum compresses the cervicomedullary cord; constriction severity predicts myelopathy in screened young children.

Central sleep apnea Craniocervical-junction compression can injure medullary respiratory control centers, producing the central apnea component of sleep-disordered breathing in infancy; this edge covers the compression-associated component rather than all central apnea.

Caudal interpedicular narrowing Vertebral dysplasia is associated with the caudal interpedicular pattern.

Show evidence (2 references)

PMID:18923003 SUPPORT Model Organism

"Chondrocyte-specific activation of Fgfr3 in mice induced premature synchondrosis closure and enhanced osteoblast differentiation around synchondroses."

Chondrocyte-specific activation establishes a causal model mechanism.

PMID:37072824 SUPPORT Human Clinical

"All patients with available CT-scan had premature fusion of skull base synchondroses."

CT documents skull-base fusion in a clinical cohort.

Jugular-foramen venous outflow impairment

Narrow jugular foramina can obstruct cerebral venous drainage, increasing venous pressure and impairing cerebrospinal-fluid resorption.

FGFR3 Growth-Plate Signaling Model

Downstream

Hydrocephalus Venous hypertension and impaired CSF resorption can produce hydrocephalus.

Show evidence (1 reference)

PMID:33579320 SUPPORT Human Clinical

"This condition causes a partial obstruction of venous flow, which increases intracranial venous pressure and causes problems with the venous resorption of cerebrospinal fluid (CSF)"

The study states the venous and CSF-resorption mechanism.

Craniofacial and upper-airway restriction

Midface and maxillomandibular retrusion reduce upper-airway dimensions; lymphoid hypertrophy, airway malacia, and hypotonia can add obstruction. The same midface hypoplasia shortens the Eustachian tubes and narrows the nasopharynx, predisposing to chronic middle-ear effusion and its conductive-hearing consequences.

FGFR3 Growth-Plate Signaling Model

Downstream

Midface retrusion Midface retrusion is an anatomical component of restriction.

Obstructive sleep apnea Midface retrusion reduces airway size, and lymphoid hypertrophy, airway malacia, and airway hypotonia combine with it to produce obstruction; retrusion severity correlates with apnea severity.

Functional abnormality of the middle ear Midface hypoplasia with short Eustachian tubes and a small pharynx predisposes to recurrent upper-airway infection and impaired middle-ear ventilation.

Otitis media with effusion Eustachian-tube dysfunction from the craniofacial anatomy produces chronic middle-ear effusion.

Conductive hearing impairment Chronic middle-ear effusion from Eustachian-tube dysfunction impairs sound conduction, producing the predominantly conductive hearing loss of achondroplasia.

Delayed speech and language development Conductive hearing loss during the language-acquisition window contributes to speech and language delay; oral motor hypotonia is a documented co-contributor that is not itself mechanistically explained.

Show evidence (1 reference)

PMID:37072824 SUPPORT Human Clinical

"We report a significant correlation between the severity of maxillo-mandibular retrusion and obstructive sleep apnea syndrome (p < 0.01)."

Clinical morphometry links retrusion with obstructive sleep apnea.

Congenital spinal-canal constraint with superimposed degeneration

Altered vertebral geometry constrains the canal; disc degeneration and sagittal deformity add to adult upper-lumbar narrowing.

FGFR3 Growth-Plate Signaling Model

Downstream

Spinal canal stenosis Congenital constraint and degeneration produce recognized stenosis.

Cervical spinal canal stenosis The congenital component can affect the cervical canal.

Show evidence (1 reference)

PMID:32170149 SUPPORT Human Clinical

"Unlike the general population, spinal stenosis and disc degeneration involve the upper part of the lumbar spine in adults with achondroplasia, associated with thoraco-lumbar kyphosis and loss of lumbar lordosis."

Adult imaging supports combined stenotic and degenerative components.

CNP-NPR2 counter-regulation of FGFR3-MAPK signaling

CNP signaling through NPR2/GC-B counteracts FGFR3-MAPK activity. CNP corrected matrix synthesis and bone shortening in a mouse model without correcting the STAT1 branch.

growth plate cartilage chondrocyte CL:1000217

receptor guanylyl cyclase signaling pathway GO:0007168 MAPK cascade GO:0000165 ↓ DECREASED

Show evidence (2 references)

PMID:14702637 SUPPORT Model Organism

"CNP prevented the shortening of achondroplastic bones by correcting the decreased extracellular matrix synthesis in the growth plate through inhibition of the MAPK pathway of FGF signaling."

Mouse data support CNP counter-regulation of MAPK.

PMID:14702637 SUPPORT Model Organism

"CNP had no effect on the STAT-1 pathway of FGF signaling that mediates the decreased proliferation and the delayed differentiation of achondroplastic chondrocytes."

The model defines the limitation on the STAT1 branch.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Ear 3

Functional abnormality of the middle ear FREQUENT HP:0011452

Show evidence (2 references)

PMID:29972438 SUPPORT Human Clinical

"The most common clinical intercurrences were middle ear dysfunction, sleep apnea, limb pain and obesity from 2 to 9 years of age."

Natural-history cohort lists middle-ear dysfunction among the most common childhood clinical intercurrences.

ORPHA:15 SUPPORT Other

"HP:0011452 | Functional abnormality of the middle ear | Frequent (79-30%)"

Orphanet classifies functional abnormality of the middle ear as frequent in achondroplasia.

Otitis media with effusion HP:0031353

Show evidence (1 reference)

PMID:39660705 SUPPORT Human Clinical

"Fifty-one patients (72.9%) had middle ear effusion at least once."

Multicenter otology cohort shows otitis media with effusion in most evaluated patients.

Conductive hearing impairment HP:0000405

Show evidence (3 references)

PMID:39660705 SUPPORT Human Clinical

"Among 53 patients who underwent audiometry, 26 showed conductive hearing loss, 2 had mixed-type hearing loss, and 4 had sensorineural hearing loss."

Pediatric multicenter cohort shows that hearing loss in achondroplasia is usually conductive or mixed.

PMID:34736503 SUPPORT Human Clinical

"The majority (15/24) had conductive hearing loss, or a combination of conductive and sensorineural hearing loss (8/24)."

Adult population-based cohort shows conductive or mixed hearing loss remains common beyond childhood.

ORPHA:15 SUPPORT Other

"HP:0000365 | Hearing impairment | Frequent (79-30%)"

Orphanet supports frequent hearing impairment generally; the conductive subtype is established by the cohort evidence above.

Head and Neck 9

Macrocephaly FREQUENT HP:0000256

Show evidence (2 references)

PMID:29972438 SUPPORT Human Clinical

"The most prevalent clinical findings were short stature, high forehead, trident hands, genu varum and macrocephaly."

Clinical cohort data identify macrocephaly as one of the most prevalent physical findings.

ORPHA:15 SUPPORT Other

"HP:0000256 | Macrocephaly | Frequent (79-30%)"

Orphanet classifies macrocephaly as frequent in achondroplasia.

Parietal bossing FREQUENT HP:0000242

Show evidence (1 reference)

ORPHA:15 SUPPORT Other

"HP:0000242 | Parietal bossing | Frequent (79-30%)"

Orphanet classifies parietal bossing as frequent in achondroplasia.

Wide anterior fontanel OCCASIONAL HP:0000260

Show evidence (1 reference)

ORPHA:15 SUPPORT Other

"HP:0000260 | Wide anterior fontanel | Occasional (29-5%)"

Orphanet classifies wide anterior fontanel as occasional in achondroplasia.

Prominent forehead HP:0011220

Show evidence (1 reference)

PMID:37072824 SUPPORT Human Clinical

"Craniofacial phenotype was characterized by maxillo-zygomatic retrusion, deep nasal root, and prominent forehead."

Multimodal craniofacial study directly documents prominent forehead in pediatric achondroplasia.

Midface retrusion HP:0011800

Show evidence (1 reference)

PMID:37072824 SUPPORT Human Clinical

"Craniofacial phenotype was characterized by maxillo-zygomatic retrusion, deep nasal root, and prominent forehead."

Maxillo-zygomatic retrusion directly supports midface retrusion as a core craniofacial phenotype.

Anteverted nares FREQUENT HP:0000463

Show evidence (1 reference)

ORPHA:15 SUPPORT Other

"HP:0000463 | Anteverted nares | Frequent (79-30%)"

Orphanet classifies anteverted nares as frequent in achondroplasia.

Foramen magnum stenosis Small foramen magnum HP:0002677

Show evidence (2 references)

PMID:32883660 SUPPORT Human Clinical

"Of 36 infants (M:F, 18:18), 2 (5.6%) did not have FMS (AFMS0); 13 (36.1%) had FMS with preservation of the cerebrospinal fluid (CSF) spaces (AFMS1); 3 (8.3%) had FMS with loss of the CSF space but no spinal cord distortion (AFMS2); 13 (36.1%) had FMS with flattening of the cervical cord without..."

Infant MRI cohort shows that most screened infants had foramen magnum stenosis, including many with cord flattening or signal change.

PMID:38554024 SUPPORT Human Clinical

"All patients were monitored by magnetic resonance imaging; 73.0% had foramen magnum stenosis, while 54.1% had Achondroplasia Foramen Magnum Score 3 or 4."

Independent pediatric cohort confirms that foramen magnum stenosis is a frequent early complication.

Depressed nasal bridge FREQUENT HP:0005280

Show evidence (1 reference)

ORPHA:15 SUPPORT Other

"HP:0005280 | Depressed nasal bridge | Frequent (79-30%)"

Orphanet classifies depressed nasal bridge as frequent in achondroplasia.

Frontal bossing FREQUENT HP:0002007

Show evidence (1 reference)

ORPHA:15 SUPPORT Other

"HP:0002007 | Frontal bossing | Frequent (79-30%)"

Orphanet classifies frontal bossing as frequent in achondroplasia.

Integument 1

Acanthosis nigricans OCCASIONAL HP:0000956

Show evidence (2 references)

ORPHA:15 SUPPORT Other

"HP:0000956 | Acanthosis nigricans | Occasional (29-5%)"

Orphanet classifies acanthosis nigricans as occasional in achondroplasia.

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"may be seen in about 10% of individuals with achondroplasia"

The 2026 clinical review supports a peripheral association while not placing it in the core skeletal mechanism graph.

Limbs 10

Trident hand FREQUENT HP:0004060

Show evidence (2 references)

PMID:29972438 SUPPORT Human Clinical

"The most prevalent clinical findings were short stature, high forehead, trident hands, genu varum and macrocephaly."

Clinical cohort data identify trident hands as one of the most prevalent physical findings.

ORPHA:15 SUPPORT Other

"HP:0004060 | Trident hand | Frequent (79-30%)"

Orphanet classifies trident hand as frequent in achondroplasia.

Bowing of the legs VERY_FREQUENT HP:0002979

Onset: CHILDHOOD

Show evidence (4 references)

PMID:29972438 SUPPORT Human Clinical

"The most prevalent clinical findings were short stature, high forehead, trident hands, genu varum and macrocephaly."

Clinical cohort data identify lower-limb deformity (including genu varum) as one of the most prevalent physical findings.

ORPHA:15 SUPPORT Other

"HP:0002979 | Bowing of the legs | Very frequent (99-80%)"

Orphanet classifies bowing of the legs as very frequent in achondroplasia.

PMID:32864841 SUPPORT Human Clinical

"genu varum, elbow contractures, and radial head dislocations were identified during childhood"

Chart-review cohort places recognition of genu varum in childhood, preserving the onset nuance of the merged entry.

+ 1 more reference

Radial head dislocation Dislocated radial head HP:0003083

Show evidence (1 reference)

PMID:32864841 SUPPORT Human Clinical

"Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."

Longitudinal chart review identifies radial head dislocation as a childhood orthopedic phenotype.

Brachydactyly FREQUENT HP:0001156

Show evidence (1 reference)

ORPHA:15 SUPPORT Other

"HP:0001156 | Brachydactyly | Frequent (79-30%)"

Orphanet classifies brachydactyly as frequent in achondroplasia.

Short middle phalanx of finger FREQUENT HP:0005819

Show evidence (1 reference)

ORPHA:15 SUPPORT Other

"HP:0005819 | Short middle phalanx of finger | Frequent (79-30%)"

Orphanet classifies short middle phalanx of finger as frequent in achondroplasia.

Short proximal phalanx of finger FREQUENT HP:0010241

Show evidence (1 reference)

ORPHA:15 SUPPORT Other

"HP:0010241 | Short proximal phalanx of finger | Frequent (79-30%)"

Orphanet classifies short proximal phalanx of finger as frequent in achondroplasia.

Limited elbow extension FREQUENT HP:0001377

Show evidence (1 reference)

ORPHA:15 SUPPORT Other

"HP:0001377 | Limited elbow extension | Frequent (79-30%)"

Orphanet classifies limited elbow extension as frequent in achondroplasia.

Knee joint hypermobility FREQUENT HP:0045086

Show evidence (2 references)

ORPHA:15 SUPPORT Other

"HP:0045086 | Knee joint hypermobility | Frequent (79-30%)"

Orphanet classifies knee joint hypermobility as frequent in achondroplasia.

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"Excess mobility of the knees, hips, and most other joints is common"

The clinical review documents knee hypermobility within the common generalized joint laxity.

Hip joint hypermobility FREQUENT HP:0045087

Show evidence (2 references)

ORPHA:15 SUPPORT Other

"HP:0045087 | Hip joint hypermobility | Frequent (79-30%)"

Orphanet classifies hip joint hypermobility as frequent in achondroplasia.

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"Excess mobility of the knees, hips, and most other joints is common"

The clinical review documents hip hypermobility within the common generalized joint laxity.

Limb undergrowth VERY_FREQUENT HP:0009826

Show evidence (1 reference)

ORPHA:15 SUPPORT Other

"HP:0009826 | Limb undergrowth | Very frequent (99-80%)"

Orphanet classifies limb undergrowth as very frequent in achondroplasia.

Musculoskeletal 9

Thoracolumbar kyphosis VERY_FREQUENT HP:0005619

Show evidence (3 references)

PMID:37493935 SUPPORT Human Clinical

"Thoracolumbar kyphosis (TLK) is common in children with achondroplasia and resolves in 90% by 10 years of age."

Supports both childhood onset and the usual tendency toward spontaneous improvement by age 10.

PMID:27927547 SUPPORT Human Clinical

"Thoracolumbar kyphosis was observed in 79%, with 52% exhibiting moderate to severe curvature."

Large orthopedic cohort documents thoracolumbar kyphosis as a common spinal phenotype.

ORPHA:15 SUPPORT Other

"HP:0005619 | Thoracolumbar kyphosis | Very frequent (99-80%)"

Orphanet classifies thoracolumbar kyphosis as very frequent in achondroplasia.

Scoliosis HP:0002650

Show evidence (1 reference)

PMID:27927547 SUPPORT Human Clinical

"Scoliosis was observed in 60%."

An orthopedic cohort documents scoliosis in 60% of its selected patient population.

Spinal canal stenosis FREQUENT HP:0003416

Show evidence (3 references)

PMID:32864841 SUPPORT Human Clinical

"Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."

Longitudinal chart review supports spinal stenosis as a cross-lifespan complication affecting both cervical and lumbar regions.

PMID:32170149 SUPPORT Human Clinical

Adult imaging study refines the adult lumbar phenotype by showing upper-lumbar predominance with associated degenerative change.

ORPHA:15 SUPPORT Other

"HP:0003416 | Spinal canal stenosis | Frequent (79-30%)"

Orphanet classifies spinal canal stenosis as frequent in achondroplasia.

Cervical spinal canal stenosis FREQUENT HP:0008445

Show evidence (2 references)

PMID:32864841 SUPPORT Human Clinical

"Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."

Longitudinal chart review explicitly reports cervical stenosis in affected patients.

ORPHA:15 SUPPORT Other

"HP:0008445 | Cervical spinal canal stenosis | Frequent (79-30%)"

Orphanet classifies cervical spinal canal stenosis as frequent in achondroplasia.

Elbow contracture HP:0034391

Show evidence (1 reference)

PMID:32864841 SUPPORT Human Clinical

"Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."

Longitudinal chart review identifies elbow contractures as a childhood orthopedic phenotype.

Lumbar hyperlordosis FREQUENT HP:0002938

Show evidence (2 references)

ORPHA:15 SUPPORT Other

"HP:0002938 | Lumbar hyperlordosis | Frequent (79-30%)"

Orphanet classifies lumbar hyperlordosis as frequent in achondroplasia.

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"Exaggerated lumbar lordosis, which develops when walking begins"

The clinical review adds the onset context, with hyperlordosis emerging when independent walking starts.

Floppy infant FREQUENT HP:0008947

Show evidence (1 reference)

ORPHA:15 SUPPORT Other

"HP:0008947 | Floppy infant | Frequent (79-30%)"

Orphanet lists floppy infant as frequent in achondroplasia, supporting infantile muscular hypotonia.

Thoracic hypoplasia OCCASIONAL HP:0005257

Show evidence (1 reference)

ORPHA:15 SUPPORT Other

"HP:0005257 | Thoracic hypoplasia | Occasional (29-5%)"

Orphanet classifies thoracic hypoplasia as occasional in achondroplasia.

Caudal interpedicular narrowing HP:0008457

Show evidence (1 reference)

PMID:29972438 SUPPORT Human Clinical

"The most prevalent radiographic findings were rhizomelic shortening of the long bones and narrowing of the interpediculate distance of the caudal spine."

Natural-history cohort identifies caudal interpedicular narrowing as one of the most prevalent radiographic findings in achondroplasia.

Nervous System 6

Obstructive sleep apnea FREQUENT HP:0002870

Show evidence (5 references)

PMID:40675782 SUPPORT Human Clinical

"Sleep-disordered breathing subtypes included obstructive sleep apnoea in 81% (55/68), central sleep apnoea in 3% (2/68), mixed sleep apnoea in 7% (5/68) and primary snoring in 9% (6/68)."

In a pediatric polysomnography cohort, 55 of 80 children had obstructive sleep apnoea and 5 additional children had mixed apnoea with an obstructive component.

PMID:40675782 SUPPORT Human Clinical

"A total of 85% (68/80) had sleep-disordered breathing and 21% reported no prior symptoms."

Pediatric polysomnography data show that sleep-disordered breathing can be clinically silent before screening.

PMID:32864841 SUPPORT Human Clinical

"Central sleep apnea and obstructive sleep apnea were present in children, while the diagnosis of obstructive sleep apnea was shown to recur in adulthood."

Longitudinal review supports both childhood occurrence and adult recurrence of obstructive sleep apnea.

+ 2 more references

Central sleep apnea HP:0010536

Show evidence (2 references)

PMID:32864841 SUPPORT Human Clinical

"Central sleep apnea and obstructive sleep apnea were present in children, while the diagnosis of obstructive sleep apnea was shown to recur in adulthood."

Longitudinal natural-history data explicitly document central sleep apnea in children with achondroplasia.

PMID:40675782 SUPPORT Human Clinical

"Sleep-disordered breathing subtypes included obstructive sleep apnoea in 81% (55/68), central sleep apnoea in 3% (2/68), mixed sleep apnoea in 7% (5/68) and primary snoring in 9% (6/68)."

Polysomnography cohort confirms central sleep apnoea as a measured pediatric sleep phenotype, although much less common than obstructive disease.

Hydrocephalus VERY_RARE HP:0000238

Show evidence (4 references)

PMID:33579320 SUPPORT Human Clinical

"Cervical myelopathy and hydrocephalus occasionally occur in young children with achondroplasia."

Supports hydrocephalus as a recognized pediatric complication without overstating its frequency.

PMID:29972438 SUPPORT Human Clinical

"One patient developed hydrocephalus at 10 years old."

Natural-history cohort provides direct longitudinal evidence that hydrocephalus can occur during follow-up.

ORPHA:15 SUPPORT Other

"HP:0000238 | Hydrocephalus | Very rare (<4-1%)"

Orphanet classifies hydrocephalus as very rare in achondroplasia.

+ 1 more reference

Delayed gross motor development HP:0002194

Show evidence (2 references)

PMID:22409389 SUPPORT Human Clinical

"children with achondroplasia are delayed in development of gross motor and ambulatory skills."

Prospective developmental cohort directly supports delayed gross motor development.

PMID:29972438 SUPPORT Human Clinical

"There was motor developmental delay in 18 patients and speech delay in 16 patients."

Independent natural-history cohort corroborates developmental delay affecting motor milestones.

Delayed speech and language development HP:0000750

Show evidence (2 references)

PMID:29972438 SUPPORT Human Clinical

"There was motor developmental delay in 18 patients and speech delay in 16 patients."

Natural-history cohort directly reports speech delay in a substantial subset of patients.

PMID:22409389 SUPPORT Human Clinical

"While delays were seen in development of later communication items, there were fewer delays seen across development of early communication, fine motor, and feeding skills."

Prospective developmental study supports delayed later communication skill acquisition.

Cervical myelopathy HP:0002318

Show evidence (1 reference)

PMID:33579320 SUPPORT Human Clinical

"Thirteen (20%) of the 65 patients showed T2 HSI on MRI, long tract sign, or respiratory difficulty that corresponded to cervical myelopathy"

A selected tertiary pediatric MRI cohort documented cervical myelopathy in 13 of 65 children; this is not used as a population frequency.

Respiratory 1

Restrictive ventilatory defect OCCASIONAL HP:0002091

Show evidence (1 reference)

ORPHA:15 SUPPORT Other

"HP:0002091 | Restrictive ventilatory defect | Occasional (29-5%)"

Orphanet classifies restrictive ventilatory defect as occasional in achondroplasia.

Constitutional 1

Limb pain HP:0009763

Show evidence (1 reference)

PMID:29972438 SUPPORT Human Clinical

"The most common clinical intercurrences were middle ear dysfunction, sleep apnea, limb pain and obesity from 2 to 9 years of age."

Natural-history cohort lists limb pain among the most common clinical intercurrences in childhood.

Growth 3

Disproportionate short stature Disproportionate short-limb short stature HP:0008873

Show evidence (1 reference)

PMID:32803853 SUPPORT Human Clinical

"Achondroplasia is a genetic disorder that results in disproportionate short stature."

Supports disproportionate short stature as a core phenotype of achondroplasia.

Rhizomelia HP:0008905

Show evidence (2 references)

PMID:29972438 SUPPORT Human Clinical

"The most prevalent radiographic findings were rhizomelic shortening of the long bones and narrowing of the interpediculate distance of the caudal spine."

Supports rhizomelic long-bone shortening as a characteristic skeletal manifestation.

ORPHA:15 SUPPORT Other

"HP:0008905 | Rhizomelia | Occasional (29-5%)"

Orphanet classifies rhizomelia as occasional in achondroplasia.

Obesity HP:0001513

Sequelae: Spinal canal stenosis

Show evidence (3 references)

PMID:3228140 SUPPORT Human Clinical

"Obesity is a significant and potentially serious health problem in achondroplasia. Body mass indices, weight-to-square of the height ratio (W/H2), and triceps skinfold measurements show that obesity is common. It begins in early childhood and is prevalent at all ages."

Classic cohort study directly supports obesity as an early and persistent complication.

PMID:29652901 SUPPORT Human Clinical

"Our results show unexpected results with the development of an atypical obesity with preferential fat deposition in the abdomen that is remarkably not associated with classical complications of obesity such as diabetes or hypercholosterolemia."

A longitudinal pediatric study characterizes the obesity as predominantly abdominal and metabolically atypical.

PMID:41167810 SUPPORT REVIEW SYNTHESIS Human Clinical

"People with achondroplasia were found to be at increased risk of obesity, impaired glucose regulation and hypertension."

A 33-study systematic review confirms increased obesity risk and links it to cardiovascular risk factors.

🧬

Genetic Associations

FGFR3 (Causative)

Gene: FGFR3 hgnc:3690 gene page relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (2 references)

CGGV:assertion_0adafa1b-e609-4b99-8e90-f73473b70771-2023-09-28T040000.000Z SUPPORT Other

ClinGen classifies the FGFR3-achondroplasia relationship as definitive.

ORPHA:15 SUPPORT Other

"FGFR3 | fibroblast growth factor receptor 3 | hgnc:3690 | Disease-causing germline mutation(s) (gain of function) in"

Orphanet identifies germline FGFR3 gain of function.

Variants (2)

c.1138G>A (p.Gly380Arg)

The predominant recurrent allele; 150 of 153 p.Gly380Arg-positive cases in one 154-person series carried c.1138G>A.

Show evidence (1 reference)

PMID:7847369 SUPPORT Human Clinical

The large series directly supplies the allele counts.

c.1138G>C (p.Gly380Arg)

A less common nucleotide substitution producing the same p.Gly380Arg protein change; three cases were observed in the same series.

Show evidence (1 reference)

PMID:7847369 SUPPORT Human Clinical

The series directly documents the c.1138G>C minority allele.

💊

Medical Actions

Vosoritide (Voxzogo)

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: vosoritide NCIT:C152918

Platform: Peptide

Dosing: once daily every 1 days

Daily CNP analogue indicated in the United States to increase linear growth in pediatric patients with achondroplasia and open epiphyses. Accelerated approval is based on annualized growth velocity; final adult height and prevention of non-growth complications are not established by the approval. A three-year external-control comparison estimated 5.75 cm additional height, explicitly not a three-year randomized comparison.

Mechanism Target:

ACTIVATES CNP-NPR2 counter-regulation of FGFR3-MAPK signaling — Vosoritide activates the CNP-NPR2 counter-regulatory branch.

Show evidence (3 references)

PMID:31269546 SUPPORT Human Clinical

"Vosoritide is a biologic analogue of C-type natriuretic peptide, a potent stimulator of endochondral ossification."

The clinical trial identifies vosoritide as a CNP analogue.

PMID:14702637 SUPPORT Model Organism

"These results demonstrate that activation of the CNP-GC-B system in endochondral bone formation constitutes a new therapeutic strategy for human achondroplasia."

Preclinical data support the CNP-GC-B/NPR2 mechanism.

PMID:34431071 SUPPORT Human Clinical

"The exposure-response relationships for changes in both annualized growth velocity and the CXM biomarker saturated at 15 μg/kg, while systemic pharmacological activity, as measured by urinary cGMP, was near maximal or saturated at exposures obtained at the highest dose studied"

Urinary cGMP and the collagen X endochondral-ossification biomarker give human target-engagement support for the guanylyl-cyclase branch this link asserts, rather than inferring engagement from growth alone.

Target Phenotypes: Limb undergrowth HP:0009826

Show evidence (9 references)

url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214938s004lbl.pdf SUPPORT Other

"VOXZOGO is a C type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses."

The current US label has no obsolete five-year minimum-age clause.

url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214938s004lbl.pdf SUPPORT Other

"This indication is approved under accelerated approval based on an improvement in annualized growth velocity."

The label identifies the surrogate endpoint and accelerated-approval basis.

PMID:32891212 SUPPORT Human Clinical

"The adjusted mean difference in annualised growth velocity between patients in the vosoritide group and placebo group was 1·57 cm/year in favour of vosoritide"

The pivotal randomized, double-blind, placebo-controlled phase 3 trial supplies the placebo-adjusted growth-velocity result underlying approval.

+ 6 more references

Navepegritide (Yuviwel)

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: navepegritide NCIT:C188658

Platform: Peptide

Dosing: once weekly every 7 days

Once-weekly CNP analogue indicated in the United States to increase linear growth in patients aged two years and older with achondroplasia and open epiphyses. The 2026 accelerated approval is based on annualized growth velocity; continued approval may be contingent on verification and description of clinical benefit in confirmatory trials.

Mechanism Target:

ACTIVATES CNP-NPR2 counter-regulation of FGFR3-MAPK signaling — CNP released from navepegritide binds NPR-B and inhibits the MAPK component of FGFR3 signaling.

Show evidence (1 reference)

url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf SUPPORT Other

"CNP released from navepegritide has the same receptor binding affinity and activity as endogenous CNP. CNP binds to natriuretic peptide receptor-B (NPR-B), which inhibits the mitogen activated protein kinase signaling (MAPK) pathway."

The current label directly supports NPR-B activation and MAPK counter-regulation.

Target Phenotypes: Limb undergrowth HP:0009826

Show evidence (6 references)

url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf SUPPORT Other

"YUVIWEL is a C-type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses."

The 2026 US label supplies the indication and eligible population.

url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf SUPPORT Other

"This indication is approved under accelerated approval based on an improvement in annualized growth velocity."

The label identifies the accelerated-approval endpoint.

url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf SUPPORT Other

"Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s)."

The label qualifies the confirmatory-evidence condition for continued approval.

+ 3 more references

Infigratinib (oral FGFR1-3 tyrosine kinase inhibitor)

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: infigratinib CHEBI:63451

Platform: Small molecule

Once-daily oral ATP-competitive FGFR1-3 tyrosine kinase inhibitor, repurposed from oncology at roughly a hundredth of the oncology dose (0.25 mg/kg/day). It is mechanistically distinct from the approved CNP analogues: vosoritide and navepegritide act on a parallel counter-regulatory arm (NPR-B/cGMP braking MAPK downstream of the receptor), whereas infigratinib inhibits the mutant receptor's kinase output directly. A phase 2 dose-finding study selected 0.25 mg/kg/day. In the 52-week phase 3 PROPEL 3 trial (NCT06164951) it increased annualized height velocity by 1.74 cm/year over placebo, and it is oral rather than injected. Two caveats belong with the result: the upper-to-lower segment ratio, the measure of *disproportion* as opposed to height, did not change, and the drug is a pan-FGFR1-3 rather than FGFR3-selective inhibitor, so long-term off-target skeletal effects are not yet characterized in children. Not approved at time of curation.

Mechanism Target:

INHIBITS Prolonged FGFR3 signaling in growth-plate chondrocytes — Infigratinib inhibits the FGFR kinase domain directly, reducing the prolonged downstream signal from the gain-of-function p.Gly380Arg receptor rather than opposing it from a parallel pathway.

Show evidence (1 reference)

PMID:42370681 SUPPORT Human Clinical

"Infigratinib, an oral FGFR1-3 tyrosine kinase inhibitor, down-regulates key pathways in the pathogenesis of achondroplasia."

States the receptor-directed mechanism that distinguishes infigratinib from the CNP-analogue class.

Target Phenotypes: Limb undergrowth HP:0009826

Show evidence (4 references)

PMID:42370681 SUPPORT Human Clinical

"In children with achondroplasia, treatment with once-daily oral infigratinib for 52 weeks resulted in a significantly greater increase from baseline in the annualized height velocity than placebo."

The phase 3 primary result.

PMID:42370681 SUPPORT Human Clinical

"The difference between infigratinib and placebo in the least-squares mean change from baseline to week 52 was 1.74 cm per year (95% confidence interval [CI], 1.31 to 2.17; P<0.001) for the annualized height velocity, 0.32 (96% CI, 0.23 to 0.41; P<0.001) for the height z score, and -0.02 (96% CI,..."

Quantifies the effect and records that the upper-to-lower segment ratio, the disproportion measure, was not improved.

PMID:42370681 SUPPORT Human Clinical

"Adverse events occurred in 71 of 74 patients (96%) in the infigratinib group and in 37 of 39 patients (95%) in the placebo group; serious adverse events occurred in 4 of 74 patients (5%) and 1 of 39 patients (3%), respectively."

The 52-week safety comparison; longer-term skeletal safety is untested.

+ 1 more reference

Meclizine (investigational oral repurposed antihistamine)

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: meclizine CHEBI:6709

Platform: Small molecule

An over-the-counter H1 antihistamine identified by drug repositioning as an inhibitor of FGFR3 signaling that promotes bone growth in an achondroplasia mouse model. Japanese phase 1b and single-arm phase 2 studies in children aged 5-10 years reported no serious adverse events, but the 26-week phase 2 study (co-administered with growth hormone) showed essentially no change in height velocity, with an increase only in arm-span velocity. Investigational; not an established therapy.

Mechanism Target:

INHIBITS Prolonged FGFR3 signaling in growth-plate chondrocytes — Reported in preclinical work to inhibit FGFR3 signaling; the molecular target is not defined.

Show evidence (1 reference)

PMID:37428729 SUPPORT BACKGROUND Model Organism

"We found that meclizine, which is an over-the-counter drug for motion sickness, inhibited the fibroblast growth factor receptor 3 (FGFR3) gene using a drug repositioning strategy, and meclizine 1 and 2 mg/kg/day promoted bone growth in a mouse model of ACH."

The phase 1b paper restates the authors' earlier preclinical finding that motivates the trials.

Show evidence (3 references)

PMID:37428729 SUPPORT Human Clinical

"No patient experienced serious AEs in either group."

Fourteen-day repeated dosing in 12 children was tolerated.

PMID:41326861 REFUTE Human Clinical

"Height velocity increased slightly from 4.35 ± 1.36 cm/year pre-treatment to 4.46 ± 1.54 cm/year post-treatment."

In nine children over 26 weeks height velocity was essentially unchanged, which does not support meclizine as a growth-promoting treatment.

PMID:41326861 SUPPORT Human Clinical

"An additive effect of meclizine and growth hormone on promoting height was not observed; however, meclizine may enhance arm span growth in children with ACH."

The only positive signal was in arm span, from an uncontrolled ad hoc analysis.

Recifercept (discontinued soluble FGFR3 decoy)

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: recifercept NCIT:C175197

Platform: Other

A recombinant soluble FGFR3 decoy designed to sequester FGF ligands and so reduce activation of the mutant receptor. It restored long-bone growth in a transgenic mouse model, but in the phase 2 study in children aged 2-10 years growth was indistinguishable from model-simulated natural history and clinical development was terminated. Recorded as a negative result for the ligand-sequestration strategy.

Mechanism Target:

INHIBITS FGFR3 p.Gly380Arg gain-of-function with impaired receptor down-regulation — Ligand sequestration was intended to normalize activation of the predominantly ligand-dependent mutant receptor.

Show evidence (1 reference)

PMID:33370388 SUPPORT Model Organism

"In addition, in a transgenic mouse model of achondroplasia, Recifercept restores reduced body weight and long bone growth in these mice."

Preclinical support for the decoy mechanism.

Show evidence (1 reference)

PMID:38685585 REFUTE Human Clinical

"For all the tested doses of recifercept, at the individual level, the observations were comparable to the simulations at 6 and 12 months post-recifercept treatment, suggesting no treatment effect. The results contributed to the decision of terminating recifercept clinical development."

The phase 2 comparison against a natural-history model showed no growth effect, and development was stopped.

Surgical limb lengthening

Category: Therapeutic Action: Limb lengthening surgery Ontology label: Surgical Procedure NCIT:C15329

Platform: Surgery

Extended limb lengthening is an elective option for selected individuals. Decisions require specialized multidisciplinary counseling about goals, prolonged treatment, complications, and patient preferences; the evidence cited here supports use, not a universal recommendation.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"Additional treatment for short stature may include extended limb lengthening;"

The current clinical review lists limb lengthening as an optional intervention.

Foramen magnum decompression

Category: Therapeutic Action: Foramen magnum decompression Ontology label: Surgical Procedure NCIT:C15329

Experienced neurosurgical teams may perform suboccipital or cervicomedullary decompression when clinical, respiratory, and imaging findings indicate significant craniocervical compression. The procedure is not equated with lumbar laminectomy.

Target Phenotypes: Small foramen magnum HP:0002677

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"suboccipital decompression as indicated for signs and symptoms of craniocervical junction compression;"

The current clinical review supports symptom- and sign-based surgical selection.

Surgery for symptomatic spinal stenosis

Category: Therapeutic Action: spinal decompression surgery Ontology label: Surgical Procedure NCIT:C15329

Adults with symptomatic spinal stenosis may require decompressive spinal surgery. Selection depends on neurologic symptoms and specialist assessment.

Target Phenotypes: Spinal canal stenosis HP:0003416

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"surgery to correct spinal stenosis in symptomatic adults;"

The current clinical review supports surgery for selected symptomatic adults.

Lifelong multidisciplinary surveillance

Category: Monitoring Action: clinical monitoring Ontology label: Clinical Evaluation NCIT:C124351

Age-specific follow-up continues across the lifespan, with visits at least every six to twelve months in infancy and childhood and every three to five years in adulthood.

Show evidence (3 references)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"Infants and children should be seen at a minimum of every six to 12 months."

The review specifies regular pediatric surveillance.

PMID:32457214 SUPPORT Other

"This document is intended to provide guidance for health care providers to help identify individual patients at high risk of developing serious sequelae and to enable intervention before complications develop."

AAP guidance supports anticipatory health supervision.

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"Adults should be seen every three to five years."

The current review specifies continued adult follow-up.

Middle-ear and hearing management

Category: Therapeutic Action: supportive care Ontology label: Supportive Care NCIT:C15747

Recurrent effusion and hearing impairment require hearing surveillance and individualized ENT management, including pressure-equalizing tubes when indicated.

Target Phenotypes: Otitis media with effusion HP:0031353 Conductive hearing impairment HP:0000405

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"aggressive management of frequent otitis media including long-lasting pressure-equalizing tubes for middle ear dysfunction;"

The current review explicitly recommends active middle-ear management.

Obstructive sleep apnea management

Category: Therapeutic Action: supportive care Ontology label: Supportive Care NCIT:C15747

Treatment is individualized and may include adenotonsillar surgery, positive airway pressure, or rarely tracheostomy after appropriate sleep and airway assessment.

Target Phenotypes: Obstructive sleep apnea HP:0002870

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"adenotonsillectomy, positive airway pressure, and, rarely, tracheostomy to correct obstructive sleep apnea;"

The current review lists the principal individualized modalities.

Genetic counseling

Category: Counseling / Informational Action: genetic counseling Ontology label: Genetic Counseling NCIT:C15240

Counseling addresses the 50% transmission risk from an affected heterozygous parent with an average-stature partner.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"If an individual with achondroplasia has a reproductive partner of average stature, each child has a 50% chance of having achondroplasia."

The current review directly states the recurrence risk.

🔬

Diagnosis

Characteristic physical examination

Examination identifies disproportionate short-limb stature with rhizomelic shortening, macrocephaly, frontal bossing and midface retrusion, brachydactyly, and trident hands.

physical examination NCIT:C20989

Results: Characteristic disproportionate skeletal and craniofacial pattern.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

The current review defines the characteristic examination pattern.

Skeletal radiographic evaluation

Characteristic clinical and radiographic findings establish the diagnosis in most individuals; radiographs define long-bone, hand, pelvic, and spinal morphology.

radiograph imaging procedure NCIT:C38101

Results: Rhizomelic long-bone shortening and characteristic spinal and pelvic pattern.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"Achondroplasia can be diagnosed by characteristic clinical and radiographic findings in most affected individuals."

The current review explicitly supports clinical-radiographic diagnosis.

FGFR3 molecular confirmation

Targeted testing for c.1138G>A and c.1138G>C is highly efficient because both produce p.Gly380Arg and account for nearly all typical cases.

molecular genetic testing NCIT:C19770

Results: Heterozygous pathogenic FGFR3 variant, usually c.1138G>A or c.1138G>C (p.Gly380Arg).

Show evidence (2 references)

PMID:9718331 SUPPORT Human Clinical

"More than 97% of achondroplasia cases are caused by one of two mutations (G1138A and G1138C) in the fibroblast growth factor receptor 3 (FGFR3) gene, which results in a specific amino acid substitution, G380R."

The study supports targeted testing for the two recurrent nucleotide substitutions.

CGGV:assertion_0adafa1b-e609-4b99-8e90-f73473b70771-2023-09-28T040000.000Z SUPPORT Other

ClinGen supports molecular confirmation through the definitive gene-disease relationship.

🩻

Imaging Findings

Rhizomelic long-bone shortening on skeletal radiographs

Skeletal radiographs show disproportionate proximal long-bone shortening. This is part of the characteristic diagnostic pattern rather than a stand-alone molecular confirmation.

Xray

Rhizomelia HP:0008905

Show evidence (1 reference)

PMID:29972438 SUPPORT Human Clinical

"To characterize the natural history of 39 achondroplastic patients diagnosed by clinical, radiological and molecular assessments. ... The most prevalent radiographic findings were rhizomelic shortening of the long bones and narrowing of the interpediculate distance of the caudal spine. ... The..."

Restores the achondroplasia cohort and distinction between clinical/radiographic diagnosis and molecular confirmation around the typical radiographic findings.

Caudal interpedicular narrowing on spinal radiographs

The interpedicular distance narrows toward the caudal spine, a characteristic vertebral radiographic feature.

Xray

Caudal interpedicular narrowing HP:0008457

Show evidence (1 reference)

PMID:29972438 SUPPORT Human Clinical

"The most prevalent radiographic findings were rhizomelic shortening of the long bones and narrowing of the interpediculate distance of the caudal spine."

A clinical cohort directly documents caudal narrowing.

Foramen-magnum stenosis and cord compression spectrum on MRI

Craniocervical MRI can show foramen-magnum narrowing, loss of surrounding CSF space, cord flattening, and T2 signal change. This evaluates a complication and is not required to establish the skeletal diagnosis.

Mri

Small foramen magnum HP:0002677

Show evidence (1 reference)

PMID:32883660 SUPPORT Human Clinical

The cohort defines an MRI severity spectrum from no stenosis to cord signal change.

Premature skull-base synchondrosis fusion on CT

CT can demonstrate premature fusion of skull-base synchondroses. This finding informs craniofacial mechanism and complication assessment but is not presented as a universal diagnostic requirement.

Show evidence (1 reference)

PMID:37072824 SUPPORT Human Clinical

"All patients with available CT-scan had premature fusion of skull base synchondroses."

CT in a small clinical cohort directly documents premature fusion.

Upper-lumbar stenosis and disc degeneration on adult MRI

Adult imaging shows preferential upper-lumbar canal narrowing and disc degeneration, often with thoracolumbar kyphosis and loss of lordosis.

Mri

Show evidence (1 reference)

PMID:32170149 SUPPORT Human Clinical

Adult MRI data define the characteristic distribution.

📈

Progression

Infancy

Age: Birth through the first two years

Hypotonia and achondroplasia-specific motor delay are typical. Craniocervical-junction compression is a distinct high-acuity risk and increases the risk of death in infancy.

Show evidence (3 references)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"In infancy, hypotonia is typical, and acquisition of developmental motor milestones is often both aberrant in pattern and delayed."

The current clinical review describes the typical infant developmental course.

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"Intelligence and life span are usually near normal, although craniocervical junction compression increases the risk of death in infancy."

The current clinical review identifies the phase-specific mortality risk. Its "near normal" life span is a qualitative clinical statement; the 42-year cohort cited under clinical_burden (PMID:17879967) measured an average reduction of about ten years, driven by excess accidental, neurological and cardiovascular deaths in adulthood.

PMID:24677650 SUPPORT Human Clinical

"Although an overall improvement in mortality, especially after the first year of life, is observed in our cohort, children with achondroplasia are still at a much higher risk of death compared with the general population."

A Texas birth-defects registry cohort (1996-2003 births) found all four deaths in the first year of life.

Early childhood

Age: Approximately two to ten years

Middle-ear dysfunction, sleep apnea, limb pain, and excess weight are common clinical burdens. Thoracolumbar kyphosis often improves after independent walking, although persistent deformity needs orthopedic follow-up.

Show evidence (2 references)

PMID:29972438 SUPPORT Human Clinical

"The most common clinical intercurrences were middle ear dysfunction, sleep apnea, limb pain and obesity from 2 to 9 years of age."

A natural-history cohort identifies the principal early-childhood burdens.

PMID:37493935 SUPPORT Human Clinical

"Thoracolumbar kyphosis (TLK) is common in children with achondroplasia and resolves in 90% by 10 years of age."

Longitudinal follow-up supports usual improvement of kyphosis in childhood.

Later childhood and adolescence

Age: Approximately ten years through skeletal maturity

Lower-limb bowing can persist as a complex deformity involving lateral bowing, differential tibial and fibular growth, internal tibial torsion, and dynamic knee instability.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

""Bowing" is actually a complex deformity arising from a combination of lateral bowing, differential growth between the tibia and fibula, internal tibial torsion, and dynamic instability of the knee"

The current clinical review describes the interacting growth and mechanical components of lower-limb bowing.

Adulthood

Age: Skeletal maturity onward

Symptomatic spinal stenosis involving L1-L4 is the most common adult medical complaint. Imaging shows preferential upper-lumbar stenosis and disc degeneration.

Show evidence (3 references)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"The most common medical complaint in adulthood is symptomatic spinal stenosis involving L1-L4"

The 2026 review identifies symptomatic upper-lumbar stenosis as the leading adult complaint.

PMID:32170149 SUPPORT Human Clinical

Adult imaging data define the characteristic upper-lumbar distribution.

PMID:17879967 SUPPORT Human Clinical

"Heart disease-related mortality, between ages 25 and 35, was more than 10 times higher than the general population. Overall survival and the average life expectancy for this ACH population were decreased by 10 years."

A 42-year follow-up of 793 individuals documents excess adult cardiovascular mortality and reduced life expectancy.

📊

Prevalence

Global live births

Birth Prevalence 4.6 per 100,000 1–9 per 100,000 (births)

A systematic review and meta-analysis estimated worldwide birth prevalence at 4.6 per 100,000 live births.

Show evidence (2 references)

PMID:32803853 SUPPORT Human Clinical

"Based on the meta-analysis, the worldwide birth prevalence of achondroplasia was estimated to be 4.6 per 100,000."

This meta-analysis provides the strongest aggregate global birth-prevalence estimate for achondroplasia.

ORPHA:15 SUPPORT Other

"1-9 / 100 000 | Worldwide | Prevalence at birth | PMID:32803853"

Orphanet epidemiology data confirm worldwide birth prevalence in the 1-9 per 100,000 range, consistent with published estimates.

Europe

Birth Prevalence 3.72 per 100,000 1–9 per 100,000 (births)

EUROCAT population-based surveillance identified 434 cases and estimated birth prevalence at 3.72 per 100,000 births.

Show evidence (1 reference)

PMID:31294928 SUPPORT Human Clinical

"The study population consisted of 434 achondroplasia cases with a prevalence of 3.72 per 100,000 births (95%CIs: 3.14-4.39)."

A large population-based European study provides the regional estimate.

⚖️

Clinical Burden

High

Care is lifelong and multidisciplinary. Infants carry a risk of sudden death from craniocervical-junction compression, children have frequent airway, otologic and orthopedic complications, adults commonly develop symptomatic spinal stenosis, and overall life expectancy is reduced by about ten years with excess accidental, neurological and cardiovascular deaths. Intelligence is usually normal.

Show evidence (3 references)

PMID:30276962 SUPPORT Human Clinical

"Sudden death and higher mortality are recognized in achondroplasia, with acute brainstem compression, a common cause of mortality in children <4 years and cardiovascular deaths being more prevalent in adults."

Summarizes the age-specific causes of excess mortality.

PMID:30276962 SUPPORT Human Clinical

"Causes of death in these patients have shifted over the last 30 years, with fewer sudden death and deaths because of pneumonia or hydrocephalus countered by more cardiovascular or cerebrovascular and accidental deaths."

An 855-patient clinic-based cohort shows that improved childhood management has shifted rather than removed excess mortality.

PMID:17879967 SUPPORT Human Clinical

"Accidental, neurological, and heart disease-related deaths were increased in adults."

Documents the adult causes of excess mortality.

🔀

Differential Diagnoses

Conditions with similar clinical presentations that must be differentiated from Achondroplasia:

Hypochondroplasia MONDO:0007793

Overlapping Features A milder FGFR3 skeletal dysplasia that can overlap mild achondroplasia.

Distinguishing Features

Skeletal and medical manifestations tend to be milder than in achondroplasia.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"The skeletal features are very similar to those seen in achondroplasia but tend to be milder."

The current review states the principal clinical distinction.

Pseudoachondroplasia Not Yet Curated MONDO:0008322

Overlapping Features A clinically and genetically distinct skeletal dysplasia whose similar name can cause diagnostic confusion.

Distinguishing Features

It is genetically distinct from FGFR3 p.Gly380Arg achondroplasia.
The radiographic and craniofacial pattern should be assessed rather than relying on nomenclature.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1152/ SUPPORT Other

"is a clinically and genetically distinct skeletal dysplasia but the similar nomenclature may cause confusion with achondroplasia."

GeneReviews explicitly warns that the similar name masks a distinct disorder.

Thanatophoric dysplasia type 2 MONDO:0008547

Overlapping Features A much more severe, usually life-limiting FGFR3 short-limb skeletal dysplasia.

Distinguishing Features

Severe, usually lethal short-limb skeletal dysplasia favors thanatophoric dysplasia.

Show evidence (1 reference)

PMID:25800480 SUPPORT Human Clinical

"Thanatophoric dysplasia (TD) is a lethal form of skeletal dysplasia with short-limb dwarfism."

The report supports the severe life-limiting short-limb phenotype.

SADDAN MONDO:0014658

Overlapping Features SADDAN is a severe FGFR3 allelic disorder in which developmental delay, structural brain abnormalities, hearing loss, and acanthosis nigricans accompany the skeletal dysplasia.

Distinguishing Features

Marked developmental and neurologic abnormalities with acanthosis nigricans favor SADDAN.
SADDAN is associated with FGFR3 p.Lys650Met rather than p.Gly380Arg.

Show evidence (2 references)

PMID:24352917 SUPPORT Human Clinical

"Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) is an extremely rare severe skeletal dysplasia characterized by significant developmental delay, brain structural abnormalities, hearing loss, and acanthosis nigricans."

The report directly states the distinguishing multisystem phenotype.

PMID:24352917 SUPPORT Human Clinical

"The disorder is the result of a single missense mutation at codon 650 (p.Lys650Met) in the fibroblast growth factor receptor 3 gene (FGFR3)."

The report identifies the distinct SADDAN allele.

🔬

Clinical Trials

NCT06164951 PHASE_III COMPLETED

PROPEL 3 — the pivotal 52-week randomized, double-blind, placebo-controlled trial of once-daily oral infigratinib in children aged 3 to <18 years with achondroplasia. Unlike the CNP-analogue trials, it tests a drug acting on the FGFR receptor kinase itself rather than on the counter-regulatory arm.

Target Phenotypes: Limb undergrowth HP:0009826 Short stature HP:0004322

Show evidence (2 references)

clinicaltrials:NCT06164951 SUPPORT Human Clinical

"This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia (ACH)"

The registry record establishes the trial's design and population.

PMID:42370681 SUPPORT Human Clinical

"In this phase 3, multicenter, double-blind, placebo-controlled trial, we randomly assigned children with achondroplasia (3 to 17 years of age) in a 2:1 ratio to receive infigratinib (at a dose of 0.25 mg per kilogram of body weight) or placebo once daily for 52 weeks."

The publication reporting this trial's results.

NCT03197766 PHASE_III COMPLETED

The pivotal 52-week randomized, double-blind, placebo-controlled phase 3 trial of once-daily subcutaneous vosoritide (BMN 111) in children with achondroplasia, whose growth-velocity result underlies the accelerated approval.

Target Phenotypes: Limb undergrowth HP:0009826

Show evidence (2 references)

clinicaltrials:NCT03197766 SUPPORT Human Clinical

"The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia."

The registry record identifies the vosoritide phase 3 trial.

PMID:32891212 SUPPORT Human Clinical

"The adjusted mean difference in annualised growth velocity between patients in the vosoritide group and placebo group was 1·57 cm/year in favour of vosoritide"

The publication reporting this trial's primary result.

NCT04085523 PHASE_II COMPLETED

ACcomplisH, the 52-week phase 2 randomized, double-blind, placebo-controlled dose-escalation trial of once-weekly navepegritide (TransCon CNP) in prepubertal children aged 2-10 years.

Target Phenotypes: Limb undergrowth HP:0009826

Show evidence (2 references)

clinicaltrials:NCT04085523 SUPPORT Human Clinical

"The trial is a multicenter, double-blind, randomized, placebo-controlled, dose escalation trial of weekly TransCon CNP administered subcutaneously in prepubertal children 2 to 10 years old, inclusive, with Achondroplasia."

The registry record establishes design and population.

PMID:37823031 SUPPORT Human Clinical

"TransCon CNP demonstrated a dose-dependent improvement in AGV."

The publication reporting this trial's dose-response result.

NCT05598320 PHASE_II COMPLETED

APPROACH, the 52-week randomized, double-blind, placebo-controlled trial of once-weekly navepegritide 100 µg/kg in children aged 2-11 years; its title calls it phase 2b and the registry lists it as phase 2/3. It is the randomized basis of the 2026 US accelerated approval.

Target Phenotypes: Limb undergrowth HP:0009826

Show evidence (2 references)

clinicaltrials:NCT05598320 SUPPORT Human Clinical

"The purpose of this clinical trial was to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of 100 µg TransCon CNP/kg compared to placebo on Annualized Growth Velocity after a 52-week randomized treatment period in children aged 2 to 11 years with genetically confirmed Achondroplasia."

The registry record establishes design, dose, and population.

PMID:41247754 SUPPORT Human Clinical

"The trial met its primary end point, demonstrating superiority of navepegritide in annualized growth velocity at week 52 vs placebo (least-squares mean treatment difference of 1.49 cm/y; 95% CI, 1.05 to 1.93; P < .001)."

The publication reporting this trial's primary result.

🐁

Animal Models

Humanized FGFR3 p.Gly380Arg knock-in mouse

Knock-in of the recurrent human allele at the endogenous locus, rather than transgenic overexpression, reproduces the principal achondroplasia skeletal features, with severity scaling with the copy number of the activated allele.

Species

Mouse

Genotype

Endogenous mouse Fgfr3 replaced by human FGFR3 p.Gly380Arg cDNA (FGFR3ACH), heterozygous and homozygous

Publication

PMID:28230213

Pathograph links

Impaired endochondral ossification and chondrodysplasia recapitulates fidelity: high The model carries the human disease allele at the endogenous locus and develops the skeletal phenotype the node describes.

Limitations: Mouse growth plate closes differently from human, so adult stature and the adult spinal-stenosis burden are not modeled; the report is descriptive and does not dissect the downstream signaling arms.

Readouts

Femur length relative to body length at one month

Direction: DECREASED

Interpretation: Femur shortening exceeding body-length shortening is the quantitative rhizomelic readout of the endochondral growth deficit this node describes, and reproduces the human limb-versus-trunk disproportion.

Show evidence (1 reference)

PMID:28230213 SUPPORT Model Organism

"which showed a 22% shortening of femur length along with a 7.1% shortening of body length"

Reports the paired femur and body-length measurements behind this readout in heterozygous knock-in mice at one month of age.

Show evidence (1 reference)

PMID:28230213 SUPPORT Model Organism

"Heterozygous (FGFR3ACH/+) and homozygous (FGFR3ACH/ACH) mice expressing human FGFR3G380R recapitulate the phenotypes observed in ACH patients, including growth retardation, disproportionate shortening of the limbs, round head, mid-face hypoplasia at birth, and kyphosis progression during..."

Supports treating the humanized knock-in as informative for the endochondral ossification node.

Show evidence (1 reference)

PMID:28230213 SUPPORT Model Organism

"The severity of the disease phenotypes corresponds to the copy number of activated FGFR3G380R, and the phenotypes become more pronounced during postnatal skeletal development."

Allele-dosage dependence in the humanized model parallels the human heterozygous-versus-homozygous severity difference.

Fgfr3-null mouse

Loss of Fgfr3 gives the reciprocal skeletal phenotype, long-bone and vertebral overgrowth, which is the genetic complement of the achondroplasia gain-of-function allele and the basis for reading FGFR3 as a negative regulator of bone growth. Inner-ear defects and deafness accompany it.

Species

Mouse

Genotype

Homozygous targeted disruption of Fgfr3

Publication

PMID:8630492

Show evidence (1 reference)

PMID:8630492 SUPPORT Model Organism

"Our results demonstrate that Fgfr3 is essential for normal endochondral ossification and inner ear development."

The null phenotype is the reciprocal-direction control for the gain-of-function model rather than a model of achondroplasia itself.

Human FGFR3 G380R transgene under mouse Fgfr3 transcriptional control Mouse

Mutant-receptor immunoreactivity extends across a larger growth-plate area, supporting impaired in vivo receptor down-regulation. This record does not claim an unsupported full phenotypic inventory.

Species

Mouse

Genotype

Human FGFR3 G380R transgene under mouse Fgfr3 transcriptional control

Show evidence (1 reference)

PMID:10611230 SUPPORT Model Organism

The experiment directly supports the modeled receptor-persistence phenotype.

Activated Fgfr3 achondroplasia model with chondrocyte CNP overexpression Mouse

Targeted CNP overexpression counteracted dwarfism and corrected reduced matrix synthesis through MAPK inhibition, providing proof of concept for CNP analogues.

Species

Mouse

Genotype

Activated Fgfr3 achondroplasia model with chondrocyte CNP overexpression

Show evidence (2 references)

PMID:14702637 SUPPORT Model Organism

"targeted overexpression of CNP in chondrocytes counteracts dwarfism in a mouse model of achondroplasia with activated fibroblast growth factor receptor 3 (FGFR-3) in the cartilage."

The intervention directly demonstrates rescue of dwarfism.

PMID:14702637 SUPPORT Model Organism

"CNP prevented the shortening of achondroplastic bones by correcting the decreased extracellular matrix synthesis in the growth plate through inhibition of the MAPK pathway of FGF signaling."

The experiment supplies the matrix and MAPK mechanism.

Constitutively active MEK1 driven by Col2a1 in chondrocytes Mouse

Chondrocyte MEK1 activation produces achondroplasia-like dwarfism and inhibits skeletal overgrowth in Fgfr3-deficient mice, supporting MAPK as a downstream effector.

Species

Mouse

Genotype

Constitutively active MEK1 driven by Col2a1 in chondrocytes

Show evidence (2 references)

PMID:14871928 SUPPORT Model Organism

"We generated transgenic mice that express a constitutively active mutant of MEK1 in chondrocytes. These mice showed a dwarf phenotype similar to achondroplasia, the most common human dwarfism, caused by activating mutations in FGFR3."

Directly demonstrates sufficiency of chondrocyte MAPK activation for an achondroplasia-like phenotype.

PMID:14871928 SUPPORT Model Organism

"Expression of a constitutively active mutant of MEK1 in chondrocytes of Fgfr3-deficient mice inhibited skeletal overgrowth, strongly suggesting that regulation of bone growth by FGFR3 is mediated at least in part by the MAPK pathway."

The epistasis experiment positions MAPK downstream of FGFR3.

{ }

Source YAML

click to show

name: Achondroplasia
synonyms:
- Achondroplasia, FGFR3-related
creation_date: '2026-02-02T00:16:36Z'
category: Mendelian
description: >-
  Achondroplasia is the most common cause of disproportionate short stature. It is
  caused by heterozygous gain-of-function variation in FGFR3, almost always
  p.Gly380Arg, which prolongs inhibitory FGFR3 signaling in growth-plate
  chondrocytes and impairs endochondral ossification. Rhizomelic limb shortening,
  macrocephaly, frontal bossing, midface retrusion, and trident hands are
  characteristic. Important complications include craniocervical-junction
  compression in infancy, sleep-disordered breathing, middle-ear dysfunction,
  limb bowing, obesity, and symptomatic spinal stenosis in adulthood. Daily
  vosoritide and once-weekly navepegritide increase growth velocity in eligible
  children with open epiphyses; both US indications use annualized growth
  velocity as an accelerated-approval endpoint, so final-height and
  complication-prevention benefits remain under study. Oral infigratinib, which
  inhibits the FGFR kinase directly, increased height velocity in a phase 3
  trial; meclizine and the soluble FGFR3 decoy recifercept have not shown a
  height-velocity effect in children. Life expectancy is reduced by about ten years.
disease_term:
  preferred_term: achondroplasia
  term:
    id: MONDO:0007037
    label: achondroplasia
parents:
- FGFR3-related skeletal dysplasia
- Rhizomelic limb shortening syndrome
inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  penetrance: COMPLETE
  de_novo_rate: approximately 80%
  parent_of_origin_effect: De novo variants are predominantly paternal in origin and associated with increased paternal age
  description: >-
    Achondroplasia has complete-penetrance autosomal-dominant inheritance. About
    80% of affected individuals have average-stature parents and a de novo FGFR3
    variant. In informative sporadic cases, the recurrent variant arose on the
    paternal chromosome; increased paternal age is an established association.
  evidence:
  - reference: PMID:8078586
    reference_title: "Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Affected individuals are fertile and achondroplasia is transmitted as a fully penetrant autosomal dominant trait, accounting for rare familial forms of the disease (10%)."
    explanation: Establishes autosomal dominant inheritance with full penetrance for achondroplasia.
  - reference: PMID:8078586
    reference_title: "Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "More than 90% of cases are sporadic and there is an increased paternal age at the time of conception of affected individuals,"
    explanation: An older series documents a high sporadic fraction and paternal-age association; the structured estimate is calibrated to the current approximately 80% estimate.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Approximately 80% of individuals with achondroplasia have parents of average stature and have achondroplasia as the result of a"
    explanation: The 2026 GeneReviews revision gives the current approximately 80% de novo estimate.
  - reference: PMID:9718331
    reference_title: Mutations in fibroblast growth-factor receptor 3 in sporadic cases of achondroplasia occur exclusively on the paternally derived chromosome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this population, the achondroplasia mutation occurred on the paternal chromosome in all 40 cases in which parental origin was unambiguous."
    explanation: Direct parental-origin analysis supports the paternal origin of recurrent de novo FGFR3 variants.
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal dominant"
    explanation: Orphanet classifies achondroplasia inheritance as autosomal dominant.
classifications:
  isds_skeletal_category:
  - classification_value: fgfr3_chondrodysplasia
    notes: >-
      ISDS Nosology and Classification of Genetic Skeletal Disorders, 2019
      revision (Mortier et al., PMID:31633310), Table 1 group 1 "FGFR3
      chondrodysplasia group"; listed as "Achondroplasia".
prevalence:
- population: Global live births
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 4.6
  notes: >-
    A systematic review and meta-analysis estimated worldwide birth prevalence
    at 4.6 per 100,000 live births.
  evidence:
  - reference: PMID:32803853
    reference_title: "Birth prevalence of achondroplasia: A systematic literature review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Based on the meta-analysis, the worldwide birth prevalence of achondroplasia was estimated to be 4.6 per 100,000."
    explanation: This meta-analysis provides the strongest aggregate global birth-prevalence estimate for achondroplasia.
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Worldwide | Prevalence at birth | PMID:32803853"
    explanation: Orphanet epidemiology data confirm worldwide birth prevalence in the 1-9 per 100,000 range, consistent with published estimates.
- population: Europe
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 3.72
  notes: >-
    EUROCAT population-based surveillance identified 434 cases and estimated
    birth prevalence at 3.72 per 100,000 births.
  evidence:
  - reference: PMID:31294928
    reference_title: "Epidemiology of achondroplasia: A population-based study in Europe."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The study population consisted of 434 achondroplasia cases with a prevalence of 3.72 per 100,000 births (95%CIs: 3.14-4.39)."
    explanation: A large population-based European study provides the regional estimate.

progression:
- phase: Infancy
  age_range: Birth through the first two years
  notes: >-
    Hypotonia and achondroplasia-specific motor delay are typical.
    Craniocervical-junction compression is a distinct high-acuity risk and
    increases the risk of death in infancy.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In infancy, hypotonia is typical, and acquisition of developmental motor milestones is often both aberrant in pattern and delayed."
    explanation: The current clinical review describes the typical infant developmental course.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Intelligence and life span are usually near normal, although craniocervical junction compression increases the risk of death in infancy."
    explanation: >-
      The current clinical review identifies the phase-specific mortality risk.
      Its "near normal" life span is a qualitative clinical statement; the
      42-year cohort cited under clinical_burden (PMID:17879967) measured an
      average reduction of about ten years, driven by excess accidental,
      neurological and cardiovascular deaths in adulthood.
  - reference: PMID:24677650
    reference_title: "Mortality in babies with achondroplasia: revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although an overall improvement in mortality, especially after the first year of life, is observed in our cohort, children with achondroplasia are still at a much higher risk of death compared with the general population."
    explanation: A Texas birth-defects registry cohort (1996-2003 births) found all four deaths in the first year of life.
- phase: Early childhood
  age_range: Approximately two to ten years
  notes: >-
    Middle-ear dysfunction, sleep apnea, limb pain, and excess weight are common
    clinical burdens. Thoracolumbar kyphosis often improves after independent
    walking, although persistent deformity needs orthopedic follow-up.
  evidence:
  - reference: PMID:29972438
    reference_title: Natural history of 39 patients with Achondroplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common clinical intercurrences were middle ear dysfunction, sleep apnea, limb pain and obesity from 2 to 9 years of age."
    explanation: A natural-history cohort identifies the principal early-childhood burdens.
  - reference: PMID:37493935
    reference_title: "Walking status and spinopelvic parameters in young children with achondroplasia: 10-year follow-up."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thoracolumbar kyphosis (TLK) is common in children with achondroplasia and resolves in 90% by 10 years of age."
    explanation: Longitudinal follow-up supports usual improvement of kyphosis in childhood.
- phase: Later childhood and adolescence
  age_range: Approximately ten years through skeletal maturity
  notes: >-
    Lower-limb bowing can persist as a complex deformity involving lateral
    bowing, differential tibial and fibular growth, internal tibial torsion,
    and dynamic knee instability.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: '"Bowing" is actually a complex deformity arising from a combination of lateral bowing, differential growth between the tibia and fibula, internal tibial torsion, and dynamic instability of the knee'
    explanation: The current clinical review describes the interacting growth and mechanical components of lower-limb bowing.
- phase: Adulthood
  age_range: Skeletal maturity onward
  notes: >-
    Symptomatic spinal stenosis involving L1-L4 is the most common adult medical
    complaint. Imaging shows preferential upper-lumbar stenosis and disc
    degeneration.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The most common medical complaint in adulthood is symptomatic spinal stenosis involving L1-L4"
    explanation: The 2026 review identifies symptomatic upper-lumbar stenosis as the leading adult complaint.
  - reference: PMID:32170149
    reference_title: Lumbar spinal stenosis and disc alterations affect the upper lumbar spine in adults with achondroplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unlike the general population, spinal stenosis and disc degeneration involve the upper part of the lumbar spine in adults with achondroplasia, associated with thoraco-lumbar kyphosis and loss of lumbar lordosis."
    explanation: Adult imaging data define the characteristic upper-lumbar distribution.
  - reference: PMID:17879967
    reference_title: "Mortality in achondroplasia study: a 42-year follow-up."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Heart disease-related mortality, between ages 25 and 35, was more than 10 times higher than the general population. Overall survival and the average life expectancy for this ACH population were decreased by 10 years."
    explanation: A 42-year follow-up of 793 individuals documents excess adult cardiovascular mortality and reduced life expectancy.
clinical_burden:
  burden_level: HIGH
  rationale: >-
    Care is lifelong and multidisciplinary. Infants carry a risk of sudden
    death from craniocervical-junction compression, children have frequent
    airway, otologic and orthopedic complications, adults commonly develop
    symptomatic spinal stenosis, and overall life expectancy is reduced by
    about ten years with excess accidental, neurological and cardiovascular
    deaths. Intelligence is usually normal.
  evidence:
  - reference: PMID:30276962
    reference_title: Multicenter study of mortality in achondroplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sudden death and higher mortality are recognized in achondroplasia, with acute brainstem compression, a common cause of mortality in children <4 years and cardiovascular deaths being more prevalent in adults."
    explanation: Summarizes the age-specific causes of excess mortality.
  - reference: PMID:30276962
    reference_title: Multicenter study of mortality in achondroplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Causes of death in these patients have shifted over the last 30 years, with fewer sudden death and deaths because of pneumonia or hydrocephalus countered by more cardiovascular or cerebrovascular and accidental deaths."
    explanation: An 855-patient clinic-based cohort shows that improved childhood management has shifted rather than removed excess mortality.
  - reference: PMID:17879967
    reference_title: "Mortality in achondroplasia study: a 42-year follow-up."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Accidental, neurological, and heart disease-related deaths were increased in adults."
    explanation: Documents the adult causes of excess mortality.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_fgfr3_gain_of_function_chondrocyte_model
  hypothesis_label: FGFR3 Growth-Plate Signaling Model
  status: CANONICAL
  description: >-
    Recurrent heterozygous FGFR3 p.Gly380Arg gain-of-function prolongs receptor
    signaling in growth-plate chondrocytes. Experiments support delayed receptor
    down-regulation while G380R activation remains predominantly ligand
    dependent. MAPK-mediated inhibition of hypertrophic differentiation and a
    qualified STAT-p21 branch impair endochondral ossification.
  notes: >-
    Strict constitutive activation is not asserted as the sole receptor-level
    mechanism. CNP-analogue growth-velocity responses support therapeutic
    counter-regulation but do not establish final-height or complication benefit.
  evidence:
  - reference: PMID:10611230
    reference_title: The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We found that dimerization and activation of the G380R mutant receptor are predominantly ligand dependent."
    explanation: Direct receptor experiments qualify strict constitutive-activation shorthand.
  - reference: PMID:10611230
    reference_title: The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Metabolic pulse-chase experiments, cell surface labeling, and kinetics of uptake of radiolabeled ligand demonstrated a selective delay in the down-regulation of the mutant receptor."
    explanation: Direct experiments identify delayed receptor down-regulation.
  - reference: PMID:20624921
    reference_title: "Physical basis behind achondroplasia, the most common form of human dwarfism."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The data analysis presented here suggests that the mutation does not increase FGFR3 dimerization, as proposed previously. Instead, FGFR3 activity in achondroplasia is increased due to increased probability for phosphorylation of the unliganded mutant dimers."
    explanation: >-
      Quantitative receptor-activation measurements attribute the gain of
      function to a higher phosphorylation probability within unliganded
      dimers rather than to increased dimerization, independently supporting
      the entry's decision not to assert strict constitutive activation.
  - reference: DOI:10.1038/s41574-021-00595-x
    reference_title: International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The condition is caused by a common, recurring, gain-of-function mutation in FGFR3, the gene that encodes fibroblast growth factor receptor 3. This mutation leads to impaired endochondral ossification of the human skeleton."
    explanation: International consensus links FGFR3 gain of function to impaired endochondral ossification.

pathophysiology:
- name: FGFR3 p.Gly380Arg gain-of-function with impaired receptor down-regulation
  role: trigger
  conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Constitutive FGFR Activation"
  description: >-
    Nearly all individuals have one of two substitutions producing p.Gly380Arg.
    The receptor is gain of function, but experiments show predominantly
    ligand-dependent activation with delayed down-regulation and resistance to
    ligand-mediated internalization.
  gene:
    preferred_term: FGFR3
    term:
      id: hgnc:3690
      label: FGFR3
  molecular_functions:
  - preferred_term: transmembrane receptor protein tyrosine kinase activity
    term:
      id: GO:0004714
      label: transmembrane receptor protein tyrosine kinase activity
    modifier: INCREASED
  biological_processes:
  - preferred_term: fibroblast growth factor receptor signaling pathway
    term:
      id: GO:0008543
      label: fibroblast growth factor receptor signaling pathway
    modifier: INCREASED
  evidence:
  - reference: PMID:7847369
    reference_title: Achondroplasia is defined by recurrent G380R mutations of FGFR3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All but one, an atypical case, were found to have a glycine-to-arginine substitution at codon 380. Of these, 150 had a G-to-A transition at nt 1138, and 3 had a G-to-C transversion at this same position."
    explanation: A 154-person series demonstrates the near-uniform recurrent p.Gly380Arg genotype.
  - reference: PMID:10611230
    reference_title: The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Moreover, this receptor was now resistant to ligand-mediated internalization, even at saturating ligand concentrations."
    explanation: Directly supports impaired internalization.
  - reference: CGGV:assertion_0adafa1b-e609-4b99-8e90-f73473b70771-2023-09-28T040000.000Z
    reference_title: FGFR3 / achondroplasia (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FGFR3 | HGNC:3690 | achondroplasia | MONDO:0007037 | AD | Definitive"
    explanation: ClinGen classifies the autosomal-dominant FGFR3 relationship as definitive.
  - reference: PMID:8630492
    reference_title: Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Skeletal defects include kyphosis, scoliosis, crooked tails and curvature and overgrowth of long bones and vertebrae. Contrasts between the skeletal phenotype and achondroplasia suggest that activation of FGFR3 causes achondroplasia."
    explanation: >-
      Targeted disruption of Fgfr3 produces the reciprocal long-bone and
      vertebral overgrowth phenotype, establishing FGFR3 as a negative
      regulator of endochondral bone growth and supporting receptor activation
      rather than loss of function as the achondroplasia mechanism.
  downstream:
  - target: Prolonged FGFR3 signaling in growth-plate chondrocytes
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: DIRECT
    description: Delayed down-regulation expands mutant-receptor signaling in growth plate.
    evidence:
    - reference: PMID:10611230
      reference_title: The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "transgenic mice expressing the human G380R mutant receptor under the mouse receptor transcriptional control demonstrated a markedly expanded area of FGFR3 immunoreactivity within their epiphyseal growth plates, compatible with an in vivo defect in receptor down-regulation."
      explanation: In vivo receptor distribution supports prolonged growth-plate signaling.

- name: Prolonged FGFR3 signaling in growth-plate chondrocytes
  conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Sustained MAPK/STAT Signaling"
  role: central_effector
  description: >-
    Delayed internalization expands mutant FGFR3 immunoreactivity in epiphyseal
    growth plates, where signal kinetics regulate chondrocyte maturation.
  cell_types:
  - preferred_term: growth plate cartilage chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  biological_processes:
  - preferred_term: MAPK cascade
    term:
      id: GO:0000165
      label: MAPK cascade
    modifier: INCREASED
  - preferred_term: ERK1 and ERK2 cascade
    term:
      id: GO:0070371
      label: ERK1 and ERK2 cascade
    modifier: INCREASED
  - preferred_term: cell surface receptor signaling pathway via STAT
    term:
      id: GO:0097696
      label: cell surface receptor signaling pathway via STAT
    modifier: INCREASED
  evidence:
  - reference: PMID:10611230
    reference_title: The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "transgenic mice expressing the human G380R mutant receptor under the mouse receptor transcriptional control demonstrated a markedly expanded area of FGFR3 immunoreactivity within their epiphyseal growth plates, compatible with an in vivo defect in receptor down-regulation."
    explanation: Transgenic mice provide in vivo evidence for expanded receptor persistence.
  downstream:
  - target: Growth-plate chondrocyte dysregulation
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: DIRECT
    description: Prolonged signaling engages MAPK and STAT-p21 growth-inhibitory programs.
    evidence:
    - reference: PMID:14871928
      reference_title: Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These observations suggest a model in which Fgfr3 signaling inhibits bone growth by inhibiting chondrocyte differentiation through the MAPK pathway and by inhibiting chondrocyte proliferation through Stat1."
      explanation: Genetic mouse experiments support MAPK and a parallel STAT1 branch.
  - target: Primary cilium shortening and disrupted ciliary signaling
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: DIRECT
    description: >-
      Sustained receptor activity shortens the chondrocyte primary cilium and
      misroutes IFT20; pharmacologic FGFR inhibition restores both, placing the
      ciliary change downstream of receptor activation.
    evidence:
    - reference: PMID:29040558
      reference_title: Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "We demonstrated that inhibiting FGFR3 with FGFR inhibitor, PD173074, rescued both PC length and IFT20 trafficking."
      explanation: >-
        Rescue of the ciliary phenotype by receptor inhibition establishes the
        direction of the edge in chondrocyte models; the magnitude of the human
        contribution is not established by this experiment.

- name: Primary cilium shortening and disrupted ciliary signaling
  role: effector
  description: >-
    Sustained FGFR3 activity shortens the chondrocyte primary cilium and
    disrupts sorting and intraflagellar transport of IFT20, with downstream
    change in cilium-based Hedgehog signaling. This branch is curated as an
    emerging consequence of receptor activation, not as an independent cause:
    its quantitative contribution relative to the direct MAPK and STAT arms
    has not been isolated in human growth plate, and the entry does not
    classify achondroplasia as a ciliopathy on this evidence.
  cell_types:
  - preferred_term: growth plate cartilage chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  biological_processes:
  - preferred_term: cilium assembly
    term:
      id: GO:0060271
      label: cilium assembly
    modifier: DYSREGULATED
  - preferred_term: intraciliary transport
    term:
      id: GO:0042073
      label: intraciliary transport
    modifier: DYSREGULATED
  - preferred_term: smoothened signaling pathway
    term:
      id: GO:0007224
      label: smoothened signaling pathway
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:29040558
    reference_title: Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Here we showed that in chondrocytes from human (ACH, TD) and mouse Fgfr3Y367C/+ cartilage, the constitutively active FGFR3 perturbed PC length and the sorting and trafficking of intraflagellar transport (IFT) 20 to the PC."
    explanation: >-
      Chondrocytes taken from human achondroplasia and thanatophoric dysplasia
      cartilage, alongside a mouse model, show the ciliary length and IFT20
      trafficking defect.
  - reference: PMID:29360984
    reference_title: Regulation of ciliary function by fibroblast growth factor signaling identifies FGFR3-related disorders achondroplasia and thanatophoric dysplasia as ciliopathies.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Here, we report in vivo evidence for significantly shortened primary cilia in ACH and TD cartilage growth plates."
    explanation: >-
      Supplies the in vivo growth-plate measurement of cilium shortening. The
      achondroplasia arm of this experiment is an Fgfr3 p.Gly369Cys mouse and
      the thanatophoric arm is a transfected cell line, so it is graded as
      model-organism evidence despite the title's ciliopathy framing.
  downstream:
  - target: Growth-plate chondrocyte dysregulation
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Restoring ciliary organization pharmacologically increases bone
      elongation in a mouse model, supporting a contributory route from the
      ciliary defect back to growth-plate dysfunction.
    evidence:
    - reference: PMID:35078974
      reference_title: Theobroma cacao improves bone growth by modulating defective ciliogenesis in a mouse model of achondroplasia.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In vivo, we confirmed that daily subcutaneous injections of (-)-epicatechin to Fgfr3Y367C/+ mice increased bone elongation and rescued the primary cilium defects observed in chondrocytes."
      explanation: >-
        A rescue experiment couples correction of the ciliary defect to
        increased bone elongation in the mouse, which is the strongest current
        support for this edge; the compound is not selective for cilia, so
        intermediates remain unspecified.

- name: Growth-plate chondrocyte dysregulation
  conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Growth-Plate Chondrocyte Dysregulation"
  role: effector
  description: >-
    MAPK inhibits hypertrophic differentiation in models. Human fetal growth
    plates support altered FGFR3/STAT/p21 expression and premature cell-cycle
    exit. STAT1 is not treated as sufficient to explain all growth inhibition.
  cell_types:
  - preferred_term: growth plate cartilage chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  - preferred_term: prehypertrophic chondrocyte
    term:
      id: CL:0020022
      label: prehypertrophic chondrocyte
  biological_processes:
  - preferred_term: MAPK cascade
    term:
      id: GO:0000165
      label: MAPK cascade
    modifier: INCREASED
  - preferred_term: chondrocyte differentiation
    term:
      id: GO:0002062
      label: chondrocyte differentiation
    modifier: DYSREGULATED
  - preferred_term: cell population proliferation
    term:
      id: GO:0008283
      label: cell population proliferation
    modifier: DECREASED
  evidence:
  - reference: PMID:14871928
    reference_title: Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These observations indicate that the MAPK pathway inhibits hypertrophic differentiation of chondrocytes and negatively regulates bone growth without inhibiting chondrocyte proliferation."
    explanation: Active MEK1 supports inhibition of hypertrophic differentiation by MAPK.
  - reference: PMID:14751560
    reference_title: Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Immunohistochemical analysis of fetal growth plates showed a phenotype-related reduction of the collagen type X-positive hypertrophic zone."
    explanation: Human fetal histology documents a reduced hypertrophic zone.
  downstream:
  - target: Impaired endochondral ossification and chondrodysplasia
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: DIRECT
    description: Dysregulated growth-plate maturation impairs endochondral bone growth.
    evidence:
    - reference: PMID:14871928
      reference_title: Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These observations indicate that the MAPK pathway inhibits hypertrophic differentiation of chondrocytes and negatively regulates bone growth without inhibiting chondrocyte proliferation."
      explanation: The model links differentiation impairment to reduced bone growth.
    - reference: PMID:14751560
      reference_title: Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Immunohistochemical analysis of fetal growth plates showed a phenotype-related reduction of the collagen type X-positive hypertrophic zone."
      explanation: Human fetal histology corroborates the impaired hypertrophic compartment.

- name: Impaired endochondral ossification and chondrodysplasia
  conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Impaired Endochondral Ossification and Chondrodysplasia"
  role: consequence
  description: >-
    Altered growth-plate maturation reduces the hypertrophic zone and impairs
    endochondral ossification. Anatomical consequences are represented through
    calibrated branches rather than an unsupported all-phenotype fan-out.
  cell_types:
  - preferred_term: hypertrophic chondrocyte
    term:
      id: CL:0000743
      label: hypertrophic chondrocyte
  - preferred_term: columnar chondrocyte
    term:
      id: CL:0000744
      label: columnar chondrocyte
  biological_processes:
  - preferred_term: endochondral ossification
    term:
      id: GO:0001958
      label: endochondral ossification
    modifier: DECREASED
  - preferred_term: growth plate cartilage development
    term:
      id: GO:0003417
      label: growth plate cartilage development
    modifier: DYSREGULATED
  evidence:
  - reference: DOI:10.1038/s41574-021-00595-x
    reference_title: International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This mutation leads to impaired endochondral ossification of the human skeleton."
    explanation: International consensus identifies the central consequence.
  downstream:
  - target: Reduced longitudinal growth of endochondral bones
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: DIRECT
    description: Impaired hypertrophic differentiation reduces longitudinal growth.
    evidence:
    - reference: PMID:14871928
      reference_title: Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These observations indicate that the MAPK pathway inhibits hypertrophic differentiation of chondrocytes and negatively regulates bone growth without inhibiting chondrocyte proliferation."
      explanation: The model links impaired differentiation to reduced bone growth.
  - target: Cranial-base and vertebral synchondrosis dysplasia
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: UNKNOWN
    description: The endochondral process affects synchondroses, but ordinary-heterozygous causal evidence is incomplete.
    evidence:
    - reference: PMID:18923003
      reference_title: FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We observed premature synchondrosis closure in the spine and cranial base in human cases of homozygous achondroplasia and thanatophoric dysplasia"
      explanation: Severe human FGFR3 dysplasias support the branch but do not directly establish it in ordinary heterozygous achondroplasia.
    - reference: PMID:18923003
      reference_title: FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Chondrocyte-specific activation of Fgfr3 in mice induced premature synchondrosis closure and enhanced osteoblast differentiation around synchondroses."
      explanation: Chondrocyte-specific mouse activation supplies causal model support for the branch.
  - target: Congenital spinal-canal constraint with superimposed degeneration
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: UNKNOWN
    description: Impaired vertebral growth plausibly contributes to congenital constraint; adult degeneration adds a second component.
    evidence:
    - reference: PMID:32864841
      reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."
      explanation: Longitudinal data establish stenosis but not the entire upstream route.
  - target: Elbow contracture
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: UNKNOWN
    description: >-
      Elbow contractures are observed during childhood in the chondrodysplasia;
      the specific growth-plate route to the joint restriction is not
      established by the cited source.
    evidence:
    - reference: PMID:32864841
      reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."
      explanation: Longitudinal data record elbow contractures appearing during childhood in achondroplasia, documenting timing rather than the causal route.
  - target: Radial head dislocation
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: UNKNOWN
    description: >-
      Radial head dislocation is observed during childhood in the
      chondrodysplasia; the specific route through elbow joint dysplasia is not
      established by the cited source.
    evidence:
    - reference: PMID:32864841
      reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."
      explanation: Longitudinal data record radial head dislocations appearing during childhood in achondroplasia, documenting timing rather than the causal route.
  - target: Limited elbow extension
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: UNKNOWN
    description: >-
      Limitation of elbow extension is part of the characteristic skeletal
      pattern of the chondrodysplasia; the specific articular mechanism is not
      established by the cited source.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
      reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Individuals with achondroplasia have short stature with rhizomelic shortening of the limbs, macrocephaly, characteristic facies with frontal bossing and midface retrusion, exaggerated lumbar lordosis, limitation of elbow extension and rotation, genu varum, brachydactyly, and trident appearance of the hands."
      explanation: The clinical review places limited elbow extension within the characteristic chondrodysplasia pattern.
  - target: Thoracic hypoplasia
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: UNKNOWN
    description: >-
      The ribs and thoracic vertebral elements grow by endochondral
      ossification and a small chest is part of the skeletal phenotype; the
      cited source documents the finding rather than the specific growth-plate
      route.
    evidence:
    - reference: ORPHA:15
      reference_title: Achondroplasia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0005257 | Thoracic hypoplasia | Occasional (29-5%)"
      explanation: Orphanet documents thoracic hypoplasia within the achondroplasia phenotype.
  - target: Restrictive ventilatory defect
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Small thoracic cage with increased chest-wall compliance
    - Reduced lung volumes
    description: >-
      A small, hypercompliant thoracic cage reduces lung volumes, producing
      restrictive pulmonary physiology in a subset of infants.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
      reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "A small chest and increased compliance of the thoracic cage combine to result in smaller lung volumes and restrictive pulmonary disease"
      explanation: The clinical review states the chest-mechanics route from a small thorax to restrictive pulmonary disease.
  - target: Bowing of the legs
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: UNKNOWN
    description: Lower-limb bowing overlaps clinically with genu varum; the specific growth-plate route is not established by the cited source.
    evidence:
    - reference: PMID:32864841
      reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."
      explanation: The same childhood angular-deformity observation supports lower-limb bowing (which overlaps clinically with genu varum) as to timing, not causal route.

- name: Reduced longitudinal growth of endochondral bones
  description: >-
    Reduced long-bone growth produces disproportionate short stature,
    rhizomelic limb shortening, and characteristic hand shortening.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Individuals with achondroplasia have short stature with rhizomelic shortening of the limbs, macrocephaly, characteristic facies with frontal bossing and midface retrusion, exaggerated lumbar lordosis, limitation of elbow extension and rotation, genu varum, brachydactyly, and trident appearance of the hands."
    explanation: The current review documents the characteristic pattern.
  downstream:
  - target: Disproportionate short stature
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: DIRECT
    description: Reduced longitudinal growth produces disproportionate stature.
    evidence:
    - reference: PMID:32803853
      reference_title: "Birth prevalence of achondroplasia: A systematic literature review and meta-analysis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Achondroplasia is a genetic disorder that results in disproportionate short stature."
      explanation: The review identifies the defining result.
  - target: Rhizomelia
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Preferential undergrowth of proximal long-bone segments
    description: Proximal long-bone undergrowth produces rhizomelia.
    evidence:
    - reference: PMID:29972438
      reference_title: Natural history of 39 patients with Achondroplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The most prevalent radiographic findings were rhizomelic shortening of the long bones and narrowing of the interpediculate distance of the caudal spine."
      explanation: Cohort radiographs document rhizomelic shortening.
  - target: Limb undergrowth
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: DIRECT
    description: Reduced longitudinal growth is expressed as limb undergrowth.
    evidence:
    - reference: ORPHA:15
      reference_title: Achondroplasia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0009826 | Limb undergrowth | Very frequent (99-80%)"
      explanation: Orphanet documents limb undergrowth as a core feature.
  - target: Brachydactyly
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced longitudinal growth of metacarpals and phalanges
    description: Shortening of endochondral hand bones produces brachydactyly.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
      reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Individuals with achondroplasia have short stature with rhizomelic shortening of the limbs, macrocephaly, characteristic facies with frontal bossing and midface retrusion, exaggerated lumbar lordosis, limitation of elbow extension and rotation, genu varum, brachydactyly, and trident appearance of the hands."
      explanation: The review supports brachydactyly within the pattern.
  - target: Trident hand
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Phalangeal shortening and separation of the third and fourth digits
    description: Hand-bone shortening contributes to the trident configuration.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
      reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Individuals with achondroplasia have short stature with rhizomelic shortening of the limbs, macrocephaly, characteristic facies with frontal bossing and midface retrusion, exaggerated lumbar lordosis, limitation of elbow extension and rotation, genu varum, brachydactyly, and trident appearance of the hands."
      explanation: The review supports the characteristic trident hand.
  - target: Short middle phalanx of finger
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced longitudinal growth of metacarpals and phalanges
    description: >-
      Shortening of the endochondral hand bones includes the middle phalanges,
      a component of the brachydactyly and trident-hand pattern.
    evidence:
    - reference: ORPHA:15
      reference_title: Achondroplasia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0005819 | Short middle phalanx of finger | Frequent (79-30%)"
      explanation: Orphanet documents middle-phalanx shortening as a frequent component of the hand phenotype.
  - target: Short proximal phalanx of finger
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced longitudinal growth of metacarpals and phalanges
    description: >-
      Shortening of the endochondral hand bones includes the proximal
      phalanges, a component of the brachydactyly and trident-hand pattern.
    evidence:
    - reference: ORPHA:15
      reference_title: Achondroplasia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0010241 | Short proximal phalanx of finger | Frequent (79-30%)"
      explanation: Orphanet documents proximal-phalanx shortening as a frequent component of the hand phenotype.
  - target: Delayed gross motor development
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Disproportionate body habitus with rhizomelic limbs and relatively large head
    description: >-
      The disproportionate body habitus alters the biomechanics of early motor
      skills and head support. Infantile hypotonia and joint hypermobility,
      which are documented but not themselves mechanistically explained, add to
      the delay (see the associated knowledge-gap discussion).
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
      reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Differences in body habitus cause motor delays and unusual patterns of motor development such as snowplowing (using the head and feet to leverage movement)"
      explanation: The clinical review directly attributes motor delay to the altered body habitus.
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
      reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Infants have difficulty in supporting their heads because of both hypotonia and large head size."
      explanation: The review identifies head size and hypotonia as combined proximate contributors to early motor difficulty.

- name: Cranial-base and vertebral synchondrosis dysplasia
  description: >-
    FGFR3-MAPK activation promotes premature closure in models and severe human
    FGFR3 dysplasias. CT in heterozygous achondroplasia documents skull-base
    fusion and age-associated craniofacial severity.
  cell_types:
  - preferred_term: growth plate cartilage chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  evidence:
  - reference: PMID:18923003
    reference_title: FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Chondrocyte-specific activation of Fgfr3 in mice induced premature synchondrosis closure and enhanced osteoblast differentiation around synchondroses."
    explanation: Chondrocyte-specific activation establishes a causal model mechanism.
  - reference: PMID:37072824
    reference_title: "Craniofacial growth and function in achondroplasia: a multimodal 3D study on 15 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients with available CT-scan had premature fusion of skull base synchondroses."
    explanation: CT documents skull-base fusion in a clinical cohort.
  downstream:
  - target: Foramen magnum stenosis
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Restricted endochondral growth of the skull base
    - Reduced bony dimensions of the foramen magnum
    description: Skull-base growth restriction contributes to narrowing.
    evidence:
    - reference: PMID:32883660
      reference_title: "Achondroplasia Foramen Magnum Score: screening infants for stenosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Of 36 infants (M:F, 18:18), 2 (5.6%) did not have FMS (AFMS0); 13 (36.1%) had FMS with preservation of the cerebrospinal fluid (CSF) spaces (AFMS1); 3 (8.3%) had FMS with loss of the CSF space but no spinal cord distortion (AFMS2); 13 (36.1%) had FMS with flattening of the cervical cord without signal change (AFMS3); and 5 (13.9%) had FMS resulting in cervical cord signal change (AFMS4)."
      explanation: MRI establishes the stenosis spectrum; the upstream link remains partly inferential.
  - target: Jugular-foramen venous outflow impairment
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced skull-base dimensions
    - Jugular-foramen narrowing
    description: Skull-base undergrowth can narrow jugular foramina.
    evidence:
    - reference: PMID:33579320
      reference_title: Predictors of cervical myelopathy and hydrocephalus in young children with achondroplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the size of the cranial base, which is formed by endochondral ossification, is smaller, and the jugular foramen is also smaller. This condition causes a partial obstruction of venous flow, which increases intracranial venous pressure and causes problems with the venous resorption of cerebrospinal fluid (CSF)"
      explanation: The study states the skull-base-to-venous-obstruction mechanism.
  - target: Craniofacial and upper-airway restriction
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Anteroposterior restriction of facial growth
    description: >-
      Premature skull-base synchondrosis fusion restricts anteroposterior
      facial growth, producing maxillary and midfacial retrusion; imaging
      associations corroborate coupled skull-base and midface severity.
    evidence:
    - reference: PMID:37072824
      reference_title: "Craniofacial growth and function in achondroplasia: a multimodal 3D study on 15 patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: |-
        Gradual premature fusion of skull base synchondro-
        ses contributes to anteroposterior facial growth restric -
        tion and subsequent maxillary and midfacial retrusion
      explanation: The craniofacial study states the causal route from premature synchondrosis fusion to midfacial retrusion.
    - reference: PMID:37072824
      reference_title: "Craniofacial growth and function in achondroplasia: a multimodal 3D study on 15 patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "3D morphometric analyses showed more severe craniofacial phenotypes associated with increasing patient age, predominantly regarding the midface-with increased maxillary retrusion in older patients-and the skull base-with closure of the spheno-occipital angle."
      explanation: Cross-sectional associations support coupled skull-base and midface morphology.
  - target: Depressed nasal bridge
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: UNKNOWN
    description: >-
      Nasal-root depression at the nasofrontal junction is associated with the
      restricted anteroposterior skull-base growth; the cited source reports
      the association rather than a resolved causal route.
    evidence:
    - reference: PMID:37072824
      reference_title: "Craniofacial growth and function in achondroplasia: a multimodal 3D study on 15 patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "excessive frontal convexity is also accentuated by the presence of a nasal root depression at the nasofrontal junction, associated with the restricted anteroposterior growth of the skull base."
      explanation: The craniofacial study ties the depressed nasal root to restricted skull-base growth as an association.
  - target: Cervical myelopathy
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Foramen magnum stenosis
    - Cervicomedullary cord compression
    description: >-
      The stenotic foramen magnum compresses the cervicomedullary cord;
      constriction severity predicts myelopathy in screened young children.
    evidence:
    - reference: PMID:33579320
      reference_title: "Predictors of cervical myelopathy and hydrocephalus in young children with achondroplasia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The group with cervical myelopathy showed foramen magnum parameters that indicated significantly lower cord thickness than in the group without cervical myelopathy"
      explanation: Foramen-magnum cord-constriction parameters distinguish children with myelopathy, supporting the compression route.
    - reference: PMID:33579320
      reference_title: "Predictors of cervical myelopathy and hydrocephalus in young children with achondroplasia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the small size of the foramen magnum does not change, which may increase the likelihood of insidious or accidental cord injury"
      explanation: The study identifies persistent foramen magnum stenosis as the substrate for cord injury.
  - target: Central sleep apnea
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Foramen magnum stenosis with cervicomedullary compression
    - Injury to medullary respiratory control centers
    description: >-
      Craniocervical-junction compression can injure medullary respiratory
      control centers, producing the central apnea component of
      sleep-disordered breathing in infancy; this edge covers the
      compression-associated component rather than all central apnea.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
      reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The risk appears to be secondary to central apnea associated with damage to respiratory control centers"
      explanation: In the craniocervical-junction section, the review attributes infant risk to central apnea from respiratory-control-center damage.
    - reference: PMID:33579320
      reference_title: "Predictors of cervical myelopathy and hydrocephalus in young children with achondroplasia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cervical myelopathy was diagnosed when there were (1) neurological abnormalities, including long tract sign, apnea, or a history of respiratory arrest"
      explanation: Apnea and respiratory arrest are treated clinically as manifestations of cervicomedullary compression.
  - target: Caudal interpedicular narrowing
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: UNKNOWN
    description: Vertebral dysplasia is associated with the caudal interpedicular pattern.
    evidence:
    - reference: PMID:29972438
      reference_title: Natural history of 39 patients with Achondroplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The most prevalent radiographic findings were rhizomelic shortening of the long bones and narrowing of the interpediculate distance of the caudal spine."
      explanation: Radiographs establish the finding but not the complete upstream route.

- name: Jugular-foramen venous outflow impairment
  description: >-
    Narrow jugular foramina can obstruct cerebral venous drainage, increasing
    venous pressure and impairing cerebrospinal-fluid resorption.
  evidence:
  - reference: PMID:33579320
    reference_title: Predictors of cervical myelopathy and hydrocephalus in young children with achondroplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This condition causes a partial obstruction of venous flow, which increases intracranial venous pressure and causes problems with the venous resorption of cerebrospinal fluid (CSF)"
    explanation: The study states the venous and CSF-resorption mechanism.
  downstream:
  - target: Hydrocephalus
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Raised intracranial venous pressure
    - Impaired cerebrospinal-fluid resorption
    description: Venous hypertension and impaired CSF resorption can produce hydrocephalus.
    evidence:
    - reference: PMID:33579320
      reference_title: Predictors of cervical myelopathy and hydrocephalus in young children with achondroplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This condition causes a partial obstruction of venous flow, which increases intracranial venous pressure and causes problems with the venous resorption of cerebrospinal fluid (CSF)"
      explanation: The source supplies both named intermediates.

- name: Craniofacial and upper-airway restriction
  description: >-
    Midface and maxillomandibular retrusion reduce upper-airway dimensions;
    lymphoid hypertrophy, airway malacia, and hypotonia can add obstruction.
    The same midface hypoplasia shortens the Eustachian tubes and narrows the
    nasopharynx, predisposing to chronic middle-ear effusion and its
    conductive-hearing consequences.
  evidence:
  - reference: PMID:37072824
    reference_title: "Craniofacial growth and function in achondroplasia: a multimodal 3D study on 15 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report a significant correlation between the severity of maxillo-mandibular retrusion and obstructive sleep apnea syndrome (p < 0.01)."
    explanation: Clinical morphometry links retrusion with obstructive sleep apnea.
  downstream:
  - target: Midface retrusion
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: UNKNOWN
    description: Midface retrusion is an anatomical component of restriction.
    evidence:
    - reference: PMID:37072824
      reference_title: "Craniofacial growth and function in achondroplasia: a multimodal 3D study on 15 patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Craniofacial phenotype was characterized by maxillo-zygomatic retrusion, deep nasal root, and prominent forehead."
      explanation: Multimodal assessment directly documents retrusion.
  - target: Obstructive sleep apnea
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced upper-airway dimensions from midface retrusion
    - Lymphoid-ring hypertrophy, airway malacia, and airway hypotonia
    description: >-
      Midface retrusion reduces airway size, and lymphoid hypertrophy, airway
      malacia, and airway hypotonia combine with it to produce obstruction;
      retrusion severity correlates with apnea severity.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
      reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "It arises because of a combination of midface retrusion resulting in smaller airway size, hypertrophy of the lymphatic ring, airway malacia"
      explanation: The clinical review states the multifactorial anatomical mechanism of obstructive sleep apnea.
    - reference: PMID:37072824
      reference_title: "Craniofacial growth and function in achondroplasia: a multimodal 3D study on 15 patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We report a significant correlation between the severity of maxillo-mandibular retrusion and obstructive sleep apnea syndrome (p < 0.01)."
      explanation: The association supports a contribution without proving sole causation.
  - target: Functional abnormality of the middle ear
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Short Eustachian tubes with impaired middle-ear ventilation
    description: >-
      Midface hypoplasia with short Eustachian tubes and a small pharynx
      predisposes to recurrent upper-airway infection and impaired middle-ear
      ventilation.
    evidence:
    - reference: PMID:34736503
      reference_title: "Hearing loss in Norwegian adults with achondroplasia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "midface hypoplasia, short Eustachian tubes, small pharynx, and the relative enlargement of tonsils and/or adenoids, are predisposing factors for recurrent upper airway infections and chronic middle ear effusion"
      explanation: The study states the anatomical predisposition underlying middle-ear dysfunction in achondroplasia.
  - target: Otitis media with effusion
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Eustachian-tube dysfunction with impaired middle-ear drainage
    description: >-
      Eustachian-tube dysfunction from the craniofacial anatomy produces
      chronic middle-ear effusion.
    evidence:
    - reference: PMID:34736503
      reference_title: "Hearing loss in Norwegian adults with achondroplasia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "midface hypoplasia, short Eustachian tubes, small pharynx, and the relative enlargement of tonsils and/or adenoids, are predisposing factors for recurrent upper airway infections and chronic middle ear effusion"
      explanation: The study names chronic middle-ear effusion as the consequence of the craniofacial predisposing factors.
  - target: Conductive hearing impairment
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Chronic middle-ear effusion
    description: >-
      Chronic middle-ear effusion from Eustachian-tube dysfunction impairs
      sound conduction, producing the predominantly conductive hearing loss of
      achondroplasia.
    evidence:
    - reference: PMID:34736503
      reference_title: "Hearing loss in Norwegian adults with achondroplasia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Conductive hearing loss is commonly caused by middle ear effusion due to Eustachian tube dysfunction"
      explanation: The study states the causal chain from Eustachian-tube dysfunction through effusion to conductive hearing loss.
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
      reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "and if inadequately treated can result in conductive hearing loss of sufficient severity to interfere with language development"
      explanation: The clinical review links inadequately treated middle-ear dysfunction to conductive hearing loss.
  - target: Delayed speech and language development
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Conductive hearing loss during language acquisition
    description: >-
      Conductive hearing loss during the language-acquisition window
      contributes to speech and language delay; oral motor hypotonia is a
      documented co-contributor that is not itself mechanistically explained.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
      reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Conductive hearing loss and oral motor hypotonia can contribute to delayed speech development"
      explanation: The clinical review names conductive hearing loss as a proximate contributor to speech delay.
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
      reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "and if inadequately treated can result in conductive hearing loss of sufficient severity to interfere with language development"
      explanation: The review states that untreated middle-ear disease can impair language development via hearing loss.

- name: Congenital spinal-canal constraint with superimposed degeneration
  description: >-
    Altered vertebral geometry constrains the canal; disc degeneration and
    sagittal deformity add to adult upper-lumbar narrowing.
  evidence:
  - reference: PMID:32170149
    reference_title: Lumbar spinal stenosis and disc alterations affect the upper lumbar spine in adults with achondroplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unlike the general population, spinal stenosis and disc degeneration involve the upper part of the lumbar spine in adults with achondroplasia, associated with thoraco-lumbar kyphosis and loss of lumbar lordosis."
    explanation: Adult imaging supports combined stenotic and degenerative components.
  downstream:
  - target: Spinal canal stenosis
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: DIRECT
    description: Congenital constraint and degeneration produce recognized stenosis.
    evidence:
    - reference: PMID:32864841
      reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."
      explanation: Longitudinal records establish cervical and lumbar stenosis.
  - target: Cervical spinal canal stenosis
    hypothesis_groups:
    - canonical_fgfr3_gain_of_function_chondrocyte_model
    causal_link_type: DIRECT
    description: The congenital component can affect the cervical canal.
    evidence:
    - reference: PMID:32864841
      reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."
      explanation: The study explicitly reports cervical stenosis.

- name: CNP-NPR2 counter-regulation of FGFR3-MAPK signaling
  conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#CNP-NPR2 Counter-Regulation and FGFR-Pathway Antagonist Therapy"
  role: therapeutic_vulnerability
  description: >-
    CNP signaling through NPR2/GC-B counteracts FGFR3-MAPK activity. CNP
    corrected matrix synthesis and bone shortening in a mouse model without
    correcting the STAT1 branch.
  cell_types:
  - preferred_term: growth plate cartilage chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  biological_processes:
  - preferred_term: receptor guanylyl cyclase signaling pathway
    term:
      id: GO:0007168
      label: receptor guanylyl cyclase signaling pathway
  - preferred_term: MAPK cascade
    term:
      id: GO:0000165
      label: MAPK cascade
    modifier: DECREASED
  evidence:
  - reference: PMID:14702637
    reference_title: Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "CNP prevented the shortening of achondroplastic bones by correcting the decreased extracellular matrix synthesis in the growth plate through inhibition of the MAPK pathway of FGF signaling."
    explanation: Mouse data support CNP counter-regulation of MAPK.
  - reference: PMID:14702637
    reference_title: Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "CNP had no effect on the STAT-1 pathway of FGF signaling that mediates the decreased proliferation and the delayed differentiation of achondroplastic chondrocytes."
    explanation: The model defines the limitation on the STAT1 branch.
phenotypes:
- name: Disproportionate short stature
  description: >
    Disproportionate short-limb short stature is a defining skeletal manifestation
    of achondroplasia.
  phenotype_term:
    preferred_term: Disproportionate short-limb short stature
    term:
      id: HP:0008873
      label: Disproportionate short-limb short stature
  evidence:
  - reference: PMID:32803853
    reference_title: "Birth prevalence of achondroplasia: A systematic literature review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Achondroplasia is a genetic disorder that results in disproportionate short stature."
    explanation: Supports disproportionate short stature as a core phenotype of achondroplasia.
- name: Rhizomelia
  description: >
    Shortening is most pronounced in the proximal long bones. Orphanet codes
    the strict HPO term HP:0008905 (Rhizomelia) as Occasional; the broader
    rhizomelic shortening pattern is characteristic but captured under
    Disproportionate short stature and Limb undergrowth.
  phenotype_term:
    preferred_term: Rhizomelia
    term:
      id: HP:0008905
      label: Rhizomelia
  evidence:
  - reference: PMID:29972438
    reference_title: "Natural history of 39 patients with Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most prevalent radiographic findings were rhizomelic shortening of the long bones and narrowing of the interpediculate distance of the caudal spine."
    explanation: Supports rhizomelic long-bone shortening as a characteristic skeletal manifestation.
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0008905 | Rhizomelia | Occasional (29-5%)"
    explanation: Orphanet classifies rhizomelia as occasional in achondroplasia.
- name: Macrocephaly
  frequency: FREQUENT
  description: >
    Macrocephaly is part of the characteristic cranial phenotype.
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:29972438
    reference_title: "Natural history of 39 patients with Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most prevalent clinical findings were short stature, high forehead, trident hands, genu varum and macrocephaly."
    explanation: Clinical cohort data identify macrocephaly as one of the most prevalent physical findings.
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000256 | Macrocephaly | Frequent (79-30%)"
    explanation: Orphanet classifies macrocephaly as frequent in achondroplasia.
- name: Parietal bossing
  frequency: FREQUENT
  description: >
    Parietal bossing is part of the cranial-vault expansion phenotype that
    accompanies macrocephaly in achondroplasia.
  phenotype_term:
    preferred_term: Parietal bossing
    term:
      id: HP:0000242
      label: Parietal bossing
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000242 | Parietal bossing | Frequent (79-30%)"
    explanation: Orphanet classifies parietal bossing as frequent in achondroplasia.
- name: Wide anterior fontanel
  frequency: OCCASIONAL
  description: >
    A widened anterior fontanel can be present as an occasional cranial
    ossification finding in achondroplasia.
  phenotype_term:
    preferred_term: Wide anterior fontanel
    term:
      id: HP:0000260
      label: Wide anterior fontanel
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000260 | Wide anterior fontanel | Occasional (29-5%)"
    explanation: Orphanet classifies wide anterior fontanel as occasional in achondroplasia.
- name: Prominent forehead
  description: >
    Prominent forehead is a characteristic craniofacial feature.
  phenotype_term:
    preferred_term: Prominent forehead
    term:
      id: HP:0011220
      label: Prominent forehead
  evidence:
  - reference: PMID:37072824
    reference_title: "Craniofacial growth and function in achondroplasia: a multimodal 3D study on 15 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Craniofacial phenotype was characterized by maxillo-zygomatic retrusion, deep nasal root, and prominent forehead."
    explanation: Multimodal craniofacial study directly documents prominent forehead in pediatric achondroplasia.
- name: Midface retrusion
  description: >
    Midface retrusion contributes to the characteristic craniofacial appearance.
  phenotype_term:
    preferred_term: Midface retrusion
    term:
      id: HP:0011800
      label: Midface retrusion
  evidence:
  - reference: PMID:37072824
    reference_title: "Craniofacial growth and function in achondroplasia: a multimodal 3D study on 15 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Craniofacial phenotype was characterized by maxillo-zygomatic retrusion, deep nasal root, and prominent forehead."
    explanation: Maxillo-zygomatic retrusion directly supports midface retrusion as a core craniofacial phenotype.
- name: Anteverted nares
  frequency: FREQUENT
  description: >
    Anteverted nares are a frequent nasal manifestation within the characteristic
    midface phenotype of achondroplasia.
  phenotype_term:
    preferred_term: Anteverted nares
    term:
      id: HP:0000463
      label: Anteverted nares
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000463 | Anteverted nares | Frequent (79-30%)"
    explanation: Orphanet classifies anteverted nares as frequent in achondroplasia.
- name: Trident hand
  frequency: FREQUENT
  description: >
    Trident hand is a characteristic hand configuration in achondroplasia.
  phenotype_term:
    preferred_term: Trident hand
    term:
      id: HP:0004060
      label: Trident hand
  evidence:
  - reference: PMID:29972438
    reference_title: "Natural history of 39 patients with Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most prevalent clinical findings were short stature, high forehead, trident hands, genu varum and macrocephaly."
    explanation: Clinical cohort data identify trident hands as one of the most prevalent physical findings.
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004060 | Trident hand | Frequent (79-30%)"
    explanation: Orphanet classifies trident hand as frequent in achondroplasia.
- name: Bowing of the legs
  frequency: VERY_FREQUENT
  description: >
    Lower-limb bowing is a very frequent orthopedic feature in achondroplasia,
    comprising genu varum (outward bowing at the knees, bow-legs) and a complex
    deformity involving lateral bowing, differential tibial and fibular growth,
    internal tibial torsion, and dynamic knee instability. It is typically
    recognized during childhood.
  phenotype_term:
    preferred_term: Bowing of the legs
    term:
      id: HP:0002979
      label: Bowing of the legs
    onset:
      onset_category: CHILDHOOD
  evidence:
  - reference: PMID:29972438
    reference_title: "Natural history of 39 patients with Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most prevalent clinical findings were short stature, high forehead, trident hands, genu varum and macrocephaly."
    explanation: Clinical cohort data identify lower-limb deformity (including genu varum) as one of the most prevalent physical findings.
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002979 | Bowing of the legs | Very frequent (99-80%)"
    explanation: Orphanet classifies bowing of the legs as very frequent in achondroplasia.
  - reference: PMID:32864841
    reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "genu varum, elbow contractures, and radial head dislocations were identified during childhood"
    explanation: Chart-review cohort places recognition of genu varum in childhood, preserving the onset nuance of the merged entry.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: '"Bowing" is actually a complex deformity arising from a combination of lateral bowing, differential growth between the tibia and fibula, internal tibial torsion, and dynamic instability of the knee'
    explanation: Sources the complex-deformity clause of the description (lateral bowing, differential tibia-fibula growth, internal tibial torsion, dynamic knee instability).
- name: Thoracolumbar kyphosis
  frequency: VERY_FREQUENT
  description: >
    Thoracolumbar kyphosis is common in young children and often improves over time.
  phenotype_term:
    preferred_term: Thoracolumbar kyphosis
    term:
      id: HP:0005619
      label: Thoracolumbar kyphosis
  evidence:
  - reference: PMID:37493935
    reference_title: "Walking status and spinopelvic parameters in young children with achondroplasia: 10-year follow-up."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thoracolumbar kyphosis (TLK) is common in children with achondroplasia and resolves in 90% by 10 years of age."
    explanation: Supports both childhood onset and the usual tendency toward spontaneous improvement by age 10.
  - reference: PMID:27927547
    reference_title: "Prevalence of Scoliosis and Thoracolumbar Kyphosis in Patients With Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thoracolumbar kyphosis was observed in 79%, with 52% exhibiting moderate to severe curvature."
    explanation: Large orthopedic cohort documents thoracolumbar kyphosis as a common spinal phenotype.
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0005619 | Thoracolumbar kyphosis | Very frequent (99-80%)"
    explanation: Orphanet classifies thoracolumbar kyphosis as very frequent in achondroplasia.
- name: Scoliosis
  description: >
    Scoliosis was reported in 60% of one orthopedic cohort; this
    specialty-clinic estimate is not treated as a population frequency.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:27927547
    reference_title: "Prevalence of Scoliosis and Thoracolumbar Kyphosis in Patients With Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Scoliosis was observed in 60%."
    explanation: An orthopedic cohort documents scoliosis in 60% of its selected patient population.
- name: Foramen magnum stenosis
  description: >
    Foramen magnum stenosis is a major infant complication that can cause cervical cord compression.
  phenotype_term:
    preferred_term: Small foramen magnum
    term:
      id: HP:0002677
      label: Small foramen magnum
  evidence:
  - reference: PMID:32883660
    reference_title: "Achondroplasia Foramen Magnum Score: screening infants for stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of 36 infants (M:F, 18:18), 2 (5.6%) did not have FMS (AFMS0); 13 (36.1%) had FMS with preservation of the cerebrospinal fluid (CSF) spaces (AFMS1); 3 (8.3%) had FMS with loss of the CSF space but no spinal cord distortion (AFMS2); 13 (36.1%) had FMS with flattening of the cervical cord without signal change (AFMS3); and 5 (13.9%) had FMS resulting in cervical cord signal change (AFMS4)."
    explanation: Infant MRI cohort shows that most screened infants had foramen magnum stenosis, including many with cord flattening or signal change.
  - reference: PMID:38554024
    reference_title: "Clinical outcomes and medical management of achondroplasia in Japanese children: A retrospective medical record review of clinical data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients were monitored by magnetic resonance imaging; 73.0% had foramen magnum stenosis, while 54.1% had Achondroplasia Foramen Magnum Score 3 or 4."
    explanation: Independent pediatric cohort confirms that foramen magnum stenosis is a frequent early complication.
- name: Spinal canal stenosis
  frequency: FREQUENT
  description: >
    Cervical and lumbar spinal canal stenosis occur across the lifespan and symptomatic lumbar disease is especially important in adults.
  phenotype_term:
    preferred_term: Spinal canal stenosis
    term:
      id: HP:0003416
      label: Spinal canal stenosis
  evidence:
  - reference: PMID:32864841
    reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."
    explanation: Longitudinal chart review supports spinal stenosis as a cross-lifespan complication affecting both cervical and lumbar regions.
  - reference: PMID:32170149
    reference_title: "Lumbar spinal stenosis and disc alterations affect the upper lumbar spine in adults with achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unlike the general population, spinal stenosis and disc degeneration involve the upper part of the lumbar spine in adults with achondroplasia, associated with thoraco-lumbar kyphosis and loss of lumbar lordosis."
    explanation: Adult imaging study refines the adult lumbar phenotype by showing upper-lumbar predominance with associated degenerative change.
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003416 | Spinal canal stenosis | Frequent (79-30%)"
    explanation: Orphanet classifies spinal canal stenosis as frequent in achondroplasia.
- name: Cervical spinal canal stenosis
  frequency: FREQUENT
  description: >
    Cervical canal stenosis is a more specific spinal stenosis manifestation
    that can occur in childhood and contributes to craniocervical risk.
  phenotype_term:
    preferred_term: Cervical spinal canal stenosis
    term:
      id: HP:0008445
      label: Cervical spinal canal stenosis
  evidence:
  - reference: PMID:32864841
    reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."
    explanation: Longitudinal chart review explicitly reports cervical stenosis in affected patients.
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0008445 | Cervical spinal canal stenosis | Frequent (79-30%)"
    explanation: Orphanet classifies cervical spinal canal stenosis as frequent in achondroplasia.
- name: Obstructive sleep apnea
  frequency: FREQUENT
  description: >
    Obstructive sleep apnea is a major respiratory complication in children and can recur later in life.
    Polysomnography can reveal sleep-disordered breathing even when children have
    no prior symptoms.
  phenotype_term:
    preferred_term: Obstructive sleep apnea
    term:
      id: HP:0002870
      label: Obstructive sleep apnea
  evidence:
  - reference: PMID:40675782
    reference_title: "Sleep-disordered breathing in children with achondroplasia assessed by polysomnography: a retrospective chart review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sleep-disordered breathing subtypes included obstructive sleep apnoea in 81% (55/68), central sleep apnoea in 3% (2/68), mixed sleep apnoea in 7% (5/68) and primary snoring in 9% (6/68)."
    explanation: In a pediatric polysomnography cohort, 55 of 80 children had obstructive sleep apnoea and 5 additional children had mixed apnoea with an obstructive component.
  - reference: PMID:40675782
    reference_title: "Sleep-disordered breathing in children with achondroplasia assessed by polysomnography: a retrospective chart review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 85% (68/80) had sleep-disordered breathing and 21% reported no prior symptoms."
    explanation: Pediatric polysomnography data show that sleep-disordered breathing can be clinically silent before screening.
  - reference: PMID:32864841
    reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Central sleep apnea and obstructive sleep apnea were present in children, while the diagnosis of obstructive sleep apnea was shown to recur in adulthood."
    explanation: Longitudinal review supports both childhood occurrence and adult recurrence of obstructive sleep apnea.
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002870 | Obstructive sleep apnea | Frequent (79-30%)"
    explanation: Orphanet classifies obstructive sleep apnea as frequent in achondroplasia.
  - reference: PMID:37072824
    reference_title: "Craniofacial growth and function in achondroplasia: a multimodal 3D study on 15 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report a significant correlation between the severity of maxillo-mandibular retrusion and obstructive sleep apnea syndrome (p < 0.01)."
    explanation: The correlation supports an anatomical contribution from maxillomandibular retrusion but does not establish sole causation.
- name: Central sleep apnea
  description: >
    Central sleep apnea occurs in some affected children and is part of the sleep-disordered breathing spectrum in achondroplasia.
  phenotype_term:
    preferred_term: Central sleep apnea
    term:
      id: HP:0010536
      label: Central sleep apnea
  evidence:
  - reference: PMID:32864841
    reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Central sleep apnea and obstructive sleep apnea were present in children, while the diagnosis of obstructive sleep apnea was shown to recur in adulthood."
    explanation: Longitudinal natural-history data explicitly document central sleep apnea in children with achondroplasia.
  - reference: PMID:40675782
    reference_title: "Sleep-disordered breathing in children with achondroplasia assessed by polysomnography: a retrospective chart review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sleep-disordered breathing subtypes included obstructive sleep apnoea in 81% (55/68), central sleep apnoea in 3% (2/68), mixed sleep apnoea in 7% (5/68) and primary snoring in 9% (6/68)."
    explanation: Polysomnography cohort confirms central sleep apnoea as a measured pediatric sleep phenotype, although much less common than obstructive disease.
- name: Functional abnormality of the middle ear
  frequency: FREQUENT
  description: >
    Middle-ear dysfunction is a frequent childhood intercurrent problem and
    underlies the more specific otitis-media-with-effusion and conductive
    hearing-loss burden.
  phenotype_term:
    preferred_term: Functional abnormality of the middle ear
    term:
      id: HP:0011452
      label: Functional abnormality of the middle ear
  evidence:
  - reference: PMID:29972438
    reference_title: "Natural history of 39 patients with Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common clinical intercurrences were middle ear dysfunction, sleep apnea, limb pain and obesity from 2 to 9 years of age."
    explanation: Natural-history cohort lists middle-ear dysfunction among the most common childhood clinical intercurrences.
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0011452 | Functional abnormality of the middle ear | Frequent (79-30%)"
    explanation: Orphanet classifies functional abnormality of the middle ear as frequent in achondroplasia.
- name: Otitis media with effusion
  description: >
    Otitis media with effusion is a common otologic complication and often leads to repeated ventilation-tube placement.
  phenotype_term:
    preferred_term: Otitis media with effusion
    term:
      id: HP:0031353
      label: Otitis media with effusion
  evidence:
  - reference: PMID:39660705
    reference_title: "Otologic Manifestations in Patients with Achondroplasia: A Multicenter Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fifty-one patients (72.9%) had middle ear effusion at least once."
    explanation: Multicenter otology cohort shows otitis media with effusion in most evaluated patients.
- name: Conductive hearing impairment
  description: >
    Hearing loss is common and is usually conductive or mixed rather than purely sensorineural.
  phenotype_term:
    preferred_term: Conductive hearing impairment
    term:
      id: HP:0000405
      label: Conductive hearing impairment
  evidence:
  - reference: PMID:39660705
    reference_title: "Otologic Manifestations in Patients with Achondroplasia: A Multicenter Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among 53 patients who underwent audiometry, 26 showed conductive hearing loss, 2 had mixed-type hearing loss, and 4 had sensorineural hearing loss."
    explanation: Pediatric multicenter cohort shows that hearing loss in achondroplasia is usually conductive or mixed.
  - reference: PMID:34736503
    reference_title: "Hearing loss in Norwegian adults with achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The majority (15/24) had conductive hearing loss, or a combination of conductive and sensorineural hearing loss (8/24)."
    explanation: Adult population-based cohort shows conductive or mixed hearing loss remains common beyond childhood.
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000365 | Hearing impairment | Frequent (79-30%)"
    explanation: Orphanet supports frequent hearing impairment generally; the conductive subtype is established by the cohort evidence above.
- name: Obesity
  description: >
    Obesity can begin in early childhood and was common across ages in a classic
    clinical series; a population frequency is not assigned here.
  phenotype_term:
    preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
  evidence:
  - reference: PMID:3228140
    reference_title: "Obesity in achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Obesity is a significant and potentially serious health problem in achondroplasia. Body mass indices, weight-to-square of the height ratio (W/H2), and triceps skinfold measurements show that obesity is common. It begins in early childhood and is prevalent at all ages."
    explanation: Classic cohort study directly supports obesity as an early and persistent complication.
  - reference: PMID:29652901
    reference_title: Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our results show unexpected results with the development of an atypical obesity with preferential fat deposition in the abdomen that is remarkably not associated with classical complications of obesity such as diabetes or hypercholosterolemia."
    explanation: A longitudinal pediatric study characterizes the obesity as predominantly abdominal and metabolically atypical.
  - reference: PMID:41167810
    reference_title: "Cardiovascular risk in achondroplasia: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "People with achondroplasia were found to be at increased risk of obesity, impaired glucose regulation and hypertension."
    explanation: A 33-study systematic review confirms increased obesity risk and links it to cardiovascular risk factors.
  sequelae:
  - target: Spinal canal stenosis
    description: Excess weight aggravates the morbidity of the anatomically narrow lumbar canal in adults.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
      reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "In adults, obesity can aggravate the morbidity associated with lumbar stenosis"
      explanation: The clinical review states that obesity worsens lumbar-stenosis morbidity; it does not claim obesity causes the stenosis.
- name: Hydrocephalus
  frequency: VERY_RARE
  description: >
    Hydrocephalus is a rare but clinically important neurosurgical complication in childhood.
    It is typically communicating and attributed to endochondral hypoplasia of the skull base, which
    narrows the jugular foramina and obstructs cerebral venous outflow, raising intracranial venous
    pressure and impairing CSF resorption.
  phenotype_term:
    preferred_term: Hydrocephalus
    term:
      id: HP:0000238
      label: Hydrocephalus
  evidence:
  - reference: PMID:33579320
    reference_title: "Predictors of cervical myelopathy and hydrocephalus in young children with achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cervical myelopathy and hydrocephalus occasionally occur in young children with achondroplasia."
    explanation: Supports hydrocephalus as a recognized pediatric complication without overstating its frequency.
  - reference: PMID:29972438
    reference_title: "Natural history of 39 patients with Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "One patient developed hydrocephalus at 10 years old."
    explanation: Natural-history cohort provides direct longitudinal evidence that hydrocephalus can occur during follow-up.
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000238 | Hydrocephalus | Very rare (<4-1%)"
    explanation: Orphanet classifies hydrocephalus as very rare in achondroplasia.
  - reference: PMID:33579320
    reference_title: "Predictors of cervical myelopathy and hydrocephalus in young children with achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the size of the cranial base, which is formed by endochondral ossification, is smaller, and the jugular foramen is also smaller. This condition causes a partial obstruction of venous flow, which increases intracranial venous pressure and causes problems with the venous resorption of cerebrospinal fluid (CSF)"
    explanation: Describes the mechanistic basis of communicating hydrocephalus in achondroplasia—endochondral hypoplasia of the skull base narrows the jugular foramina, causing venous outflow obstruction, intracranial venous hypertension, and impaired CSF resorption.
- name: Delayed gross motor development
  description: >
    Children with achondroplasia show delayed acquisition of gross motor and ambulatory skills.
  phenotype_term:
    preferred_term: Delayed gross motor development
    term:
      id: HP:0002194
      label: Delayed gross motor development
  evidence:
  - reference: PMID:22409389
    reference_title: "Development in children with achondroplasia: a prospective clinical cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "children with achondroplasia are delayed in development of gross motor and ambulatory skills."
    explanation: Prospective developmental cohort directly supports delayed gross motor development.
  - reference: PMID:29972438
    reference_title: "Natural history of 39 patients with Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There was motor developmental delay in 18 patients and speech delay in 16 patients."
    explanation: Independent natural-history cohort corroborates developmental delay affecting motor milestones.
- name: Delayed speech and language development
  description: >
    Speech and language delay is reported in pediatric achondroplasia cohorts.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:29972438
    reference_title: "Natural history of 39 patients with Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There was motor developmental delay in 18 patients and speech delay in 16 patients."
    explanation: Natural-history cohort directly reports speech delay in a substantial subset of patients.
  - reference: PMID:22409389
    reference_title: "Development in children with achondroplasia: a prospective clinical cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While delays were seen in development of later communication items, there were fewer delays seen across development of early communication, fine motor, and feeding skills."
    explanation: Prospective developmental study supports delayed later communication skill acquisition.
- name: Elbow contracture
  description: >
    Elbow contractures are recognized childhood orthopedic manifestations.
  phenotype_term:
    preferred_term: Elbow contracture
    term:
      id: HP:0034391
      label: Elbow contracture
  evidence:
  - reference: PMID:32864841
    reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."
    explanation: Longitudinal chart review identifies elbow contractures as a childhood orthopedic phenotype.
- name: Radial head dislocation
  description: >
    Radial head dislocation is an orthopedic manifestation recognized during childhood.
  phenotype_term:
    preferred_term: Radial head dislocation
    term:
      id: HP:0003083
      label: Dislocated radial head
  evidence:
  - reference: PMID:32864841
    reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."
    explanation: Longitudinal chart review identifies radial head dislocation as a childhood orthopedic phenotype.
- name: Lumbar hyperlordosis
  frequency: FREQUENT
  description: >
    Exaggerated lumbar lordosis is a characteristic spinal deformity in achondroplasia.
  phenotype_term:
    preferred_term: Lumbar hyperlordosis
    term:
      id: HP:0002938
      label: Lumbar hyperlordosis
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002938 | Lumbar hyperlordosis | Frequent (79-30%)"
    explanation: Orphanet classifies lumbar hyperlordosis as frequent in achondroplasia.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Exaggerated lumbar lordosis, which develops when walking begins"
    explanation: The clinical review adds the onset context, with hyperlordosis emerging when independent walking starts.
- name: Brachydactyly
  frequency: FREQUENT
  description: >
    Short fingers are a characteristic hand phenotype in achondroplasia.
  phenotype_term:
    preferred_term: Brachydactyly
    term:
      id: HP:0001156
      label: Brachydactyly
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001156 | Brachydactyly | Frequent (79-30%)"
    explanation: Orphanet classifies brachydactyly as frequent in achondroplasia.
- name: Short middle phalanx of finger
  frequency: FREQUENT
  description: >
    Shortening of the middle phalanges contributes to the characteristic short
    fingers and trident hand configuration.
  phenotype_term:
    preferred_term: Short middle phalanx of finger
    term:
      id: HP:0005819
      label: Short middle phalanx of finger
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0005819 | Short middle phalanx of finger | Frequent (79-30%)"
    explanation: Orphanet classifies short middle phalanx of finger as frequent in achondroplasia.
- name: Short proximal phalanx of finger
  frequency: FREQUENT
  description: >
    Shortening of proximal phalanges is another frequent phalangeal component of
    the achondroplasia hand phenotype.
  phenotype_term:
    preferred_term: Short proximal phalanx of finger
    term:
      id: HP:0010241
      label: Short proximal phalanx of finger
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0010241 | Short proximal phalanx of finger | Frequent (79-30%)"
    explanation: Orphanet classifies short proximal phalanx of finger as frequent in achondroplasia.
- name: Limited elbow extension
  frequency: FREQUENT
  description: >
    Limited elbow extension is a common upper-limb joint restriction in achondroplasia.
  phenotype_term:
    preferred_term: Limited elbow extension
    term:
      id: HP:0001377
      label: Limited elbow extension
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001377 | Limited elbow extension | Frequent (79-30%)"
    explanation: Orphanet classifies limited elbow extension as frequent in achondroplasia.
- name: Floppy infant
  frequency: FREQUENT
  description: >
    Infantile hypotonia is frequently observed and contributes to delayed motor milestones.
  phenotype_term:
    preferred_term: Floppy infant
    term:
      id: HP:0008947
      label: Floppy infant
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0008947 | Floppy infant | Frequent (79-30%)"
    explanation: Orphanet lists floppy infant as frequent in achondroplasia, supporting infantile muscular hypotonia.
- name: Depressed nasal bridge
  frequency: FREQUENT
  description: >
    Depressed nasal bridge is part of the characteristic midface hypoplasia.
  phenotype_term:
    preferred_term: Depressed nasal bridge
    term:
      id: HP:0005280
      label: Depressed nasal bridge
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0005280 | Depressed nasal bridge | Frequent (79-30%)"
    explanation: Orphanet classifies depressed nasal bridge as frequent in achondroplasia.
- name: Frontal bossing
  frequency: FREQUENT
  description: >
    Frontal bossing is a characteristic craniofacial feature of achondroplasia.
  phenotype_term:
    preferred_term: Frontal bossing
    term:
      id: HP:0002007
      label: Frontal bossing
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002007 | Frontal bossing | Frequent (79-30%)"
    explanation: Orphanet classifies frontal bossing as frequent in achondroplasia.
- name: Restrictive ventilatory defect
  frequency: OCCASIONAL
  description: >
    Restrictive lung disease can occur due to thoracic hypoplasia and reduced chest wall compliance.
  phenotype_term:
    preferred_term: Restrictive ventilatory defect
    term:
      id: HP:0002091
      label: Restrictive ventilatory defect
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002091 | Restrictive ventilatory defect | Occasional (29-5%)"
    explanation: Orphanet classifies restrictive ventilatory defect as occasional in achondroplasia.
- name: Thoracic hypoplasia
  frequency: OCCASIONAL
  description: >
    Thoracic hypoplasia provides a structural thoracic context for occasional
    restrictive ventilatory physiology in achondroplasia.
  phenotype_term:
    preferred_term: Thoracic hypoplasia
    term:
      id: HP:0005257
      label: Thoracic hypoplasia
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0005257 | Thoracic hypoplasia | Occasional (29-5%)"
    explanation: Orphanet classifies thoracic hypoplasia as occasional in achondroplasia.
- name: Acanthosis nigricans
  frequency: OCCASIONAL
  description: >
    Acanthosis nigricans is an occasional skin manifestation in achondroplasia.
  phenotype_term:
    preferred_term: Acanthosis nigricans
    term:
      id: HP:0000956
      label: Acanthosis nigricans
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000956 | Acanthosis nigricans | Occasional (29-5%)"
    explanation: Orphanet classifies acanthosis nigricans as occasional in achondroplasia.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "may be seen in about 10% of individuals with achondroplasia"
    explanation: The 2026 clinical review supports a peripheral association while not placing it in the core skeletal mechanism graph.
- name: Knee joint hypermobility
  frequency: FREQUENT
  description: >
    Knee joint hypermobility is a frequent finding in achondroplasia.
  phenotype_term:
    preferred_term: Knee joint hypermobility
    term:
      id: HP:0045086
      label: Knee joint hypermobility
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0045086 | Knee joint hypermobility | Frequent (79-30%)"
    explanation: Orphanet classifies knee joint hypermobility as frequent in achondroplasia.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Excess mobility of the knees, hips, and most other joints is common"
    explanation: The clinical review documents knee hypermobility within the common generalized joint laxity.
- name: Hip joint hypermobility
  frequency: FREQUENT
  description: >
    Hip joint hypermobility is a frequent finding in achondroplasia.
  phenotype_term:
    preferred_term: Hip joint hypermobility
    term:
      id: HP:0045087
      label: Hip joint hypermobility
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0045087 | Hip joint hypermobility | Frequent (79-30%)"
    explanation: Orphanet classifies hip joint hypermobility as frequent in achondroplasia.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Excess mobility of the knees, hips, and most other joints is common"
    explanation: The clinical review documents hip hypermobility within the common generalized joint laxity.
- name: Limb undergrowth
  frequency: VERY_FREQUENT
  description: >
    Limb undergrowth is the core skeletal manifestation of achondroplasia, reflecting impaired endochondral ossification of the appendicular skeleton.
  phenotype_term:
    preferred_term: Limb undergrowth
    term:
      id: HP:0009826
      label: Limb undergrowth
  evidence:
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0009826 | Limb undergrowth | Very frequent (99-80%)"
    explanation: Orphanet classifies limb undergrowth as very frequent in achondroplasia.
- name: Cervical myelopathy
  description: >
    Cervical (high) myelopathy from cervicomedullary compression at the stenotic foramen
    magnum is a major early complication and can present with long-tract signs, central
    apnea, or respiratory arrest.
  phenotype_term:
    preferred_term: Cervical myelopathy
    term:
      id: HP:0002318
      label: Cervical myelopathy
  evidence:
  - reference: PMID:33579320
    reference_title: "Predictors of cervical myelopathy and hydrocephalus in young children with achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirteen (20%) of the 65 patients showed T2 HSI on MRI, long tract sign, or respiratory difficulty that corresponded to cervical myelopathy"
    explanation: A selected tertiary pediatric MRI cohort documented cervical myelopathy in 13 of 65 children; this is not used as a population frequency.
- name: Caudal interpedicular narrowing
  description: >
    Caudal narrowing of lumbar interpedicular distance is a characteristic
    radiographic finding in achondroplasia.
  phenotype_term:
    preferred_term: Caudal interpedicular narrowing
    term:
      id: HP:0008457
      label: Caudal interpedicular narrowing
  evidence:
  - reference: PMID:29972438
    reference_title: "Natural history of 39 patients with Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most prevalent radiographic findings were rhizomelic shortening of the long bones and narrowing of the interpediculate distance of the caudal spine."
    explanation: Natural-history cohort identifies caudal interpedicular narrowing as one of the most prevalent radiographic findings in achondroplasia.
- name: Limb pain
  description: >
    Limb pain was among the common clinical intercurrences reported from ages
    two to nine years in one natural-history cohort; individual mechanisms vary.
  phenotype_term:
    preferred_term: Limb pain
    term:
      id: HP:0009763
      label: Limb pain
  evidence:
  - reference: PMID:29972438
    reference_title: "Natural history of 39 patients with Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common clinical intercurrences were middle ear dysfunction, sleep apnea, limb pain and obesity from 2 to 9 years of age."
    explanation: Natural-history cohort lists limb pain among the most common clinical intercurrences in childhood.
imaging_findings:
- name: Rhizomelic long-bone shortening on skeletal radiographs
  modality: XRAY
  description: >-
    Skeletal radiographs show disproportionate proximal long-bone shortening.
    This is part of the characteristic diagnostic pattern rather than a
    stand-alone molecular confirmation.
  phenotype_term:
    preferred_term: Rhizomelia
    term:
      id: HP:0008905
      label: Rhizomelia
  diagnostic: false
  evidence:
  - reference: PMID:29972438
    reference_title: Natural history of 39 patients with Achondroplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To characterize the natural history of 39 achondroplastic patients diagnosed by clinical,
      radiological and molecular assessments. ... The most prevalent radiographic findings were
      rhizomelic shortening of the long bones and narrowing of the interpediculate distance of the
      caudal spine. ... The diagnoses were made early based on clinical and radiographic findings.
      All cases were confirmed molecularly.
    explanation: >-
      Restores the achondroplasia cohort and distinction between clinical/radiographic diagnosis and
      molecular confirmation around the typical radiographic findings.
- name: Caudal interpedicular narrowing on spinal radiographs
  modality: XRAY
  description: >-
    The interpedicular distance narrows toward the caudal spine, a
    characteristic vertebral radiographic feature.
  phenotype_term:
    preferred_term: Caudal interpedicular narrowing
    term:
      id: HP:0008457
      label: Caudal interpedicular narrowing
  diagnostic: false
  evidence:
  - reference: PMID:29972438
    reference_title: Natural history of 39 patients with Achondroplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most prevalent radiographic findings were rhizomelic shortening of the long bones and narrowing of the interpediculate distance of the caudal spine."
    explanation: A clinical cohort directly documents caudal narrowing.
- name: Foramen-magnum stenosis and cord compression spectrum on MRI
  modality: MRI
  description: >-
    Craniocervical MRI can show foramen-magnum narrowing, loss of surrounding
    CSF space, cord flattening, and T2 signal change. This evaluates a
    complication and is not required to establish the skeletal diagnosis.
  phenotype_term:
    preferred_term: Small foramen magnum
    term:
      id: HP:0002677
      label: Small foramen magnum
  diagnostic: false
  evidence:
  - reference: PMID:32883660
    reference_title: "Achondroplasia Foramen Magnum Score: screening infants for stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of 36 infants (M:F, 18:18), 2 (5.6%) did not have FMS (AFMS0); 13 (36.1%) had FMS with preservation of the cerebrospinal fluid (CSF) spaces (AFMS1); 3 (8.3%) had FMS with loss of the CSF space but no spinal cord distortion (AFMS2); 13 (36.1%) had FMS with flattening of the cervical cord without signal change (AFMS3); and 5 (13.9%) had FMS resulting in cervical cord signal change (AFMS4)."
    explanation: The cohort defines an MRI severity spectrum from no stenosis to cord signal change.
- name: Premature skull-base synchondrosis fusion on CT
  modality: CT
  description: >-
    CT can demonstrate premature fusion of skull-base synchondroses. This
    finding informs craniofacial mechanism and complication assessment but is
    not presented as a universal diagnostic requirement.
  diagnostic: false
  evidence:
  - reference: PMID:37072824
    reference_title: "Craniofacial growth and function in achondroplasia: a multimodal 3D study on 15 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients with available CT-scan had premature fusion of skull base synchondroses."
    explanation: CT in a small clinical cohort directly documents premature fusion.
- name: Upper-lumbar stenosis and disc degeneration on adult MRI
  modality: MRI
  description: >-
    Adult imaging shows preferential upper-lumbar canal narrowing and disc
    degeneration, often with thoracolumbar kyphosis and loss of lordosis.
  diagnostic: false
  evidence:
  - reference: PMID:32170149
    reference_title: Lumbar spinal stenosis and disc alterations affect the upper lumbar spine in adults with achondroplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unlike the general population, spinal stenosis and disc degeneration involve the upper part of the lumbar spine in adults with achondroplasia, associated with thoraco-lumbar kyphosis and loss of lumbar lordosis."
    explanation: Adult MRI data define the characteristic distribution.

genetic:
- name: FGFR3
  gene_term:
    preferred_term: FGFR3
    term:
      id: hgnc:3690
      label: FGFR3
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    Achondroplasia is genetically homogeneous. Two substitutions at nucleotide
    1138 produce p.Gly380Arg in the FGFR3 transmembrane domain. Experimental
    evidence supports gain of function with impaired receptor down-regulation;
    strict ligand-independent activation is not required by this record.
  gene_disease_validity:
  - validity_classification: DEFINITIVE
    classified_by: CLINGEN
    external_id: CGGV:assertion_0adafa1b-e609-4b99-8e90-f73473b70771-2023-09-28T040000.000Z
    evidence:
    - reference: CGGV:assertion_0adafa1b-e609-4b99-8e90-f73473b70771-2023-09-28T040000.000Z
      reference_title: FGFR3 / achondroplasia (Definitive)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "FGFR3 | HGNC:3690 | achondroplasia | MONDO:0007037 | AD | Definitive"
      explanation: ClinGen's autosomal-dominant FGFR3-achondroplasia assertion, copied as recorded.
  variants:
  - name: c.1138G>A (p.Gly380Arg)
    description: >-
      The predominant recurrent allele; 150 of 153 p.Gly380Arg-positive cases
      in one 154-person series carried c.1138G>A.
    evidence:
    - reference: PMID:7847369
      reference_title: Achondroplasia is defined by recurrent G380R mutations of FGFR3.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "All but one, an atypical case, were found to have a glycine-to-arginine substitution at codon 380. Of these, 150 had a G-to-A transition at nt 1138, and 3 had a G-to-C transversion at this same position."
      explanation: The large series directly supplies the allele counts.
  - name: c.1138G>C (p.Gly380Arg)
    description: >-
      A less common nucleotide substitution producing the same p.Gly380Arg
      protein change; three cases were observed in the same series.
    evidence:
    - reference: PMID:7847369
      reference_title: Achondroplasia is defined by recurrent G380R mutations of FGFR3.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "All but one, an atypical case, were found to have a glycine-to-arginine substitution at codon 380. Of these, 150 had a G-to-A transition at nt 1138, and 3 had a G-to-C transversion at this same position."
      explanation: The series directly documents the c.1138G>C minority allele.
  evidence:
  - reference: CGGV:assertion_0adafa1b-e609-4b99-8e90-f73473b70771-2023-09-28T040000.000Z
    reference_title: FGFR3 / achondroplasia (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FGFR3 | HGNC:3690 | achondroplasia | MONDO:0007037 | AD | Definitive"
    explanation: ClinGen classifies the FGFR3-achondroplasia relationship as definitive.
  - reference: ORPHA:15
    reference_title: Achondroplasia
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FGFR3 | fibroblast growth factor receptor 3 | hgnc:3690 | Disease-causing germline mutation(s) (gain of function) in"
    explanation: Orphanet identifies germline FGFR3 gain of function.

treatments:
- name: Vosoritide (Voxzogo)
  action_category: THERAPEUTIC
  therapeutic_modality: PEPTIDE
  dosing_interval: once daily
  dosing_interval_days: 1
  description: >-
    Daily CNP analogue indicated in the United States to increase linear growth
    in pediatric patients with achondroplasia and open epiphyses. Accelerated
    approval is based on annualized growth velocity; final adult height and
    prevention of non-growth complications are not established by the approval.
    A three-year external-control comparison estimated 5.75 cm additional
    height, explicitly not a three-year randomized comparison.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: vosoritide
      term:
        id: NCIT:C152918
        label: Vosoritide
  target_phenotypes:
  - preferred_term: Limb undergrowth
    term:
      id: HP:0009826
      label: Limb undergrowth
  target_mechanisms:
  - target: CNP-NPR2 counter-regulation of FGFR3-MAPK signaling
    treatment_effect: ACTIVATES
    description: Vosoritide activates the CNP-NPR2 counter-regulatory branch.
    evidence:
    - reference: PMID:31269546
      reference_title: C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Vosoritide is a biologic analogue of C-type natriuretic peptide, a potent stimulator of endochondral ossification."
      explanation: The clinical trial identifies vosoritide as a CNP analogue.
    - reference: PMID:14702637
      reference_title: Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These results demonstrate that activation of the CNP-GC-B system in endochondral bone formation constitutes a new therapeutic strategy for human achondroplasia."
      explanation: Preclinical data support the CNP-GC-B/NPR2 mechanism.
    - reference: PMID:34431071
      reference_title: Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The exposure-response relationships for changes in both annualized growth velocity and the CXM biomarker saturated at 15 μg/kg, while systemic pharmacological activity, as measured by urinary cGMP, was near maximal or saturated at exposures obtained at the highest dose studied"
      explanation: >-
        Urinary cGMP and the collagen X endochondral-ossification biomarker give
        human target-engagement support for the guanylyl-cyclase branch this
        link asserts, rather than inferring engagement from growth alone.
  evidence:
  - reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214938s004lbl.pdf
    reference_title: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214938s004lbl.pdf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "VOXZOGO is a C type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses."
    explanation: The current US label has no obsolete five-year minimum-age clause.
  - reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214938s004lbl.pdf
    reference_title: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214938s004lbl.pdf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This indication is approved under accelerated approval based on an improvement in annualized growth velocity."
    explanation: The label identifies the surrogate endpoint and accelerated-approval basis.
  - reference: PMID:32891212
    reference_title: "Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The adjusted mean difference in annualised growth velocity between patients in the vosoritide group and placebo group was 1·57 cm/year in favour of vosoritide"
    explanation: >-
      The pivotal randomized, double-blind, placebo-controlled phase 3 trial
      supplies the placebo-adjusted growth-velocity result underlying approval.
  - reference: PMID:32891212
    reference_title: "Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is not known whether final adult height will be increased, or what the harms of long-term therapy might be."
    explanation: >-
      The trial investigators state the limit of the randomized result
      themselves, corroborating the entry's refusal to extrapolate from growth
      velocity to final height or complication prevention.
  - reference: PMID:39740666
    reference_title: Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Data from the CLARITY achondroplasia study provided an external untreated control population and reference data."
    explanation: This specifies that the comparator was external and untreated.
  - reference: PMID:39740666
    reference_title: Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three-year comparisons of treated versus untreated children demonstrated an additional height gain of 5.75 cm"
    explanation: The extension analysis reports the calibrated external-control height estimate.
  - reference: PMID:42001280
    reference_title: Evaluating the impact of vosoritide on complications of achondroplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: "Incidence of leg malalignment; foramen magnum stenosis; spinal stenosis; kyphosis; lordosis; hydrocephalus; ear, nose, and throat complications; and pain was generally lower than NH rates."
    explanation: >-
      Pooled complication rates from six vosoritide trials (230 children) were
      compared with published natural-history rates rather than a concurrent
      control, so this is a signal that complications are not worsened, not a
      demonstration that they are prevented.
  - reference: PMID:42001280
    reference_title: Evaluating the impact of vosoritide on complications of achondroplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Vosoritide was not associated with worsening of complications in children with achondroplasia and may reduce their frequency."
    explanation: The authors' own conclusion is hedged ("may reduce"), consistent with complication benefit remaining unproven.
  - reference: PMID:42495828
    reference_title: Retrospective study of foramen magnum development in patients with achondroplasia starting vosoritide before age 3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: "Compared with untreated cohorts, steeper growth rates were observed in 8 of the 9 patients for the anteroposterior diameter and in all patients for the transverse diameter."
    explanation: >-
      A nine-patient single-centre MRI series suggests early vosoritide may
      enlarge the foramen magnum faster than untreated reference curves; one
      child still needed decompression, and the design is uncontrolled.

- name: Navepegritide (Yuviwel)
  action_category: THERAPEUTIC
  therapeutic_modality: PEPTIDE
  dosing_interval: once weekly
  dosing_interval_days: 7
  description: >-
    Once-weekly CNP analogue indicated in the United States to increase linear
    growth in patients aged two years and older with achondroplasia and open
    epiphyses. The 2026 accelerated approval is based on annualized growth
    velocity; continued approval may be contingent on verification and
    description of clinical benefit in confirmatory trials.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: navepegritide
      term:
        id: NCIT:C188658
        label: Navepegritide
  target_phenotypes:
  - preferred_term: Limb undergrowth
    term:
      id: HP:0009826
      label: Limb undergrowth
  target_mechanisms:
  - target: CNP-NPR2 counter-regulation of FGFR3-MAPK signaling
    treatment_effect: ACTIVATES
    description: CNP released from navepegritide binds NPR-B and inhibits the MAPK component of FGFR3 signaling.
    evidence:
    - reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf
      reference_title: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "CNP released from navepegritide has the same receptor binding affinity and activity as endogenous CNP. CNP binds to natriuretic peptide receptor-B (NPR-B), which inhibits the mitogen activated protein kinase signaling (MAPK) pathway."
      explanation: The current label directly supports NPR-B activation and MAPK counter-regulation.
  evidence:
  - reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf
    reference_title: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "YUVIWEL is a C-type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses."
    explanation: The 2026 US label supplies the indication and eligible population.
  - reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf
    reference_title: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This indication is approved under accelerated approval based on an improvement in annualized growth velocity."
    explanation: The label identifies the accelerated-approval endpoint.
  - reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf
    reference_title: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s)."
    explanation: The label qualifies the confirmatory-evidence condition for continued approval.
  - reference: PMID:41247754
    reference_title: "Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The trial met its primary end point, demonstrating superiority of navepegritide in annualized growth velocity at week 52 vs placebo (least-squares mean treatment difference of 1.49 cm/y; 95% CI, 1.05 to 1.93; P < .001)."
    explanation: The randomized trial quantifies the placebo-adjusted growth-velocity result.
  - reference: PMID:37823031
    reference_title: "Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At 52 weeks, TransCon CNP 100 μg CNP/kg/week significantly improved AGV vs placebo"
    explanation: The dose-finding phase 2 trial found the 100 µg/kg/week dose effective (5.42 vs 4.35 cm/year), the dose carried into APPROACH.
  - reference: PMID:42234372
    reference_title: "Navepegritide: First Approval."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Navepegritide received its first approval on 27 February 2026 in the USA for use in increasing linear growth in paediatric patients aged ≥ 2 years with achondroplasia with open epiphyses"
    explanation: Dates the US accelerated approval, as summarized in an AdisInsight drug profile.

- name: Infigratinib (oral FGFR1-3 tyrosine kinase inhibitor)
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Once-daily oral ATP-competitive FGFR1-3 tyrosine kinase inhibitor, repurposed
    from oncology at roughly a hundredth of the oncology dose (0.25 mg/kg/day). It
    is mechanistically distinct from the approved CNP analogues: vosoritide and
    navepegritide act on a parallel counter-regulatory arm (NPR-B/cGMP braking
    MAPK downstream of the receptor), whereas infigratinib inhibits the mutant
    receptor's kinase output directly. A phase 2 dose-finding study selected
    0.25 mg/kg/day. In the 52-week phase 3 PROPEL 3 trial (NCT06164951) it increased annualized
    height velocity by 1.74 cm/year over placebo, and it is oral rather than
    injected. Two caveats belong with the result: the upper-to-lower segment
    ratio, the measure of *disproportion* as opposed to height, did not change,
    and the drug is a pan-FGFR1-3 rather than FGFR3-selective inhibitor, so
    long-term off-target skeletal effects are not yet characterized in children.
    Not approved at time of curation.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: infigratinib
      term:
        id: CHEBI:63451
        label: BGJ-398
  target_phenotypes:
  - preferred_term: Limb undergrowth
    term:
      id: HP:0009826
      label: Limb undergrowth
  target_mechanisms:
  - target: Prolonged FGFR3 signaling in growth-plate chondrocytes
    treatment_effect: INHIBITS
    description: >-
      Infigratinib inhibits the FGFR kinase domain directly, reducing the
      prolonged downstream signal from the gain-of-function p.Gly380Arg
      receptor rather than opposing it from a parallel pathway.
    evidence:
    - reference: PMID:42370681
      reference_title: "Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Infigratinib, an oral FGFR1-3 tyrosine kinase inhibitor, down-regulates key pathways in the pathogenesis of achondroplasia."
      explanation: >-
        States the receptor-directed mechanism that distinguishes infigratinib
        from the CNP-analogue class.
  evidence:
  - reference: PMID:42370681
    reference_title: "Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In children with achondroplasia, treatment with once-daily oral infigratinib for 52 weeks resulted in a significantly greater increase from baseline in the annualized height velocity than placebo."
    explanation: The phase 3 primary result.
  - reference: PMID:42370681
    reference_title: "Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The difference between infigratinib and placebo in the least-squares mean change from baseline to week 52 was 1.74 cm per year (95% confidence interval [CI], 1.31 to 2.17; P<0.001) for the annualized height velocity, 0.32 (96% CI, 0.23 to 0.41; P<0.001) for the height z score, and -0.02 (96% CI, -0.06 to 0.01) for the upper-to-lower body segment ratio."
    explanation: >-
      Quantifies the effect and records that the upper-to-lower segment ratio,
      the disproportion measure, was not improved.
  - reference: PMID:42370681
    reference_title: "Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Adverse events occurred in 71 of 74 patients (96%) in the infigratinib group and in 37 of 39 patients (95%) in the placebo group; serious adverse events occurred in 4 of 74 patients (5%) and 1 of 39 patients (3%), respectively."
    explanation: The 52-week safety comparison; longer-term skeletal safety is untested.
  - reference: PMID:39555818
    reference_title: Oral Infigratinib Therapy in Children with Achondroplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In cohort 5, an increased annualized height velocity was observed, which persisted throughout the duration of the study, with a mean change from baseline at 18 months of 2.50 cm per year (95% confidence interval [CI], 1.22 to 3.79; P = 0.001)."
    explanation: The phase 2 dose-finding study identified the 0.25 mg/kg cohort-5 dose taken into phase 3.

- name: Meclizine (investigational oral repurposed antihistamine)
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    An over-the-counter H1 antihistamine identified by drug repositioning as an
    inhibitor of FGFR3 signaling that promotes bone growth in an achondroplasia
    mouse model. Japanese phase 1b and single-arm phase 2 studies in children
    aged 5-10 years reported no serious adverse events, but the 26-week phase 2
    study (co-administered with growth hormone) showed essentially no change in
    height velocity, with an increase only in arm-span velocity. Investigational;
    not an established therapy.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: meclizine
      term:
        id: CHEBI:6709
        label: Meclizine
  target_mechanisms:
  - target: Prolonged FGFR3 signaling in growth-plate chondrocytes
    treatment_effect: INHIBITS
    description: Reported in preclinical work to inhibit FGFR3 signaling; the molecular target is not defined.
    evidence:
    - reference: PMID:37428729
      reference_title: Phase 1b study on the repurposing of meclizine hydrochloride for children with achondroplasia.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: BACKGROUND
      snippet: "We found that meclizine, which is an over-the-counter drug for motion sickness, inhibited the fibroblast growth factor receptor 3 (FGFR3) gene using a drug repositioning strategy, and meclizine 1 and 2 mg/kg/day promoted bone growth in a mouse model of ACH."
      explanation: The phase 1b paper restates the authors' earlier preclinical finding that motivates the trials.
  evidence:
  - reference: PMID:37428729
    reference_title: Phase 1b study on the repurposing of meclizine hydrochloride for children with achondroplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No patient experienced serious AEs in either group."
    explanation: Fourteen-day repeated dosing in 12 children was tolerated.
  - reference: PMID:41326861
    reference_title: "Efficacy and Safety of Oral Meclizine for Growth Promotion in Children with Achondroplasia: A Phase 2 Clinical Trial."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Height velocity increased slightly from 4.35 ± 1.36 cm/year pre-treatment to 4.46 ± 1.54 cm/year post-treatment."
    explanation: >-
      In nine children over 26 weeks height velocity was essentially unchanged,
      which does not support meclizine as a growth-promoting treatment.
  - reference: PMID:41326861
    reference_title: "Efficacy and Safety of Oral Meclizine for Growth Promotion in Children with Achondroplasia: A Phase 2 Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An additive effect of meclizine and growth hormone on promoting height was not observed; however, meclizine may enhance arm span growth in children with ACH."
    explanation: The only positive signal was in arm span, from an uncontrolled ad hoc analysis.

- name: Recifercept (discontinued soluble FGFR3 decoy)
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  description: >-
    A recombinant soluble FGFR3 decoy designed to sequester FGF ligands and so
    reduce activation of the mutant receptor. It restored long-bone growth in a
    transgenic mouse model, but in the phase 2 study in children aged 2-10
    years growth was indistinguishable from model-simulated natural history and
    clinical development was terminated. Recorded as a negative result for the
    ligand-sequestration strategy.
  notes: >-
    therapeutic_modality is OTHER because a recombinant soluble-receptor ligand
    trap is neither an antibody nor a replacement of a deficient protein, so no
    narrower TherapeuticModalityEnum value applies.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: recifercept
      term:
        id: NCIT:C175197
        label: Recifercept
  target_mechanisms:
  - target: FGFR3 p.Gly380Arg gain-of-function with impaired receptor down-regulation
    treatment_effect: INHIBITS
    description: Ligand sequestration was intended to normalize activation of the predominantly ligand-dependent mutant receptor.
    evidence:
    - reference: PMID:33370388
      reference_title: "In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In addition, in a transgenic mouse model of achondroplasia, Recifercept restores reduced body weight and long bone growth in these mice."
      explanation: Preclinical support for the decoy mechanism.
  evidence:
  - reference: PMID:38685585
    reference_title: Natural disease course modeling of achondroplasia to evaluate the efficacy of recifercept in the absence of a placebo control arm in phase II study.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "For all the tested doses of recifercept, at the individual level, the observations were comparable to the simulations at 6 and 12 months post-recifercept treatment, suggesting no treatment effect. The results contributed to the decision of terminating recifercept clinical development."
    explanation: The phase 2 comparison against a natural-history model showed no growth effect, and development was stopped.

- name: Surgical limb lengthening
  therapeutic_modality: SURGERY
  action_category: THERAPEUTIC
  description: >-
    Extended limb lengthening is an elective option for selected individuals.
    Decisions require specialized multidisciplinary counseling about goals,
    prolonged treatment, complications, and patient preferences; the evidence
    cited here supports use, not a universal recommendation.
  treatment_term:
    preferred_term: Limb lengthening surgery
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Additional treatment for short stature may include extended limb lengthening;"
    explanation: The current clinical review lists limb lengthening as an optional intervention.

- name: Foramen magnum decompression
  action_category: THERAPEUTIC
  description: >-
    Experienced neurosurgical teams may perform suboccipital or
    cervicomedullary decompression when clinical, respiratory, and imaging
    findings indicate significant craniocervical compression. The procedure is
    not equated with lumbar laminectomy.
  treatment_term:
    preferred_term: Foramen magnum decompression
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_phenotypes:
  - preferred_term: Small foramen magnum
    term:
      id: HP:0002677
      label: Small foramen magnum
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "suboccipital decompression as indicated for signs and symptoms of craniocervical junction compression;"
    explanation: The current clinical review supports symptom- and sign-based surgical selection.

- name: Surgery for symptomatic spinal stenosis
  action_category: THERAPEUTIC
  description: >-
    Adults with symptomatic spinal stenosis may require decompressive spinal
    surgery. Selection depends on neurologic symptoms and specialist assessment.
  treatment_term:
    preferred_term: spinal decompression surgery
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_phenotypes:
  - preferred_term: Spinal canal stenosis
    term:
      id: HP:0003416
      label: Spinal canal stenosis
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "surgery to correct spinal stenosis in symptomatic adults;"
    explanation: The current clinical review supports surgery for selected symptomatic adults.

- name: Lifelong multidisciplinary surveillance
  action_category: MONITORING
  description: >-
    Age-specific follow-up continues across the lifespan, with visits at least
    every six to twelve months in infancy and childhood and every three to five
    years in adulthood.
  treatment_term:
    preferred_term: clinical monitoring
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Infants and children should be seen at a minimum of every six to 12 months."
    explanation: The review specifies regular pediatric surveillance.
  - reference: PMID:32457214
    reference_title: Health Supervision for People With Achondroplasia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This document is intended to provide guidance for health care providers to help identify individual patients at high risk of developing serious sequelae and to enable intervention before complications develop."
    explanation: AAP guidance supports anticipatory health supervision.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Adults should be seen every three to five years."
    explanation: The current review specifies continued adult follow-up.

- name: Middle-ear and hearing management
  action_category: THERAPEUTIC
  description: >-
    Recurrent effusion and hearing impairment require hearing surveillance and
    individualized ENT management, including pressure-equalizing tubes when
    indicated.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Otitis media with effusion
    term:
      id: HP:0031353
      label: Otitis media with effusion
  - preferred_term: Conductive hearing impairment
    term:
      id: HP:0000405
      label: Conductive hearing impairment
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "aggressive management of frequent otitis media including long-lasting pressure-equalizing tubes for middle ear dysfunction;"
    explanation: The current review explicitly recommends active middle-ear management.

- name: Obstructive sleep apnea management
  action_category: THERAPEUTIC
  description: >-
    Treatment is individualized and may include adenotonsillar surgery, positive
    airway pressure, or rarely tracheostomy after appropriate sleep and airway
    assessment.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Obstructive sleep apnea
    term:
      id: HP:0002870
      label: Obstructive sleep apnea
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "adenotonsillectomy, positive airway pressure, and, rarely, tracheostomy to correct obstructive sleep apnea;"
    explanation: The current review lists the principal individualized modalities.

- name: Genetic counseling
  action_category: COUNSELING_INFORMATIONAL
  description: >-
    Counseling addresses the 50% transmission risk from an affected
    heterozygous parent with an average-stature partner.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "If an individual with achondroplasia has a reproductive partner of average stature, each child has a 50% chance of having achondroplasia."
    explanation: The current review directly states the recurrence risk.

diagnosis:
- name: Characteristic physical examination
  description: >-
    Examination identifies disproportionate short-limb stature with rhizomelic
    shortening, macrocephaly, frontal bossing and midface retrusion,
    brachydactyly, and trident hands.
  diagnosis_term:
    preferred_term: physical examination
    term:
      id: NCIT:C20989
      label: Physical Examination
  results: Characteristic disproportionate skeletal and craniofacial pattern.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Individuals with achondroplasia have short stature with rhizomelic shortening of the limbs, macrocephaly, characteristic facies with frontal bossing and midface retrusion, exaggerated lumbar lordosis, limitation of elbow extension and rotation, genu varum, brachydactyly, and trident appearance of the hands."
    explanation: The current review defines the characteristic examination pattern.
- name: Skeletal radiographic evaluation
  description: >-
    Characteristic clinical and radiographic findings establish the diagnosis
    in most individuals; radiographs define long-bone, hand, pelvic, and spinal
    morphology.
  diagnosis_term:
    preferred_term: radiograph imaging procedure
    term:
      id: NCIT:C38101
      label: X-Ray Imaging
  results: Rhizomelic long-bone shortening and characteristic spinal and pelvic pattern.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Achondroplasia can be diagnosed by characteristic clinical and radiographic findings in most affected individuals."
    explanation: The current review explicitly supports clinical-radiographic diagnosis.
- name: FGFR3 molecular confirmation
  description: >-
    Targeted testing for c.1138G>A and c.1138G>C is highly efficient because
    both produce p.Gly380Arg and account for nearly all typical cases.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  results: Heterozygous pathogenic FGFR3 variant, usually c.1138G>A or c.1138G>C (p.Gly380Arg).
  evidence:
  - reference: PMID:9718331
    reference_title: Mutations in fibroblast growth-factor receptor 3 in sporadic cases of achondroplasia occur exclusively on the paternally derived chromosome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "More than 97% of achondroplasia cases are caused by one of two mutations (G1138A and G1138C) in the fibroblast growth factor receptor 3 (FGFR3) gene, which results in a specific amino acid substitution, G380R."
    explanation: The study supports targeted testing for the two recurrent nucleotide substitutions.
  - reference: CGGV:assertion_0adafa1b-e609-4b99-8e90-f73473b70771-2023-09-28T040000.000Z
    reference_title: FGFR3 / achondroplasia (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FGFR3 | HGNC:3690 | achondroplasia | MONDO:0007037 | AD | Definitive"
    explanation: ClinGen supports molecular confirmation through the definitive gene-disease relationship.

differential_diagnoses:
- name: Hypochondroplasia
  disease_term:
    preferred_term: hypochondroplasia
    term:
      id: MONDO:0007793
      label: hypochondroplasia
  description: >-
    A milder FGFR3 skeletal dysplasia that can overlap mild achondroplasia.
  distinguishing_features:
  - Skeletal and medical manifestations tend to be milder than in achondroplasia.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The skeletal features are very similar to those seen in achondroplasia but tend to be milder."
    explanation: The current review states the principal clinical distinction.
- name: Pseudoachondroplasia
  disease_term:
    preferred_term: pseudoachondroplasia
    term:
      id: MONDO:0008322
      label: pseudoachondroplasia
  description: >-
    A clinically and genetically distinct skeletal dysplasia whose similar name
    can cause diagnostic confusion.
  distinguishing_features:
  - It is genetically distinct from FGFR3 p.Gly380Arg achondroplasia.
  - The radiographic and craniofacial pattern should be assessed rather than relying on nomenclature.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "is a clinically and genetically distinct skeletal dysplasia but the similar nomenclature may cause confusion with achondroplasia."
    explanation: GeneReviews explicitly warns that the similar name masks a distinct disorder.
- name: Thanatophoric dysplasia type 2
  disease_term:
    preferred_term: thanatophoric dysplasia type 2
    term:
      id: MONDO:0008547
      label: thanatophoric dysplasia type 2
  description: >-
    A much more severe, usually life-limiting FGFR3 short-limb skeletal dysplasia.
  distinguishing_features:
  - Severe, usually lethal short-limb skeletal dysplasia favors thanatophoric dysplasia.
  evidence:
  - reference: PMID:25800480
    reference_title: "A case of thanatophoric dysplasia type 2: a novel mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thanatophoric dysplasia (TD) is a lethal form of skeletal dysplasia with short-limb dwarfism."
    explanation: The report supports the severe life-limiting short-limb phenotype.
- name: SADDAN
  disease_term:
    preferred_term: severe achondroplasia-developmental delay-acanthosis nigricans syndrome
    term:
      id: MONDO:0014658
      label: severe achondroplasia-developmental delay-acanthosis nigricans syndrome
  description: >-
    SADDAN is a severe FGFR3 allelic disorder in which developmental delay,
    structural brain abnormalities, hearing loss, and acanthosis nigricans
    accompany the skeletal dysplasia.
  distinguishing_features:
  - Marked developmental and neurologic abnormalities with acanthosis nigricans favor SADDAN.
  - SADDAN is associated with FGFR3 p.Lys650Met rather than p.Gly380Arg.
  evidence:
  - reference: PMID:24352917
    reference_title: Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) is an extremely rare severe skeletal dysplasia characterized by significant developmental delay, brain structural abnormalities, hearing loss, and acanthosis nigricans."
    explanation: The report directly states the distinguishing multisystem phenotype.
  - reference: PMID:24352917
    reference_title: Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disorder is the result of a single missense mutation at codon 650 (p.Lys650Met) in the fibroblast growth factor receptor 3 gene (FGFR3)."
    explanation: The report identifies the distinct SADDAN allele.

clinical_trials:
- name: NCT06164951
  phase: PHASE_III
  status: COMPLETED
  description: >-
    PROPEL 3 — the pivotal 52-week randomized, double-blind, placebo-controlled
    trial of once-daily oral infigratinib in children aged 3 to <18 years with
    achondroplasia. Unlike the CNP-analogue trials, it tests a drug acting on
    the FGFR receptor kinase itself rather than on the counter-regulatory arm.
  target_phenotypes:
  - preferred_term: Limb undergrowth
    term:
      id: HP:0009826
      label: Limb undergrowth
  - preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: clinicaltrials:NCT06164951
    reference_title: "A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age With Achondroplasia: PROPEL 3"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia (ACH)"
    explanation: The registry record establishes the trial's design and population.
  - reference: PMID:42370681
    reference_title: "Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this phase 3, multicenter, double-blind, placebo-controlled trial, we randomly assigned children with achondroplasia (3 to 17 years of age) in a 2:1 ratio to receive infigratinib (at a dose of 0.25 mg per kilogram of body weight) or placebo once daily for 52 weeks."
    explanation: The publication reporting this trial's results.

- name: NCT03197766
  phase: PHASE_III
  status: COMPLETED
  description: >-
    The pivotal 52-week randomized, double-blind, placebo-controlled phase 3
    trial of once-daily subcutaneous vosoritide (BMN 111) in children with
    achondroplasia, whose growth-velocity result underlies the accelerated
    approval.
  target_phenotypes:
  - preferred_term: Limb undergrowth
    term:
      id: HP:0009826
      label: Limb undergrowth
  evidence:
  - reference: clinicaltrials:NCT03197766
    reference_title: "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia."
    explanation: The registry record identifies the vosoritide phase 3 trial.
  - reference: PMID:32891212
    reference_title: "Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The adjusted mean difference in annualised growth velocity between patients in the vosoritide group and placebo group was 1·57 cm/year in favour of vosoritide"
    explanation: The publication reporting this trial's primary result.
- name: NCT04085523
  phase: PHASE_II
  status: COMPLETED
  description: >-
    ACcomplisH, the 52-week phase 2 randomized, double-blind,
    placebo-controlled dose-escalation trial of once-weekly navepegritide
    (TransCon CNP) in prepubertal children aged 2-10 years.
  target_phenotypes:
  - preferred_term: Limb undergrowth
    term:
      id: HP:0009826
      label: Limb undergrowth
  evidence:
  - reference: clinicaltrials:NCT04085523
    reference_title: "ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Prepubertal Children With Achondroplasia Followed by an Open-Label Extension Period"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The trial is a multicenter, double-blind, randomized, placebo-controlled, dose escalation trial of weekly TransCon CNP administered subcutaneously in prepubertal children 2 to 10 years old, inclusive, with Achondroplasia."
    explanation: The registry record establishes design and population.
  - reference: PMID:37823031
    reference_title: "Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "TransCon CNP demonstrated a dose-dependent improvement in AGV."
    explanation: The publication reporting this trial's dose-response result.
- name: NCT05598320
  phase: PHASE_II
  status: COMPLETED
  description: >-
    APPROACH, the 52-week randomized, double-blind, placebo-controlled trial of
    once-weekly navepegritide 100 µg/kg in children aged 2-11 years; its title
    calls it phase 2b and the registry lists it as phase 2/3. It is the
    randomized basis of the 2026 US accelerated approval.
  target_phenotypes:
  - preferred_term: Limb undergrowth
    term:
      id: HP:0009826
      label: Limb undergrowth
  evidence:
  - reference: clinicaltrials:NCT05598320
    reference_title: "A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children With Achondroplasia Followed by an Open Label Extension Period"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this clinical trial was to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of 100 µg TransCon CNP/kg compared to placebo on Annualized Growth Velocity after a 52-week randomized treatment period in children aged 2 to 11 years with genetically confirmed Achondroplasia."
    explanation: The registry record establishes design, dose, and population.
  - reference: PMID:41247754
    reference_title: "Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The trial met its primary end point, demonstrating superiority of navepegritide in annualized growth velocity at week 52 vs placebo (least-squares mean treatment difference of 1.49 cm/y; 95% CI, 1.05 to 1.93; P < .001)."
    explanation: The publication reporting this trial's primary result.

animal_models:
- species: Mouse
  name: Humanized FGFR3 p.Gly380Arg knock-in mouse
  genotype: Endogenous mouse Fgfr3 replaced by human FGFR3 p.Gly380Arg cDNA (FGFR3ACH), heterozygous and homozygous
  publication: PMID:28230213
  description: >-
    Knock-in of the recurrent human allele at the endogenous locus, rather than
    transgenic overexpression, reproduces the principal achondroplasia skeletal
    features, with severity scaling with the copy number of the activated
    allele.
  associated_phenotypes:
  - Growth retardation
  - Disproportionate limb shortening
  - Midface hypoplasia
  - Progressive kyphosis
  modeled_mechanisms:
  - target: Impaired endochondral ossification and chondrodysplasia
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      The model carries the human disease allele at the endogenous locus and
      develops the skeletal phenotype the node describes.
    limitations: >-
      Mouse growth plate closes differently from human, so adult stature and
      the adult spinal-stenosis burden are not modeled; the report is
      descriptive and does not dissect the downstream signaling arms.
    readouts:
    - name: Femur length relative to body length at one month
      target: Impaired endochondral ossification and chondrodysplasia
      direction: DECREASED
      interpretation: >-
        Femur shortening exceeding body-length shortening is the quantitative
        rhizomelic readout of the endochondral growth deficit this node
        describes, and reproduces the human limb-versus-trunk disproportion.
      evidence:
      - reference: PMID:28230213
        reference_title: Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "which showed a 22% shortening of femur length along with a 7.1% shortening of body length"
        explanation: >-
          Reports the paired femur and body-length measurements behind this
          readout in heterozygous knock-in mice at one month of age.
    evidence:
    - reference: PMID:28230213
      reference_title: Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Heterozygous (FGFR3ACH/+) and homozygous (FGFR3ACH/ACH) mice expressing human FGFR3G380R recapitulate the phenotypes observed in ACH patients, including growth retardation, disproportionate shortening of the limbs, round head, mid-face hypoplasia at birth, and kyphosis progression during postnatal development."
      explanation: >-
        Supports treating the humanized knock-in as informative for the
        endochondral ossification node.
  evidence:
  - reference: PMID:28230213
    reference_title: Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The severity of the disease phenotypes corresponds to the copy number of activated FGFR3G380R, and the phenotypes become more pronounced during postnatal skeletal development."
    explanation: >-
      Allele-dosage dependence in the humanized model parallels the human
      heterozygous-versus-homozygous severity difference.
- species: Mouse
  name: Fgfr3-null mouse
  genotype: Homozygous targeted disruption of Fgfr3
  publication: PMID:8630492
  description: >-
    Loss of Fgfr3 gives the reciprocal skeletal phenotype, long-bone and
    vertebral overgrowth, which is the genetic complement of the achondroplasia
    gain-of-function allele and the basis for reading FGFR3 as a negative
    regulator of bone growth. Inner-ear defects and deafness accompany it.
  associated_phenotypes:
  - Long-bone and vertebral overgrowth
  - Kyphosis and scoliosis
  - Profound deafness
  evidence:
  - reference: PMID:8630492
    reference_title: Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our results demonstrate that Fgfr3 is essential for normal endochondral ossification and inner ear development."
    explanation: >-
      The null phenotype is the reciprocal-direction control for the
      gain-of-function model rather than a model of achondroplasia itself.
- species: Mouse
  genotype: Human FGFR3 G380R transgene under mouse Fgfr3 transcriptional control
  description: >-
    Mutant-receptor immunoreactivity extends across a larger growth-plate area,
    supporting impaired in vivo receptor down-regulation. This record does not
    claim an unsupported full phenotypic inventory.
  evidence:
  - reference: PMID:10611230
    reference_title: The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "transgenic mice expressing the human G380R mutant receptor under the mouse receptor transcriptional control demonstrated a markedly expanded area of FGFR3 immunoreactivity within their epiphyseal growth plates, compatible with an in vivo defect in receptor down-regulation."
    explanation: The experiment directly supports the modeled receptor-persistence phenotype.
- species: Mouse
  genotype: Activated Fgfr3 achondroplasia model with chondrocyte CNP overexpression
  description: >-
    Targeted CNP overexpression counteracted dwarfism and corrected reduced
    matrix synthesis through MAPK inhibition, providing proof of concept for CNP
    analogues.
  associated_phenotypes:
  - Rescue of bone shortening
  - Restored extracellular matrix synthesis
  evidence:
  - reference: PMID:14702637
    reference_title: Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "targeted overexpression of CNP in chondrocytes counteracts dwarfism in a mouse model of achondroplasia with activated fibroblast growth factor receptor 3 (FGFR-3) in the cartilage."
    explanation: The intervention directly demonstrates rescue of dwarfism.
  - reference: PMID:14702637
    reference_title: Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "CNP prevented the shortening of achondroplastic bones by correcting the decreased extracellular matrix synthesis in the growth plate through inhibition of the MAPK pathway of FGF signaling."
    explanation: The experiment supplies the matrix and MAPK mechanism.
- species: Mouse
  genotype: Constitutively active MEK1 driven by Col2a1 in chondrocytes
  description: >-
    Chondrocyte MEK1 activation produces achondroplasia-like dwarfism and
    inhibits skeletal overgrowth in Fgfr3-deficient mice, supporting MAPK as a
    downstream effector.
  associated_phenotypes:
  - Achondroplasia-like dwarfism
  evidence:
  - reference: PMID:14871928
    reference_title: Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We generated transgenic mice that express a constitutively active mutant of MEK1 in chondrocytes. These mice showed a dwarf phenotype similar to achondroplasia, the most common human dwarfism, caused by activating mutations in FGFR3."
    explanation: Directly demonstrates sufficiency of chondrocyte MAPK activation for an achondroplasia-like phenotype.
  - reference: PMID:14871928
    reference_title: Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Expression of a constitutively active mutant of MEK1 in chondrocytes of Fgfr3-deficient mice inhibited skeletal overgrowth, strongly suggesting that regulation of bone growth by FGFR3 is mediated at least in part by the MAPK pathway."
    explanation: The epistasis experiment positions MAPK downstream of FGFR3.

discussions:
- discussion_id: ach_calvarial_vault_feature_mechanism
  prompt: >-
    What mechanism links FGFR3 p.Gly380Arg to macrocephaly and the calvarial
    and upper-facial features (frontal bossing, prominent forehead, parietal
    bossing, wide anterior fontanel, anteverted nares)?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Macrocephaly
  - phenotypes#Frontal bossing
  - phenotypes#Prominent forehead
  - phenotypes#Parietal bossing
  - phenotypes#Wide anterior fontanel
  - phenotypes#Anteverted nares
  rationale: >-
    These features are well documented, but the cited sources provide
    descriptive or association-level statements only. Proposed contributors
    include relative sparing of membranous calvarial growth against a
    restricted endochondral skull base, markedly delayed sutural closure,
    frontal-bone ossification delay (raised as a possibility in the
    craniofacial 3D study), and, for macrocephaly, brain and CSF-compartment
    factors related to venous outflow. None is established as the causal route
    in ordinary heterozygous achondroplasia, so no causal edge is asserted for
    these phenotypes.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Sutural closure is markedly delayed (as evidenced by anterior fontanelle closure as late as age 5-6 years)."
    explanation: Documents the delayed membranous sutural closure that is a candidate contributor to the calvarial phenotype without stating a causal route.
- discussion_id: ach_hypotonia_joint_laxity_mechanism
  prompt: >-
    By what mechanism does FGFR3 gain of function produce infantile hypotonia
    and generalized joint hypermobility, and through them thoracolumbar
    kyphosis?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Floppy infant
  - phenotypes#Knee joint hypermobility
  - phenotypes#Hip joint hypermobility
  - phenotypes#Thoracolumbar kyphosis
  rationale: >-
    Hypotonia and generalized joint laxity are documented proximate
    contributors to motor delay and dynamic knee instability, and infantile
    thoracolumbar kyphosis is managed clinically as a consequence of truncal
    hypotonia during unsupported sitting, usually resolving as trunk strength
    increases and walking begins. No cited source establishes how FGFR3 gain
    of function produces the hypotonia or the ligamentous laxity (candidate
    contributors include craniocervical compression for hypotonia), so no
    causal edge is asserted for these phenotypes.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This results in delayed acquisition of gross motor skills and dynamic knee varus in some children"
    explanation: Documents childhood joint hypermobility as a proximate contributor to motor delay while leaving its own mechanism unexplained.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
    reference_title: Achondroplasia - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Kyphosis improves significantly or resolves in the majority of children upon assuming an orthograde posture and beginning to walk"
    explanation: Supports the postural, trunk-strength-dependent behavior of infantile thoracolumbar kyphosis.
- discussion_id: ach_obesity_mechanism
  prompt: >-
    Why is obesity so prevalent from early childhood in achondroplasia, beyond
    reduced stature-adjusted caloric needs?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Obesity
  rationale: >-
    Obesity begins in early childhood and is prevalent at all ages, and
    caloric needs are reduced, but no cited source establishes a mechanistic
    route from FGFR3 gain of function to the energy-balance phenotype.
    Wiring obesity through the skeletal growth-plate nodes would manufacture a
    causal claim, so the phenotype is deliberately left without a causal edge.
- discussion_id: ach_acanthosis_nigricans_mechanism
  prompt: >-
    Is acanthosis nigricans in achondroplasia driven directly by FGFR3
    activation in epidermal keratinocytes, as in other FGFR3-activating
    disorders, rather than by insulin resistance?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Acanthosis nigricans
  rationale: >-
    Acanthosis nigricans recurs across the FGFR3-activating disorder family
    (SADDAN, thanatophoric dysplasia, Crouzon syndrome with acanthosis
    nigricans, familial acanthosis nigricans), suggesting direct receptor
    activation in skin. Direct evidence in ordinary heterozygous
    achondroplasia is not present in the cited sources, and the skeletal
    growth-plate nodes would be the wrong upstream route regardless, so the
    phenotype is left without a causal edge.
- discussion_id: ach_signaling_arm_attribution
  prompt: >-
    Which achondroplasia features depend on the MAPK arm, which on the STAT1
    arm, and what weight should the p38 branch carry, given that the only
    approved and late-stage drugs act on one arm?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Prolonged FGFR3 signaling in growth-plate chondrocytes
  - pathophysiology#CNP-NPR2 counter-regulation of FGFR3-MAPK signaling
  rationale: >-
    Mouse genetics separates the arms — CNP overexpression corrects matrix
    synthesis through MAPK without touching STAT1, constitutively active MEK1
    causes Stat1-independent dwarfism — and a CDK8 inhibitor now moves the
    STAT1-Ser727 branch in a mouse model without affecting MAPK activation. No
    study has tested the two interventions together, and no human data assign
    specific clinical features to specific arms; the vosoritide result is
    consistent with the model but does not rank the arms against each other. A
    third, p38 branch is proposed on the strength of a single ATDC5 cell-line
    study and is not curated as a pathophysiology node here for that reason.
  proposed_experiments:
  - experiment_id: ach_cnp_analogue_plus_cdk8_inhibition
    name: Combined CNP-analogue and CDK8-inhibitor treatment in a humanized knock-in model
    description: >-
      Treat humanized FGFR3 p.Gly380Arg knock-in mice with a CNP analogue
      alone, a CDK8 inhibitor alone, both together, and vehicle, then compare
      long-bone length, growth-plate zone architecture, and phospho-STAT1
      Ser727 versus phospho-ERK in the growth plate.
    perturbations:
    - name: CNP-analogue treatment
      target: pathophysiology#CNP-NPR2 counter-regulation of FGFR3-MAPK signaling
      description: Activates the counter-regulatory branch that brakes MAPK output.
    - name: CDK8 inhibition
      target: pathophysiology#Growth-plate chondrocyte dysregulation
      description: Targets the STAT1-Ser727 arm reported to act independently of MAPK.
    readouts:
    - name: Long-bone length and growth-plate zone architecture
      target: pathophysiology#Impaired endochondral ossification and chondrodysplasia
      direction: RESTORED
      interpretation: >-
        A more-than-additive effect of the two agents would indicate that the
        arms contribute separably to the growth deficit.
    controls:
    - name: Vehicle-treated knock-in littermates
      description: Untreated disease-model arm establishing the untreated growth trajectory.
    - name: Wild-type littermates
      description: Isogenic unaffected comparator for growth-plate architecture.
    - name: Single-agent arms
      description: >-
        Each agent given alone, so that any combined effect can be judged
        against the better single agent rather than against vehicle.
    decision_criterion: >-
      Whether combined treatment exceeds the better single agent on long-bone
      length while each agent moves only its own phospho-marker.
    would_support:
    - pathophysiology#Growth-plate chondrocyte dysregulation
    supporting_outcome:
    - >-
      Combined treatment produces greater long-bone elongation than either
      agent alone, with each agent reducing only its own phospho-readout,
      establishing that the two arms contribute separably.
    refuting_outcome:
    - >-
      Combined treatment matches the better single agent, indicating the arms
      converge on a shared limiting step rather than acting separably.
  evidence:
  - reference: PMID:39674288
    reference_title: CDK8 inhibitor KY-065 rescues skeletal abnormalities in achondroplasia model mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The CDK8 expression and STAT1Ser727 phosphorylation were upregulated in chondrocytes isolated from ACH model mice, and KY-065 repressed its phosphorylation and restored normal chondrogenic differentiation without affecting MAPK activation."
    explanation: >-
      Establishes that the STAT1 arm is separately druggable in a mouse model
      without engaging MAPK, which is what makes the arm-attribution question
      experimentally answerable.
  - reference: PMID:40373614
    reference_title: TACC3 facilitates chondrocyte differentiation by attenuating abnormally activated FGFR3 signaling in achondroplasia - An in vitro study.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "These results suggest that TACC3 might play a role through the p38 signaling pathway in chondrocyte differentiation defects caused by FGFR3 mutations."
    explanation: >-
      The whole current basis for a p38 branch is this ATDC5 cell-line result,
      whose authors state it only as a suggestion; it is recorded here rather
      than curated as an established signaling arm.
  notes: >-
    Corresponds to gap KG-1 in the OpenScientist report for this hypothesis.
- discussion_id: ach_ciliary_contribution_unquantified
  prompt: >-
    How much of the human growth-plate phenotype is attributable to the ciliary
    branch, as opposed to the direct MAPK and STAT arms it lies downstream of?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Primary cilium shortening and disrupted ciliary signaling
  rationale: >-
    Cilium shortening and IFT20 mis-sorting are reproducible in chondrocytes
    from human achondroplasia and thanatophoric dysplasia cartilage and in
    mouse models, and a ciliogenesis-restoring compound increases bone
    elongation in the mouse. What has not been done is a measurement that
    separates the ciliary contribution from the receptor's direct signaling
    output: every available intervention acts upstream of both, and the rescue
    compound is not cilia-selective. Until such an experiment exists, the
    "achondroplasia is a ciliopathy" reading found in the source literature is
    an interpretive proposal rather than an established classification, and
    this entry curates the branch without adopting that label.
  evidence:
  - reference: PMID:35078974
    reference_title: Theobroma cacao improves bone growth by modulating defective ciliogenesis in a mouse model of achondroplasia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Transcriptomic analysis in an Fgfr3 mouse model showed that ciliary mRNA expression was modified and influenced significantly by the Indian hedgehog and PKA pathways."
    explanation: >-
      Shows the ciliary program is transcriptionally entangled with hedgehog
      and PKA signaling in the model, which is why an intervention that
      restores ciliogenesis does not isolate a ciliary contribution.
  notes: >-
    Corresponds to gap KG-3 in the OpenScientist report for this hypothesis.
- discussion_id: ach_statin_rescue_mechanism_unresolved
  prompt: >-
    If statins do not act on FGFR signaling in cartilage, what mechanism
    accounts for the previously reported statin rescue of FGFR3-related
    chondrodysplasia?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Prolonged FGFR3 signaling in growth-plate chondrocytes
  - treatments#
  rationale: >-
    A dedicated study found no effect of four statins on FGFR3 protein levels
    or on FGFR-mediated growth arrest, matrix loss, senescence, or hypertrophic
    differentiation across chondrocyte lines, embryonic tibia cultures, and
    limb-bud micromasses. That result narrows the earlier rescue reports: it
    rules out a chondrocyte-intrinsic FGFR mechanism, but it does not exclude
    an indirect or systemic effect, so statins are recorded here as an
    unresolved question rather than as a refuted therapy outright. No statin
    treatment entry is curated for this disease.
  evidence:
  - reference: PMID:28583899
    reference_title: Statins do not inhibit the FGFR signaling in chondrocytes.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We conclude that statins do not inhibit the FGFR signaling in chondrocytes. Therefore the statin-mediated rescue of FGFR3-related chondrodysplasia, described before, is likely not intrinsic to the growth plate cartilage."
    explanation: >-
      The authors state both halves of the gap: the chondrocyte-intrinsic FGFR
      mechanism is excluded, and the mechanism behind the earlier rescue is
      left open.
  notes: >-
    Corresponds to gap KG-7 in the OpenScientist report for this hypothesis.

notes: >-
  Intelligence is usually near normal, while motor and sometimes speech milestones
  can be delayed for physical, hearing, or airway-related reasons. Clinical care is
  lifelong and multidisciplinary. Current CNP analogues have demonstrated improved
  growth velocity; claims about final adult height and prevention of neurologic,
  respiratory, otologic, or orthopedic complications require separate evidence.
datasets: []
references:
- reference: CGGV:assertion_0adafa1b-e609-4b99-8e90-f73473b70771-2023-09-28T040000.000Z
  title: "FGFR3 / achondroplasia (Definitive)"
  findings: []
- reference: DOI:10.1038/s41574-021-00595-x
  title: "International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia"
  findings: []
- reference: ORPHA:15
  title: "Achondroplasia"
  findings: []
- reference: PMID:10611230
  title: "The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation."
  findings: []
- reference: PMID:14702637
  title: "Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway."
  findings: []
- reference: PMID:14751560
  title: "Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias."
  findings: []
- reference: PMID:14871928
  title: "Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype."
  findings: []
- reference: PMID:18923003
  title: "FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway."
  findings: []
- reference: PMID:22409389
  title: "Development in children with achondroplasia: a prospective clinical cohort study."
  findings: []
- reference: PMID:24352917
  title: "Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation."
  findings: []
- reference: PMID:25800480
  title: "A case of thanatophoric dysplasia type 2: a novel mutation."
  findings: []
- reference: PMID:27927547
  title: "Prevalence of Scoliosis and Thoracolumbar Kyphosis in Patients With Achondroplasia."
  findings: []
- reference: PMID:29972438
  title: "Natural history of 39 patients with Achondroplasia."
  findings: []
- reference: PMID:31269546
  title: "C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia."
  findings: []
- reference: PMID:31294928
  title: "Epidemiology of achondroplasia: A population-based study in Europe."
  findings: []
- reference: PMID:32170149
  title: "Lumbar spinal stenosis and disc alterations affect the upper lumbar spine in adults with achondroplasia."
  findings: []
- reference: PMID:3228140
  title: "Obesity in achondroplasia."
  findings: []
- reference: PMID:32457214
  title: "Health Supervision for People With Achondroplasia."
  findings: []
- reference: PMID:32803853
  title: "Birth prevalence of achondroplasia: A systematic literature review and meta-analysis."
  findings: []
- reference: PMID:32864841
  title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
  findings: []
- reference: PMID:32883660
  title: "Achondroplasia Foramen Magnum Score: screening infants for stenosis."
  findings: []
- reference: PMID:33579320
  title: "Predictors of cervical myelopathy and hydrocephalus in young children with achondroplasia."
  findings: []
- reference: PMID:34736503
  title: "Hearing loss in Norwegian adults with achondroplasia."
  findings: []
- reference: PMID:37072824
  title: "Craniofacial growth and function in achondroplasia: a multimodal 3D study on 15 patients."
  findings: []
- reference: PMID:37493935
  title: "Walking status and spinopelvic parameters in young children with achondroplasia: 10-year follow-up."
  findings: []
- reference: PMID:38554024
  title: "Clinical outcomes and medical management of achondroplasia in Japanese children: A retrospective medical record review of clinical data."
  findings: []
- reference: PMID:39660705
  title: "Otologic Manifestations in Patients with Achondroplasia: A Multicenter Study."
  findings: []
- reference: PMID:39740666
  title: "Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study."
  findings: []
- reference: PMID:40675782
  title: "Sleep-disordered breathing in children with achondroplasia assessed by polysomnography: a retrospective chart review."
  findings: []
- reference: PMID:41247754
  title: "Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial."
  findings: []
- reference: PMID:7847369
  title: "Achondroplasia is defined by recurrent G380R mutations of FGFR3."
  findings: []
- reference: PMID:8078586
  title: "Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia."
  findings: []
- reference: PMID:9718331
  title: "Mutations in fibroblast growth-factor receptor 3 in sporadic cases of achondroplasia occur exclusively on the paternally derived chromosome."
  findings: []
- reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214938s004lbl.pdf
  title: "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214938s004lbl.pdf"
  findings: []
- reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf
  title: "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf"
  findings: []
- reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1152/
  title: "Achondroplasia - GeneReviews® - NCBI Bookshelf"
  tags:
  - GeneReviews
  findings: []
- reference: PMID:17879967
  title: "Mortality in achondroplasia study: a 42-year follow-up."
  findings: []
- reference: PMID:20624921
  title: "Physical basis behind achondroplasia, the most common form of human dwarfism."
  findings: []
- reference: PMID:24677650
  title: "Mortality in babies with achondroplasia: revisited."
  findings: []
- reference: PMID:28230213
  title: "Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia."
  findings: []
- reference: PMID:28583899
  title: "Statins do not inhibit the FGFR signaling in chondrocytes."
  findings: []
- reference: PMID:29040558
  title: "Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia."
  findings: []
- reference: PMID:29360984
  title: "Regulation of ciliary function by fibroblast growth factor signaling identifies FGFR3-related disorders achondroplasia and thanatophoric dysplasia as ciliopathies."
  findings: []
- reference: PMID:29652901
  title: "Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia."
  findings: []
- reference: PMID:30276962
  title: "Multicenter study of mortality in achondroplasia."
  findings: []
- reference: PMID:32891212
  title: "Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial."
  findings: []
- reference: PMID:33370388
  title: "In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia."
  findings: []
- reference: PMID:34431071
  title: "Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia."
  findings: []
- reference: PMID:35078974
  title: "Theobroma cacao improves bone growth by modulating defective ciliogenesis in a mouse model of achondroplasia."
  findings: []
- reference: PMID:37428729
  title: "Phase 1b study on the repurposing of meclizine hydrochloride for children with achondroplasia."
  findings: []
- reference: PMID:37823031
  title: "Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial."
  findings: []
- reference: PMID:38685585
  title: "Natural disease course modeling of achondroplasia to evaluate the efficacy of recifercept in the absence of a placebo control arm in phase II study."
  findings: []
- reference: PMID:39555818
  title: "Oral Infigratinib Therapy in Children with Achondroplasia."
  findings: []
- reference: PMID:39674288
  title: "CDK8 inhibitor KY-065 rescues skeletal abnormalities in achondroplasia model mice."
  findings: []
- reference: PMID:40373614
  title: "TACC3 facilitates chondrocyte differentiation by attenuating abnormally activated FGFR3 signaling in achondroplasia - An in vitro study."
  findings: []
- reference: PMID:41167810
  title: "Cardiovascular risk in achondroplasia: a systematic review."
  findings: []
- reference: PMID:41326861
  title: "Efficacy and Safety of Oral Meclizine for Growth Promotion in Children with Achondroplasia: A Phase 2 Clinical Trial."
  findings: []
- reference: PMID:42001280
  title: "Evaluating the impact of vosoritide on complications of achondroplasia."
  findings: []
- reference: PMID:42234372
  title: "Navepegritide: First Approval."
  findings: []
- reference: PMID:42370681
  title: "Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia."
  findings: []
- reference: PMID:42495828
  title: "Retrospective study of foramen magnum development in patients with achondroplasia starting vosoritide before age 3."
  findings: []
- reference: PMID:8630492
  title: "Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3."
  findings: []
- reference: clinicaltrials:NCT03197766
  title: "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia"
  findings: []
- reference: clinicaltrials:NCT04085523
  title: "ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Prepubertal Children With Achondroplasia Followed by an Open-Label Extension Period"
  findings: []
- reference: clinicaltrials:NCT05598320
  title: "A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children With Achondroplasia Followed by an Open Label Extension Period"
  findings: []
- reference: clinicaltrials:NCT06164951
  title: "A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age With Achondroplasia: PROPEL 3"
  findings: []

📚